Heterocyclic inhibitors of GLUT9 for treatment of disease

By developing heterocyclic compounds that inhibit GLUT9 activity, the drug interaction and side effects problems in existing hyperuricemia treatment methods have been solved, and effective management of hyperuricemia and gout has been achieved.

CN119013265APending Publication Date: 2024-11-22HORIZON THERAPEUTICS IRELAND DAC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380025578.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-07
Filing Date
2023-01-06
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing treatments for hyperuricemia are problematic such as drug-drug interactions, allergic reactions, immunogenicity and poor management of chronic gout, and there are safety and choices of existing drugs such as benbromalon and probenecid. Insufficient sex.

Method used

A novel heterocyclic compound and pharmaceutical composition has been developed to treat or prevent diseases caused by GLUT9 such as hyperuricemia and gout by inhibiting the activity of glucose transporter member 9 (GLUT9). This compound can be used for intravenous, subcutaneous, oral, inhaled, nasal or topical administration to form dosage forms such as tablets, capsules, liquids, etc.

Benefits of technology

Effectively inhibiting GLUT9 activity and reducing blood uric acid levels provide new methods to treat hyperuricemia and gout, avoiding many side effects of existing drugs, and improving the management effect of chronic gout.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005028250380000031
    Figure BDA0005028250380000031
  • Figure BDA0005028250380000081
    Figure BDA0005028250380000081
  • Figure BDA0005028250380000101
    Figure BDA0005028250380000101
Patent Text Reader

Abstract

The present invention relates to heterocyclic compounds and methods useful as GLUT9 inhibitors for the treatment or prevention of hyperuricemia and gout.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 297,511, filed January 7, 2022, which is incorporated herein by reference in its entirety.

[0003] References to sequence listings

[0004] This application contains a sequence listing that has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy created on December 27, 2022 is named 58651-602-601_SL.xml and is 11,787 bytes in size. Background Art

[0005] Disclosed herein are novel heterocyclic compounds and compositions, and their use as medicaments for treating diseases. Also provided are methods for inhibiting glucose transporter member 9 (GLUT9) activity in a human or animal subject for treating diseases such as hyperuricemia and gout.

[0006] Uric acid is the final metabolite in the human purine decomposition pathway. Under physiological pH conditions, uric acid exists largely as urate, the ionic form of uric acid. The amount of urate in the body depends on the balance between the amount of purine obtained through food intake, the amount of urate synthesized in the body, and the amount of urate secreted in the urine or through the gastrointestinal tract. Hyperuricemia is a disease characterized by abnormally high levels of uric acid in the blood. In humans, the upper limit of the normal range of uric acid is about 360 μmol / L (about 6 mg / dL) (for women) and about 400 μmol / L (about 6.8 mg / dL) (for men). When the concentration of uric acid is higher than the biochemical limit of solubility, for example, a serum uric acid level of about 6.8 mg / dL, monosodium urate crystals can be precipitated in tissues. Hyperuricemia can lead to the accumulation of monosodium urate crystals and cause gout symptoms, such as acute joint inflammation (gout attacks), tophi formation, gouty arthritis and uric acid nephropathy (including uric acid kidney stones). Gout is the most common cause of arthritis in developed countries. The management of chronic gout requires maintaining serum uric acid (SUA) below 6 mg / dL.

[0007] High serum urate increases with body mass index, hypercholesterolemia, hypertriglyceridemia, fasting plasma glucose and insulin resistance. In addition, increasing evidence shows that urate is a dose-effect of the risk of metabolic syndrome, and the urate level increase may have adverse cardiovascular effects. In addition, chronic kidney disease, hypertension, diabetes, heart disease (such as cardiovascular disease, heart failure, atrial fibrillation), arteriosclerotic disease, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and psoriasis are also relevant to high serum urate levels.

[0008] Therefore, treatment of hyperuricemia is essential. Currently, excessive production and insufficient excretion of uric acid are the main causes of hyperuricemia. More than 90% of hyperuricemia is caused by insufficient uric acid excretion. The secretion of uric acid depends on urate transporters, such as urate transporter 1 (SLC22A12 / URAT1) and glucose transporter 9 (SLC2A9 / GLUT9). Therefore, URAT1 and GLUT9 have become important targets for the development of uric acid-lowering drugs.

[0009] Urate-lowering therapies include uricases, which break down uric acid; xanthine oxidase inhibitors, which block uric acid production; and uricosuric drugs, which enhance uric acid secretion. Xanthine oxidase inhibitors, such as allopurinol and febuxostat, are widely used and administered orally. Uricase, such as pegloticase, is administered by infusion. It is a pegylated recombinant mammalian uricase, and is used to treat gout that is difficult to treat with conventional therapy (e.g., oral allopurinol). Most mammals, including humans, do not have functional uricases. Uricase degrades uric acid into a more soluble molecule, allantoin, which is easily eliminated by the kidneys. Although research has made significant progress, gout is still poorly managed, which can cause the condition to become chronic. Xanthine oxidase inhibitor therapy can lead to allergic syndromes, and uricase therapy can lead to immunogenicity, such as it causes a difficult problem in gout management.

[0010] Additional small molecule uricosuric drugs used in the clinic mainly include benzbromarone, probenecid and lesinurad. Benzbromarone and probenecid can inhibit URAT1 and GLUT9 and thus promote uric acid secretion. However, due to fulminant hepatitis caused by benzbromarone, it has been withdrawn from the market in most countries. Because of its low selectivity, probenecid can cause drug-drug interactions, and therefore its clinical use is limited. Lesinurad is a more selective URAT1 inhibitor developed by AstraZeneca and has been approved by the FDA in October 2015 for the treatment of hyperuricemia, but it should be used in combination with xanthine oxidase inhibitors (allopurinol / febuxostat). RDEA3170 is derived from lesinurad and is currently in Phase II clinical trials. In addition to the above drugs, losartan, fenofibrate, atorvastatin, and others also have uric acid-lowering effects, but their mechanisms have not yet been fully elucidated. Therefore, finding new drugs to treat hyperuricemia is of great significance.

[0011] Novel compounds and pharmaceutical compositions, some of which have been found to inhibit GLUT9, have been discovered, as well as methods of synthesizing and using these compounds, including methods of treating GLUT9-mediated diseases in patients by administering the compounds. Summary of the Invention

[0012] The compounds disclosed herein may possess useful GLUT9 inhibitory activity and may be used to treat or prevent diseases or conditions in which GLUT9 plays an active role.

[0013] In one aspect, described herein is a compound of formula (I'):

[0014]

[0015] or a pharmaceutically acceptable salt thereof, wherein:

[0016] m is an integer from 0 to 4;

[0017] X is selected from CH and N;

[0018] Y is selected from CH, S, O and N;

[0019] Z is selected from the key and CR 7 ;

[0020] R 1 is selected from aryl and heteroaryl;

[0021] R 2is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which may be optionally substituted with one or more R 6 replace;

[0022] R 3 Selected from:

[0023] optionally SO2-alkyl-substituted alkyl,

[0024] Alkoxyalkyl,

[0025] Alkoxyalkoxyalkyl,

[0026] haloalkyl,

[0027] Haloalkoxyalkyl,

[0028] cycloalkylalkyl, and

[0029] cycloalkoxyalkyl;

[0030] Each R 4 Independently selected from:

[0031] Optionally, R 5 Substituted alkoxy,

[0032] Optionally, R 5 Substituted alkylamino,

[0033] Optionally, R 5 substituted dialkylamino,

[0034] SO2R 8a ,

[0035] Alkylthio,

[0036] Haloalkoxy,

[0037] Cycloalkoxy,

[0038] Cycloalkylalkoxy,

[0039] Halogenated,

[0040] Alkyl, and

[0041] alkyl halide;

[0042] or R 1 Two R on adjacent carbon atoms 4 the substituents together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy, or alkoxyalkyl;

[0043] Each R 5 independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino, haloalkoxy, and alkoxyalkoxy;

[0044] Each R 6 independently selected from hydroxy, hydroxyalkoxy, carboxyl, methylcarboxyl, carboxylalkyl, carboxylalkoxy, halo, alkyl, alkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, cyano, and tetrazolyl;

[0045] R 7 is selected from hydrogen and halo; and

[0046] R 8a and R 8b Each is independently selected from alkyl, amino, alkylamino, dialkylamino;

[0047] Where X and Y are not both CH.

[0048] Also described herein are pharmaceutical compositions comprising a compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical compositions are formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, transdermal administration, or ophthalmic administration. In some embodiments, the pharmaceutical compositions are formulated for administration to a mammal by oral administration. In some embodiments, the pharmaceutical compositions are in the form of tablets, pills, capsules, liquids, suspensions, gels, dispersions, solutions, emulsions, ointments, or lotions. In some embodiments, the pharmaceutical compositions are in the form of tablets, pills, or capsules.

[0049] Any of the aforementioned aspects is a further embodiment, wherein an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, is: (a) administered systemically to a mammal; and / or (b) administered orally to a mammal; and / or (c) administered intravenously to a mammal; and / or (d) administered by inhalation; and / or (e) administered by nasal administration; and / or (f) administered to a mammal by injection; and / or (g) administered topically to a mammal; and / or (h) administered by ocular administration; and / or (i) administered rectally to a mammal; and / or (j) administered non-systemically or topically to a mammal.

[0050] Any of the foregoing aspects are other embodiments comprising a single administration of an effective amount of a compound, including other embodiments wherein the compound is administered to a mammal once a day or multiple times a day. In some embodiments, the compound is administered on a continuous dosing schedule. In some embodiments, the compound is administered on a continuous daily dosing schedule.

[0051] In any embodiments disclosed herein, the mammal is a human.

[0052] In some embodiments, the compounds provided herein are administered orally to humans.

[0053] Also described herein, in some embodiments, is a compound described herein, or a pharmaceutically acceptable salt thereof, for use as a medicament.

[0054] In some embodiments, also described herein is a compound described herein, or a pharmaceutically acceptable salt thereof, for use in treating a condition selected from hyperuricemia and gout.

[0055] In some embodiments, also described herein is a compound described herein, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for preventing or treating a disease or condition ameliorated by inhibiting GLUT9.

[0056] Also described herein, in some embodiments, is a method of inhibiting GLUT9 comprising contacting GLUT9 with a compound described herein or a pharmaceutically acceptable salt thereof.

[0057] In some embodiments, a method of treating a GLUT9-mediated disease is described herein, comprising administering to a patient in need thereof a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the disease is selected from hyperuricemia, gout, and uncontrolled gout, including comorbidities and related diseases.

[0058] In some embodiments, a method for treating a GLUT9-mediated disease is also described herein, comprising administering: a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof; and another therapeutic agent. In some embodiments, the other agents are selected from uric acid synthesis inhibitors, uricosuric drugs, and uric acid catabolism agents. In some such embodiments, the uricosuric drug is selected from probenecid, lesinade, benzbromarone, and sulfinpyrazone. In some such embodiments, the uric acid synthesis inhibitor is selected from allopurinol and febuxostat. In some such embodiments, the uric acid catabolism agent is pegloticase. In some other embodiments, the other agent is colchicine.

[0059] Also described herein, in some embodiments, is a method for reducing blood uric acid levels in a patient, comprising administering to the patient a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof.

[0060] An article of manufacture is provided that includes packaging material; a compound described herein, or a pharmaceutically acceptable salt thereof, within the packaging material; and a label indicating that the compound or composition, or a pharmaceutically acceptable salt, tautomer, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, is for inhibiting GLUT9, or for treating, preventing, or ameliorating one or more symptoms of a disease or condition that would benefit from inhibition of GLUT9.

[0061] Other objects, features and advantages of the compounds, methods and compositions described herein will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, while indicating specific embodiments, are given by way of illustration only, as various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art based on these embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 The nucleic acid sequence of human GLUT9B / GLUT9 variant 2 / Q96S37-2 / Glut9 isoform 2 (SEQ ID NO: 3) is shown.

[0063] Figure 2 The amino acid sequence of human GLUT9B / GLUT9 variant 2 / Q96S37-2 / Glut9 isoform 2 (SEQ ID NO: 4) is shown.

[0064] Figure 3 The nucleic acid sequence of human URAT1 (SEQ ID NO: 5) is shown.

[0065] Figure 4 The amino acid sequence of human URAT1 (SEQ ID NO: 6) is shown.

[0066] Figure 5 The pIRESpuro vector from Takara Bio is shown.

[0067] Figure 6 Shown are the cloning strategies for GLUT9B and URAT1 used to generate bicistronic vectors for stable cell line generation.

[0068] Figure 7 Shows the conversion of uric acid to allantoin.

[0069] Figure 8 The Aspergillus oryzae uricase vector from GenScript is shown. DETAILED DESCRIPTION

[0070] The compounds disclosed herein may have applicable GLUT9 inhibitory activity and may be used to treat or prevent diseases or conditions in which GLUT9 plays an active role. Therefore, in a broad aspect, certain embodiments also provide pharmaceutical compositions comprising one or more compounds disclosed herein and a pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions. Certain embodiments provide methods for inhibiting GLUT9. Other embodiments provide methods for treating GLUT9-mediated disorders in patients in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound or composition according to the present invention. Also provided are uses of certain compounds disclosed herein for the manufacture of medicaments for treating diseases or conditions improved by inhibiting GLUT9.

[0071] Compounds of the present disclosure

[0072] Disclosed herein are compounds that can be used to inhibit GLUT9 activity. In some embodiments, the compounds described herein can be used to treat or prevent a disease or condition in which GLUT9 plays an active role.

[0073] In one aspect, described herein is a compound of formula (I'):

[0074]

[0075] or a pharmaceutically acceptable salt thereof, wherein:

[0076] m is an integer from 0 to 4;

[0077] X is selected from CH and N;

[0078] Y is selected from CH, S, O and N;

[0079] Z is selected from the key and CR 7 ;

[0080] R 1 is selected from aryl and heteroaryl;

[0081] R 2 is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which may be optionally substituted with one or more R 6 replace;

[0082] R 3 Selected from:

[0083] optionally SO2-alkyl-substituted alkyl,

[0084] Alkoxyalkyl,

[0085] Alkoxyalkoxyalkyl,

[0086] haloalkyl,

[0087] Haloalkoxyalkyl,

[0088] cycloalkylalkyl, and

[0089] cycloalkoxyalkyl;

[0090] Each R 4 Independently selected from:

[0091] Optionally, R 5 Substituted alkoxy,

[0092] Optionally, R 5 Substituted alkylamino,

[0093] Optionally, R 5 substituted dialkylamino,

[0094] SO2R 8a ,

[0095] Alkylthio,

[0096] Haloalkoxy,

[0097] Cycloalkoxy,

[0098] Cycloalkylalkoxy,

[0099] Halogenated,

[0100] Alkyl, and

[0101] alkyl halide;

[0102] or R 1 Two R on adjacent carbon atoms 4 the substituents together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy, or alkoxyalkyl;

[0103] Each R 5 independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino, haloalkoxy, and alkoxyalkoxy;

[0104] Each R 6 independently selected from hydroxy, hydroxyalkoxy, carboxyl, methylcarboxyl, carboxylalkyl, carboxylalkoxy, halo, alkyl, alkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, cyano, and tetrazolyl;

[0105] R 7 is selected from hydrogen and halo; and

[0106] R 8a and R 8bEach is independently selected from alkyl, amino, alkylamino, dialkylamino;

[0107] Where X and Y are not both CH.

[0108] For any and all embodiments, the substituents are selected from a subset of the listed alternatives. For example, in some embodiments, X is CH. In other embodiments, X is N.

[0109] In some embodiments, Y is CH or N. In some embodiments, Y is CH. In some embodiments, Y is N. In some embodiments, Y is O. In some embodiments, Y is S.

[0110] In some embodiments, Z is a bond. In some embodiments, Z is CR 7 In some embodiments, R 7 In some embodiments, R 7 In some embodiments, R 7 In some embodiments, Z is a bond, CH, CF, or CCl. In some embodiments, Z is CH or CCl. In some embodiments, Z is a bond or CH. In some embodiments, Z is CH.

[0111] In some embodiments, X is CH; and Y is S, O, or N.

[0112] In some embodiments, X is CH; Y is N; and Z is CR 7 In some embodiments, X is CH; Y is N; and Z is CH.

[0113] In some embodiments, X is N; and Y is CH, S, O, or N.

[0114] In some embodiments, X is N; Y is CH; and Z is CR 7 In some embodiments, X is N; Y is CH; and Z is CH.

[0115] In some embodiments, X is N; Y is N; and Z is CR 7 In some embodiments, X is N; Y is N; and Z is CH.

[0116] In some embodiments, X is selected from CH and N; Y is selected from CH and N; and Z is CR 7 In some embodiments, X is CH; Y is N; and Z is CR 7 ; or X is N; Y is CH; and Z is CR 7 ; or X is N; Y is N; and Z is CR 7 In some embodiments, X is CH; Y is N; and Z is CR7 In some embodiments, X is N; Y is CH; and Z is CR 7 In some embodiments, X is N; Y is N; and Z is CR 7 In some such embodiments, R 7 is hydrogen, F, or Cl. In some such embodiments, R 7 is hydrogen. In some such embodiments, R 7 is F. In some such embodiments, R 7 For Cl.

[0117] In some embodiments, X is selected from CH and N; Y is selected from CH and N; and Z is CH. In some embodiments, X is CH; Y is N; and Z is CH; or X is N; Y is CH; and Z is CH; or X is N; Y is N; and Z is CH. In some embodiments, X is CH; Y is N; and Z is CH. In some embodiments, X is N; Y is CH; and Z is CH. In some embodiments, X is N; Y is N; and Z is CH. In some embodiments, X is N; Y is N; and Z is CH.

[0118] In some embodiments, the compound is a compound of formula (I'-A) or a pharmaceutically acceptable salt thereof:

[0119]

[0120] In some embodiments, the compound is a compound of Formula (I'-B) or (I'-C) or a pharmaceutically acceptable salt thereof:

[0121]

[0122]

[0123] In some embodiments, R 1 In some embodiments, R 1 is phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl. In some embodiments, R 1 is phenyl, naphthyl, a monocyclic heteroaryl or a bicyclic heteroaryl, wherein the heteroaryl contains 0-4 N atoms, 0-1 O atoms and 0-1 S atoms in the ring, or wherein the heteroaryl contains 1-4 N atoms, 0-1 O atoms and 0-1 S atoms in the ring. In some embodiments, R 1 is phenyl, monocyclic heteroaryl or bicyclic heteroaryl. In some embodiments, R 1 is phenyl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl or bicyclic heteroaryl.

[0124] In some embodiments, R 1 In some embodiments, R 1In some embodiments, R 1 It is phenyl.

[0125] In some embodiments, R 1 In some embodiments, R 1 is a monocyclic heteroaryl or a bicyclic heteroaryl. In some embodiments, R 1 is a monocyclic heteroaryl group or a bicyclic heteroaryl group, wherein the heteroaryl group contains 0-4 N atoms, 0-1 O atoms and 0-1 S atoms in the ring, or wherein the heteroaryl group contains 1-4 N atoms, 0-1 O atoms and 0-1 S atoms in the ring.

[0126] In some embodiments, R 1 In some embodiments, R 1 is a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl. 1 is a 5-membered monocyclic heteroaryl group or a 6-membered monocyclic heteroaryl group, wherein the heteroaryl group contains 0-4 N atoms, 0-1 O atoms and 0-1 S atoms in the ring, or wherein the heteroaryl group contains 1-4 N atoms, 0-1 O atoms and 0-1 S atoms in the ring.

[0127] In some embodiments, R 1 is a 5-membered monocyclic heteroaryl. In some embodiments, R 1 is a 5-membered monocyclic heteroaryl group, wherein the heteroaryl group contains 0-4 N atoms, 0-1 O atoms and 0-1 S atoms in the ring, or wherein the heteroaryl group contains 1-4 N atoms, 0-1 O atoms and 0-1 S atoms in the ring. In some embodiments, R 1 is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl or tetrazolyl.

[0128] In some embodiments, R 1 is a 6-membered monocyclic heteroaryl. In some embodiments, R 1 is a 6-membered monocyclic heteroaryl group, wherein the heteroaryl group contains 1-4 N atoms. In some embodiments, R 1 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl.

[0129] In some embodiments, R 1 In some embodiments, R 1 is a C2-C9 bicyclic heteroaryl. In some embodiments, R 1 is a bicyclic heteroaryl group containing 0-4 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring system, or containing 1-4 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring system.1 is a bicyclic heteroaryl group containing 1 O atom and 0 or 1 N atom in the ring system. 1 In some embodiments, R 1 is benzofuranyl or furopyridinyl. In some embodiments, R 1 It is benzofuranyl.

[0130] In some embodiments, R 1Phenyl; 1H-indol-5-yl; 1H-indol-6-yl; thien-2-yl; thiazol-5-yl; 3-oxo-2,3-dihydrobenzofuran-5-yl; 2,3-dihydrobenzofuran-5-yl; furo[2,3-b]pyridin-5-yl; 2,3-dihydrofuro[2,3-b]pyridin-5-yl; pyridin-3-yl; pyridin-4-yl; benzo[d]oxazol-6-yl; 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; chroman-6-yl; 3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl; 3-oxo-3,4-dihydro-2H- Benzo[b][1,4]oxazin-6-yl; furo[2,3-b]pyridin-5-yl; 2,3-dihydrobenzofuran-5-yl; 2H-indazol-6-yl; 1H-pyrrolo[2,3-b]pyridin-4-yl; [1,2,4]triazolo[1,5-a]pyridin-6-yl; imidazo[1,2-a]pyrimidin-6-yl; 2H-indazol-6-yl; 2H-indazol-5-yl; quinolin-3-yl; quinolin-4-yl; 1H-pyrazol-5-yl; thieno[3,2-b]thien-2-yl; benzo[c][1,2,5]thiadiazol-5-yl; imidazo[1,2-a]pyridine -6-yl; 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl; imidazo[1,5-a]pyridin-6-yl; imidazo[1,2-a]pyridin-7-yl; 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl; thieno[2,3-b]pyridin-5-yl; imidazo[1,2-b]pyridazin-6-yl; [1,2,4]triazolo[1,5-a]pyridin-7-yl; 2H-indazol-7-yl; 1H-pyrrolo[2,3-b]pyridin-4-yl; 2H-indazol-4-yl; 2,3-dihydro-1H-pyrido[2, 3-b][1,4]oxazin-7-yl; 1H-pyrazolo[3,4-b]pyridin-5-yl; 2H-pyrazolo[3,4-b]pyridin-5-yl; 3H-imidazo[4,5-b]pyridin-6-yl; imidazo[1,2-b]pyridazin-6-yl; quinolin-4-yl; benzo[b]thiophen-5-yl; chroman-6-yl; 1-oxo-1,3-dihydroisobenzofuran-5-yl; 1,1-dioxo-2,3-dihydrobenzo[b]thiophen-5-yl; 1,1-dioxothiochroman-6-yl; benzofuran-5-yl; or benzo[d][1,3]dioxol-5-yl.

[0131] In some embodiments, R 1phenyl; 3-oxo-2,3-dihydrobenzofuran-5-yl; 2,3-dihydrobenzofuran-5-yl; 2,3-dihydrofuro[2,3-b]pyridin-5-yl; 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; chroman-6-yl; 3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl; 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin- 6-yl; furo[2,3-b]pyridin-5-yl; 2,3-dihydrobenzofuran-5-yl; benzo[b]thiophen-5-yl; chroman-6-yl; 1-oxo-1,3-dihydroisobenzofuran-5-yl; 1,1-dioxo-2,3-dihydrobenzo[b]thiophen-5-yl; 1,1-dioxothiochroman-6-yl; benzofuran-5-yl; or benzo[d][1,3]dioxol-5-yl.

[0132] In some embodiments, m is an integer from 0 to 4. In some embodiments, m is from 0 to 3. In some embodiments, m is from 0 to 2. In some embodiments, m is from 0 to 1. In some embodiments, m is 0, 1, 2, 3, or 4. In some embodiments, m is from 1 to 4. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.

[0133] In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted alkoxy, optionally R 5 Substituted alkylamino, optionally R 5 Substituted dialkylamino, SO2R 8a , alkylthio, haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl and haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents taken together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy, or alkoxyalkyl.

[0134] In some embodiments, each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl, and haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents taken together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy, or alkoxyalkyl.

[0135] In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C6 alkylamino, optionally R 5 Substituted di-(C1-C6 alkyl)-amino, SO2R 8a , C1-C6 alkylthio, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents taken together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C6 alkoxy)-C1-C6 alkyl.

[0136] In some embodiments, each R 4 Independently selected from optionally R 5 Substituted C1-C6 alkoxy, SO2R 8a , C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents taken together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C6 alkoxy)-C1-C6 alkyl.

[0137] In some embodiments, each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl, and haloalkyl. In some embodiments, each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl, and haloalkyl. In some embodiments, each R 4 are independently selected from alkoxy, haloalkoxy and halo.

[0138] In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5Substituted C1-C6 alkylamino, optionally R 5 Substituted di-(C1-C6 alkyl)-amino, SO2R 8a , C1-C6 alkylthio, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl. In some embodiments, each R 4 Independently selected from optionally R 5 Substituted C1-C6 alkoxy, SO2R 8a , C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl. In some embodiments, each R 4 In some embodiments, each R 4 Independently selected from C1-C6 alkoxy, C1-C6 haloalkoxy, F and Cl.

[0139] In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C4 alkylamino, optionally R 5 Substituted di-(C1-C4 alkyl)-amino, SO2R 8a , C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl. In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C4 alkylamino, optionally R 5 Substituted di-(C1-C4 alkyl)-amino, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl. In some embodiments, each R 4 In some embodiments, each R 4 Independently selected from: C1-C6 alkoxy, C1-C4 haloalkoxy and halo.

[0140] In some embodiments, when an R 4 SO2R 8a When R8a is selected from C1-C6 alkyl, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)-amino. In some embodiments, when one R 4 SO2R 8a When R 8a In some embodiments, when one R 4 SO2R 8a When R 8a Selected from -CH3, -NH2, -NH(CH3) and -N(CH3)2.

[0141] In some embodiments, or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy, or alkoxyalkyl. 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or a fused heteroaryl.

[0142] In some embodiments, R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C6 alkoxy)-C1-C6 alkyl. In some embodiments, R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C4 alkoxy)-C1-C6 alkyl. In some embodiments, R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused 5-membered heterocycloalkyl containing 1 or 2 O atoms or a fused 5-membered heteroaryl containing 1 O atom and 0 or 1 N atoms, either of which may be optionally substituted with one or more C1-C4 alkyl, halo, C1-C4 alkoxy, or (C1-C4 alkoxy)-C1-C4 alkyl. In some embodiments, R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused dioxolane or fused furan ring, either of which may be optionally substituted with one or more C1-C4 alkyl, halo, C1-C4 alkoxy, or (C1-C4 alkoxy)-C1-C4 alkyl. In some embodiments, R 1Two R on adjacent carbon atoms 4 The substituents together form a fused 5-membered heterocycloalkyl containing 1 or 2 O atoms or a fused 5-membered heteroaryl containing 1 O atom and 0 or 1 N atoms. In some embodiments, R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused dioxolane ring or a fused furan ring.

[0143] In some embodiments, R 1 is phenyl, and R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C6 alkoxy)-C1-C6 alkyl. In some embodiments, R 1 is phenyl, and R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C4 alkoxy)-C1-C6 alkyl. In some embodiments, R 1 is phenyl, and R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused 5-membered heterocycloalkyl containing 1 or 2 O atoms or a fused 5-membered heteroaryl containing 1 O atom and 0 or 1 N atoms, either of which may be optionally substituted with one or more C1-C4 alkyl, halo, C1-C4 alkoxy, or (C1-C4 alkoxy)-C1-C4 alkyl. In some embodiments, R 1 is phenyl, and R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused dioxolane or fused furan ring, either of which may be optionally substituted with one or more C1-C4 alkyl, halo, C1-C4 alkoxy, or (C1-C4 alkoxy)-C1-C4 alkyl. In some embodiments, R 1 is phenyl, and R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused 5-membered heterocycloalkyl containing 1 or 2 O atoms or a fused 5-membered heteroaryl containing 1 O atom and 0 or 1 N atoms. In some embodiments, R 1 is phenyl, and R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused dioxolane ring or a fused furan ring.

[0144] In some embodiments, each R 5 In some embodiments, each R 5 In some embodiments, each R 5 is selected from alkoxy, amino, alkylamino and dialkylamino.

[0145] In some embodiments, each R 5 In some embodiments, each R 5 In some embodiments, each R 5 Independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)-amino and C1-C6 haloalkoxy.

[0146] In some embodiments, each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl, and haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy or alkoxyalkyl; each R 5 are independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino and haloalkoxy; and m is an integer from 0 to 3.

[0147] In some embodiments, each R 4 are independently selected from alkoxy, haloalkoxy and halo; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl; and m is an integer from 0 to 3.

[0148] In some embodiments, each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a, haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl, and haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy or alkoxyalkyl; each R 5 are independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino and haloalkoxy; and m is an integer from 0 to 3.

[0149] In some embodiments, each R 4 are independently selected from alkoxy, haloalkoxy and halo; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl; and m is an integer from 0 to 3.

[0150] In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy and halo; or R 1 Two R on adjacent carbon atoms 4 The substituents taken together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy, or alkoxyalkyl.

[0151] In some embodiments, each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a and halogenated; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or a fused heteroaryl.

[0152] In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C6 alkylamino, optionally R 5 Substituted di-(C1-C6 alkyl)-amino, SO2R 8a , C1-C6 alkylthio, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl; or R 1 Two R on adjacent carbon atoms 4The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C6 alkoxy)-C1-C6 alkyl; and each R 5 Independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C6 alkylamino, di-C1-C6 alkylamino, C1-C6 haloalkoxy and (C1-C6 alkoxy)-C1-C6 alkoxy.

[0153] In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C4 alkylamino, optionally R 5 Substituted di-(C1-C4 alkyl)-amino, SO2R 8a , C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C4 alkoxy)-C1-C6 alkyl; and each R 5 Independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)-amino, C1-C6 haloalkoxy and (C1-C4 alkoxy)-C1-C6 alkoxy.

[0154] In some embodiments, each R 4 Independently selected from: optionally through R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy and halo; or two R 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more alkyl, halo, oxo, alkyl, or alkoxyalkyl. 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a and halogenated; or two R 4 The substituents together form a fused heterocycloalkyl or heteroaryl. In some embodiments, R 4 It is an alkoxy group.

[0155] In some embodiments, R 3is selected from the group consisting of: alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, and cycloalkoxyalkyl, optionally substituted with SO2-alkyl. 3 is selected from alkyl, alkoxyalkyl, haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, and cycloalkoxyalkyl optionally substituted with SO2-alkyl. 3 is selected from the group consisting of alkyl, alkoxyalkyl, haloalkyl, and haloalkoxyalkyl. 3 In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 is selected from the group consisting of optionally SO2-alkyl-substituted alkyl, haloalkyl, haloalkoxyalkyl, cycloalkylalkyl and cycloalkoxyalkyl.

[0156] In some embodiments, R 3 is selected from the group consisting of: C1-C6 alkyl optionally substituted with SO2-(C1-C6 alkyl), (C1-C6 alkoxy)-C1-C6 alkyl, (C1-C6 alkoxy)-(C1-C6 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, (C1-C6 haloalkoxy)-C1-C6 alkyl, (C3-C6 cycloalkyl)-C1-C6 alkyl, and (C3-C6 cycloalkyloxy)-C1-C6 alkyl. In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, (C1-C4 haloalkoxy)-C1-C6 alkyl, (C3-C6 cycloalkyl)-C1-C6 alkyl and (C3-C6 cycloalkyloxy)-C1-C6 alkyl. In some embodiments, R 3 In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C1-C6 alkyl and (C1-C4 haloalkoxy)-C1-C6 alkyl. In some embodiments, R 3 In some embodiments, R 3 is a C1-C6 alkyl group. In some embodiments, R 3 is a C1-C6 haloalkyl group. In some embodiments, R 3is (C1-C4 haloalkoxy)-C1-C6 alkyl. In some embodiments, R 3 for -CH2CH2CH3, -CH2CH2CH2CH3, -CH2CH2CH2CH2CH3, -CH2CH2CH2F, -CH2CH2CH2CH2F, -CH2CH2CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CH2CHF2, -CH2CH2CH2CH2 CHF2, -CH2CH2CF3, -CH2CH2CH2CF3, -CH2CH2CH2CH2CF3, -CH2CH2CF2CF3, -CH2CH2CF2CH3, -CH2CH2CH2CHF2, -CH2CF2CH2CH3, -CH2OCH3, -CH2OCH2CH3, -CH In some embodiments, R 3 for -CH2CH2CH3, -CH2CH2CH2CH3, -CH2CH2CH2CH2CH3, -CH2CH2CH2F, -CH2CH2CH2CH2F, -CH2CH2CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CH2CHF2, -CH2CH2CH2CH2CHF2, -CH2CH2CF3, -CH2C H2CH2CF3, -CH2CH2CH2CH2CF3, -CH2CH2CF2CF3, -CH2CH2CF2CH3, -CH2CH2CH2CHF2, -CH2CF2CH2CH3, -CH2CH2CH2OCH3, -CH2CH2CH2CH2OCH3, -CH2CH2CH2OCF3, or -CH2CH2CH2CH2OCF3.

[0157] In some embodiments, R 2 is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which may be optionally substituted with one or more R 6 In some embodiments, R 2is a monocyclic or bicyclic heterocycloalkyl group, any of which may be optionally substituted with one or more R 6 In some embodiments, R 2 is a monocyclic or bicyclic heteroaryl group, any of which may be optionally substituted with one or more R 6 replace.

[0158] In some embodiments, R 2 is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which may be optionally substituted by one to three R 6 In some embodiments, R 2 is a monocyclic or bicyclic heterocycloalkyl group, which may be optionally substituted by one to three R 6 In some embodiments, R 2 is a monocyclic or bicyclic heteroaryl group, which may be optionally substituted by one to three R 6 replace.

[0159] In some embodiments, R 2 is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which may be optionally substituted by one or two R 6 In some embodiments, R 2 is a monocyclic or bicyclic heterocycloalkyl group, which may be optionally substituted by one or two R 6 In some embodiments, R 2 is a monocyclic or bicyclic heteroaryl group, which may be optionally substituted by one or two R 6 replace.

[0160] In some embodiments, R 2 is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which is substituted by one R 6 In some embodiments, R 2 is a monocyclic or bicyclic heterocycloalkyl group, which is 6 In some embodiments, R 2 is a monocyclic or bicyclic heteroaryl group, which is 6 replace.

[0161] In some embodiments, R 2 is a monocyclic or bicyclic heterocycloalkyl group, which is 6 In some embodiments, R 2 is a monocyclic heterocycloalkyl, a fused bicyclic heterocycloalkyl, a bridged bicyclic heterocycloalkyl or a spiro bicyclic heterocycloalkyl, any of which is substituted by one R 6 replace.

[0162] In some embodiments, R 2 For an R 6 In some embodiments, R 2is a monocyclic heterocycloalkyl group, which is 6 substituted, wherein the heterocycloalkyl group is a 3, 4, 5, or 6-membered ring and contains 0-2 N atoms, 0-2 O atoms, and 0-1 S atoms in the ring. In some embodiments, R 2 is a monocyclic heterocycloalkyl group, which is 6 substituted, wherein the heterocycloalkyl group is a 3, 4, 5, or 6-membered ring and contains 1-2 N atoms, 0-2 O atoms, and 0-1 S atoms in the ring. In some embodiments, R 2 is aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl, any of which is substituted by one R 6 In some embodiments, R 2 is aziridinyl, azetidinyl, pyrrolidinyl or piperidinyl, any of which is substituted by one R 6 In some embodiments, R 2 is pyrrolidinyl or piperidinyl, any of which is substituted by one R 6 In some embodiments, R 2 For an R 6 In some embodiments, R 2 For an R 6 Substituted piperidinyl.

[0163] In some embodiments, R 2 is a fused bicyclic heterocycloalkyl, a bridged bicyclic heterocycloalkyl or a spiro bicyclic heterocycloalkyl, any of which is fused through one R 6 replace.

[0164] In some embodiments, each R 6 independently selected from hydroxy, hydroxyalkoxy, carboxyl, methylcarboxyl, carboxylalkyl, carboxylalkoxy, halo, alkyl, alkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, cyano and tetrazolyl. In some embodiments, each R 6 independently selected from hydroxy, carboxyl, carboxylalkyl, carboxylalkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl and tetrazolyl. In some embodiments, R 6 Selected from carboxyl, carboxylalkyl, C(=O)NHSO2R 8b , heterocycloalkyl and tetrazolyl. In some embodiments, R 6 is selected from carboxyl, carboxyalkyl and heterocycloalkyl.

[0165] In some embodiments, each R 6independently selected from hydroxy, hydroxyalkoxy, carboxyl, methylcarboxyl, carboxylalkyl, carboxylalkoxy, halo, alkyl, alkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, cyano and tetrazolyl. In some embodiments, each R 6 Independently selected from carboxyl, carboxylalkyl, halo, alkyl, SO2R 8b 、C(=O)NHSO2R 8b In some embodiments, each R 6 Independently selected from carboxyl, carboxylalkyl, halo, alkyl, SO2R 8b 、C(=O)NHSO2R 8b In some embodiments, R 6 It is a carboxyl group.

[0166] In some embodiments, each R 6 independently selected from -C(=O)OH, -CH2C(=O)OH, -C(=O)O-C1-C6 alkyl, -C(=O)NHSO2R 8b In some embodiments, R 6 Selected from -C(=O)OH, -CH2C(=O)OH, -C(=O)O-C1-C4 alkyl, -C(=O)NHSO2R 8b In some embodiments, R 6 It is -C(=O)OH.

[0167] In some embodiments, when an R 6 -C(=O)NHSO2R 8b When R 8b is selected from C1-C6 alkyl, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)-amino. In some embodiments, when one R 6 -C(=O)NHSO2R 8b When R 8b In some embodiments, when one R 6 -C(=O)NHSO2R 8b When R 8b Selected from -CH3, -NH2, -NH(CH3) and -N(CH3)2.

[0168] In some embodiments, R 2 For one or more R 6 Substituted monocyclic or bicyclic heterocycloalkyl; each R 6independently selected from hydroxy, carboxyl, carboxylalkyl, carboxylalkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl and tetrazolyl; and R 8b Selected from alkyl, amino, alkylamino, dialkylamino.

[0169] In some embodiments, R 2 For an R 6 Substituted monocyclic heterocycloalkyl; R 6 Selected from carboxyl, carboxylalkyl, C(=O)NHSO2R 8b , heterocycloalkyl and tetrazolyl; and R 8b Selected from alkyl, amino, alkylamino, dialkylamino.

[0170] In some embodiments, R 2 For an R 6 substituted piperidinyl; and R 6 is selected from carboxyl, carboxyalkyl and heterocycloalkyl.

[0171] In some embodiments, the compound is of formula (IV):

[0172]

[0173] or a pharmaceutically acceptable salt thereof, wherein:

[0174] m is an integer from 0 to 3;

[0175] R 2 For one or more R 6 substituted monocyclic or bicyclic heterocycloalkyl;

[0176] R 3 is selected from the group consisting of optionally SO2-alkyl-substituted alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, and cycloalkoxyalkyl;

[0177] Each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl, and haloalkyl; and

[0178] or R 1 Two R on adjacent carbon atoms 4 the substituents together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy, or alkoxyalkyl;

[0179] Each R 5independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino, and haloalkoxy;

[0180] Each R 6 independently selected from hydroxy, carboxyl, carboxylalkyl, carboxylalkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, and tetrazolyl; and

[0181] R 8b Selected from alkyl, amino, alkylamino, dialkylamino.

[0182] In some embodiments, R 2 For an R 6 Substituted monocyclic heterocycloalkyl.

[0183] In some embodiments, the compound is a compound of Formula (V) or a pharmaceutically acceptable salt thereof:

[0184]

[0185] In some embodiments,

[0186] R 3 selected from the group consisting of alkyl, alkoxyalkyl, haloalkyl and haloalkoxyalkyl;

[0187] Each R 4 independently selected from alkoxy, haloalkoxy, and halo;

[0188] or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl;

[0189] R 6 Selected from carboxyl, carboxylalkyl, C(=O)NHSO2R 8b , heterocycloalkyl, and tetrazolyl; and

[0190] R 8b Selected from alkyl, amino, alkylamino, dialkylamino.

[0191] In some embodiments,

[0192] R 3 selected from alkyl and alkoxyalkyl;

[0193] Each R 4 independently selected from alkoxy, haloalkoxy, and halo;

[0194] or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl; and

[0195] R 6 is selected from carboxyl, carboxyalkyl and heterocycloalkyl.

[0196] In some embodiments, the compound is of formula (VI):

[0197]

[0198] or a pharmaceutically acceptable salt thereof, wherein:

[0199] m is an integer from 0 to 4;

[0200] Y is N or CH;

[0201] R 3 Selected from:

[0202] C1-C6 alkyl optionally substituted with SO2-(C1-C6 alkyl),

[0203] (C1-C6 alkoxy)-C1-C6 alkyl,

[0204] (C1-C6 alkoxy)-(C1-C6 alkoxy)-C1-C6 alkyl,

[0205] C1-C6 haloalkyl,

[0206] (C1-C6 haloalkoxy)-C1-C6 alkyl,

[0207] (C3-C6 cycloalkyl)-C1-C6 alkyl, and

[0208] (C3-C6 cycloalkoxy)-C1-C6 alkyl;

[0209] Each R 4 Independently selected from:

[0210] Optionally, R 5 Substituted C1-C6 alkoxy,

[0211] Optionally, R 5 Substituted C1-C6 alkylamino,

[0212] Optionally, R 5 substituted di-(C1-C6 alkyl)-amino,

[0213] SO2R 8a ,

[0214] C1-C6 alkylthio,

[0215] C1-C6 haloalkoxy,

[0216] C3-C6 cycloalkoxy,

[0217] (C3-C6 cycloalkyl)-C1-C6 alkoxy,

[0218] Halogenated,

[0219] C1-C6 alkyl, and

[0220] C1-C6 haloalkyl;

[0221] or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C6 alkoxy)-C1-C6 alkyl;

[0222] Each R 5 independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C6 alkylamino, di-C1-C6 alkylamino, C1-C6 haloalkoxy and (C1-C6 alkoxy)-C1-C6 alkoxy;

[0223] R 6 Selected from -C(=O)OH, -CH2C(=O)OH, -C(=O)O-C1-C6 alkyl, -C(=O)NHSO2R 8b and tetrazolyl;

[0224] R 8a and R 8b Each is independently selected from C1-C6 alkyl, amino, C1-C6 alkylamino, and di-(C1-C6 alkyl)-amino.

[0225] In some embodiments, R 3 In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 is (C1-C4 alkoxy)-C3-C6 alkyl. In some embodiments, R 3 In some embodiments, Y is (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, Y is N. In some embodiments, Y is CH.

[0226] In some embodiments,

[0227] Y is N or CH;

[0228] R 3 Selected from: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, (C1-C4 haloalkoxy)-C1-C6 alkyl, (C3-C6 cycloalkyl)-C1-C6 alkyl and (C3-C6 cycloalkyloxy)-C1-C6 alkyl;

[0229] Each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C4 alkylamino, optionally R 5 Substituted di-(C1-C4 alkyl)-amino, SO2R 8a , C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl;

[0230] or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C4 alkoxy)-C1-C6 alkyl;

[0231] Each R 5 independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)-amino, C1-C6 haloalkoxy and (C1-C4 alkoxy)-C1-C6 alkoxy;

[0232] R 6 Selected from -C(=O)OH, -CH2C(=O)OH, -C(=O)O-C1-C4 alkyl, -C(=O)NHSO2R 8b and tetrazolyl;

[0233] R 8a and R 8b Each is independently selected from C1-C6 alkyl, amino, C1-C4 alkylamino, and di-(C1-C4 alkyl)-amino.

[0234] In some embodiments, R 3 In some embodiments, R 3Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 is (C1-C4 alkoxy)-C3-C6 alkyl. In some embodiments, R 3 In some embodiments, Y is (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, Y is N. In some embodiments, Y is CH.

[0235] In some embodiments, the compound is of formula (VI-1):

[0236]

[0237] or a pharmaceutically acceptable salt thereof, wherein:

[0238] m is an integer from 0 to 4;

[0239] Y is N or CH;

[0240] R 3 Selected from: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, (C1-C4 haloalkoxy)-C1-C6 alkyl, (C3-C6 cycloalkyl)-C1-C6 alkyl and (C3-C6 cycloalkyloxy)-C1-C6 alkyl;

[0241] Each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C4 alkylamino, optionally R 5 substituted di-(C1-C4 alkyl)-amino, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl;

[0242] or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused 5-membered heterocycloalkyl or a fused 5-membered heteroaryl, either of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C4 alkoxy)-C1-C6 alkyl;

[0243] Each R 5Independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)-amino, C1-C6 haloalkoxy and (C1-C4 alkoxy)-C1-C6 alkoxy.

[0244] In some embodiments, R 3 In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 is (C1-C4 alkoxy)-C3-C6 alkyl. In some embodiments, R 3 In some embodiments, Y is (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, Y is N. In some embodiments, Y is CH.

[0245] In some embodiments, the compound is of formula (VI-2):

[0246]

[0247] or a pharmaceutically acceptable salt thereof, wherein:

[0248] m is an integer from 0 to 4;

[0249] Y is N or CH;

[0250] R 3 Selected from: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl and (C1-C4 haloalkoxy)-C1-C6 alkyl;

[0251] Each R 4 Independently selected from: C1-C6 alkoxy, C1-C4 haloalkoxy, halo, C1-C4 alkyl and C1-C4 haloalkyl;

[0252] or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused 5-membered heterocycloalkyl containing 1 or 2 O atoms or a fused 5-membered heteroaryl containing 1 O atom and 0 or 1 N atoms, either of which may be optionally substituted with one or more C1-C4 alkyl, halo, C1-C4 alkoxy, or (C1-C4 alkoxy)-C1-C4 alkyl.

[0253] In some embodiments, R 3 In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 is (C1-C4 alkoxy)-C3-C6 alkyl. In some embodiments, R 3 In some embodiments, Y is (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, Y is N. In some embodiments, Y is CH.

[0254] In some embodiments, the compound is of formula (VI-3):

[0255]

[0256] or a pharmaceutically acceptable salt thereof, wherein:

[0257] m is an integer from 0 to 2;

[0258] Y is N or CH;

[0259] R 3 is selected from the group consisting of: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, and (C1-C4 haloalkoxy)-C1-C6 alkyl; and

[0260] Each R 4 Independently selected from the group consisting of: C1-C6 alkoxy, C1-C4 haloalkoxy, halo, C1-C4 alkyl and C1-C4 haloalkyl.

[0261] In some embodiments, m is 0 or 1; and R 4 Selected from: C1-C6 alkoxy, C1-C4 haloalkoxy and halo. In some embodiments, R 3 In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 is (C1-C4 alkoxy)-C3-C6 alkyl. In some embodiments, R 3 In some embodiments, Y is (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, Y is N. In some embodiments, Y is CH.

[0262] In some embodiments, the compound is of formula (VI-4):

[0263]

[0264] or a pharmaceutically acceptable salt thereof, wherein:

[0265] m is an integer from 0 to 2;

[0266] Y is N or CH;

[0267] R 3 is selected from the group consisting of: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, and (C1-C4 haloalkoxy)-C1-C6 alkyl; and

[0268] Each R 4 Independently selected from the group consisting of: C1-C6 alkoxy, C1-C4 haloalkoxy, halo, C1-C4 alkyl and C1-C4 haloalkyl.

[0269] In some embodiments, m is 0 or 1; and R 4 In some embodiments, R 3 In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, R 3 is (C1-C4 alkoxy)-C3-C6 alkyl. In some embodiments, R 3 In some embodiments, Y is (C1-C4 haloalkoxy)-C3-C6 alkyl. In some embodiments, Y is N. In some embodiments, Y is CH.

[0270] In some embodiments, the compound is of formula (I):

[0271]

[0272] or a pharmaceutically acceptable salt thereof, wherein:

[0273] m is an integer from 0 to 4;

[0274] X is selected from CH and N;

[0275] Y is selected from CH, S, O and N;

[0276] Z is selected from the key and CR 7 ;

[0277] R 1 is selected from aryl and heteroaryl,

[0278] R 2 is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which may be optionally substituted with one or more R 6 replace;

[0279] R 3 Selected from:

[0280] optionally SO2-alkyl-substituted alkyl,

[0281] Alkoxyalkyl,

[0282] haloalkyl,

[0283] Haloalkoxyalkyl,

[0284] cycloalkylalkyl, and

[0285] cycloalkoxyalkyl;

[0286] Each R 4 Independently selected from:

[0287] Optionally, R 5 Substituted alkoxy,

[0288] SO2R 8a ,

[0289] Haloalkoxy,

[0290] Cycloalkoxy,

[0291] cycloalkylalkoxy, and

[0292] Halogenated,

[0293] or two R 4 the substituents together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkyl, or alkoxyalkyl;

[0294] Each R 5 independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino, and haloalkoxy;

[0295] Each R 6 independently selected from hydroxy, hydroxyalkoxy, carboxyl, methylcarboxyl, carboxylalkyl, carboxylalkoxy, halo, alkyl, alkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, cyano, and tetrazolyl;

[0296] R 7 is selected from hydrogen and halo; and

[0297] R 8a and R 8b each independently selected from alkyl, amino, alkylamino, and dialkylamino;

[0298] Where X and Y are not both CH.

[0299] In some embodiments, the compound is of formula (II):

[0300]

[0301] or a pharmaceutically acceptable salt thereof, wherein:

[0302] m is an integer from 0 to 3;

[0303] R 2 is optionally through one or more R 6 substituted monocyclic or bicyclic heterocycloalkyl;

[0304] Each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a and halogenated, or two R 4 The substituents together form a fused heterocycloalkyl or heteroaryl group;

[0305] R 5 Selected from alkoxy, amino, alkylamino, dialkylamino;

[0306] Each R 6 Independently selected from carboxyl, carboxylalkyl, halo, alkyl, SO2R 8b 、C(=O)NHSO2R 8b and tetrazolyl; and

[0307] R 8a and R 8b Each is independently selected from alkyl, amino, alkylamino, and dialkylamino.

[0308] In some embodiments, the compound is of formula (III):

[0309]

[0310] or a pharmaceutically acceptable salt thereof, wherein:

[0311] m is an integer from 0 to 3;

[0312] Each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a and halogenated, or two R 4 The substituents together form a fused heterocycloalkyl or heteroaryl group;

[0313] R 5 Selected from alkoxy, amino, alkylamino, dialkylamino;

[0314] R 6 Selected from carboxyl, carboxylalkyl, halo, alkyl, SO2R 8b 、C(=O)NHSO2R 8b and tetrazolyl; and

[0315] R 8a and R 8b Each is independently selected from alkyl, amino, alkylamino, and dialkylamino.

[0316] Also provided are embodiments wherein any of the above embodiments can be combined with any one or more of these embodiments, provided that the combinations are not mutually exclusive.

[0317] As used herein, two embodiments are "mutually exclusive" when one embodiment is defined as something different from the other. For example, an embodiment in which two groups combine to form a cycloalkyl is mutually exclusive with an embodiment in which one group is ethyl and the other group is hydrogen. Similarly, an embodiment in which one group is CH2 is mutually exclusive with an embodiment in which the same group is NH.

[0318] That is, any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are selected by one skilled in the art to provide stable moieties and compounds.

[0319] Exemplary compounds of the present invention include those described in the following table:

[0320] Table 1:

[0321]

[0322]

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338]

[0339]

[0340]

[0341]

[0342]

[0343]

[0344]

[0345]

[0346]

[0347]

[0348]

[0349]

[0350]

[0351]

[0352]

[0353]

[0354]

[0355]

[0356]

[0357]

[0358]

[0359]

[0360]

[0361]

[0362] In some embodiments, the compound is a pharmaceutically acceptable salt of a compound described in Table 1.

[0363] Also provided herein are compounds selected from the examples disclosed herein.

[0364] definition

[0365] As used herein, the following terms have the indicated meanings.

[0366] When a range of values ​​is disclosed and the notation "n1 ... to n2" or "between n1 ... and n2" is used, where n1 and n2 are numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range therebetween. Such ranges can be integers or continuous between and including the endpoints. For example, a range of "2 to 6 carbons" is intended to include two, three, four, five, and six carbons, since carbons appear in integer units. For example, compare the range "1 to 3 μM (micromolar)" (which is intended to include 1 μM, 3 μM, and any number in between) with any number of significant figures (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).

[0367] As used herein, the term "about" is intended to qualify the numerical value it modifies, expressing the value as a variable within a range. When a specific range is not recited (such as the margin of error or standard deviation of the mean value given in a data graph or data table), the term "about" should be understood to mean the range that will encompass the recited value and the range that would be included by rounding the number up or down (taking into account significant figures) and the larger of the range that will encompass ±20% of the recited value.

[0368] As used herein, alone or in combination, the term "acyl" refers to a carbonyl group attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety wherein the atom attached to the carbonyl is carbon. An "acetyl" group refers to a -C(=O)CH3 group. An "alkylcarbonyl" or "alkanoyl" group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl, and aroyl.

[0369] As used herein, alone or in combination, the term "alkenyl" refers to a straight or branched hydrocarbon group having one or more double bonds and containing 2 to 20 carbon atoms. In certain embodiments, the alkenyl group will contain 2 to 6 carbon atoms. The term "alkenylene" refers to a carbon-carbon double bond system attached at two or more positions, such as vinylene [(-CH=CH-), (-C::C-)]. Examples of suitable alkenyl groups include vinyl, propenyl, 2-methylpropenyl, 1,4-butadienyl, etc. Unless otherwise specified, the term "alkenyl" may include "alkenylene". In one embodiment, the alkenyl group has the formula -C (R) = CR2, wherein R refers to the rest of the alkenyl group, which may be the same or different. In some embodiments, R is H or an alkyl group. In some embodiments, the alkenyl group is selected from ethenyl (i.e., vinyl (vinyl)), propenyl (i.e., allyl (allyl)), butenyl, pentenyl, pentadienyl, etc. Non-limiting examples of alkenyl groups include -CH=CH2, -C(CH3)=CH2, -CH=CHCH3, -C(CH3)=CHCH3, and -CH2CH=CH2.

[0370]

[0046] The term "alkylene," as used herein, alone or in combination, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the portion to which the alkenyl group is attached.

[0371] As used herein, alone or in combination, the term "alkoxy" refers to an alkyl ether radical, wherein the term alkyl is as defined below. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, and the like. In some embodiments, alkoxy refers to an (alkyl)-O- group, wherein alkyl is as defined herein. In some embodiments, alkoxy is a C1-C6 alkoxy radical, which refers to a (C1-C6 alkyl)-O- group.

[0372] "Alkyl" refers to an aliphatic hydrocarbon group. As used herein, alone or in combination, the term "alkyl" refers to a straight or branched chain alkyl group containing 1 to 20 carbon atoms. In certain embodiments, the alkyl group will contain 1 to 10 carbon atoms. In other embodiments, the alkyl group will contain 1 to 8 carbon atoms. The alkyl group may optionally be substituted as defined herein. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, octyl, nonyl, etc. In some embodiments, the alkyl group is a C1-C6 alkyl group. In one aspect, the alkyl group is a methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl group. As used herein, alone or in combination, the term "alkylene" refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached to two or more positions, such as a methylene group (-CH2-). In some embodiments, the alkylene group is a C1-C6 alkylene group. In other embodiments, the alkylene group is a C1-C4 alkylene group. Typical alkylene groups include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc. In some embodiments, the alkylene group is -CH2-. Unless otherwise specified, the term "alkyl" may include "alkylene".

[0373] "Alkoxyalkyl" refers to an alkyl group, as defined herein, in which one hydrogen atom is replaced by an alkoxy group. In some embodiments, the alkoxyalkyl group is a (C1-C6 alkoxy)-C1-C6 alkyl group, which may also be viewed as a (C1-C6 alkyl)-O-(C1-C6 alkyl)-group. In some embodiments, the alkoxyalkyl group is a (C1-C4 alkoxy)-C1-C6 alkyl group, which may also be viewed as a (C1-C4 alkyl)-O-(C1-C6 alkyl)-group. Typical alkoxyalkyl groups include, but are not limited to, -CH2OCH3, -CH2CH2OCH3, -CH2CH2CH2OCH3, -CH2CH2CH2OCH3, -CH2OCH2CH3, -CH2CH2OCH2CH3, -CH2CH2CH2OCH2CH3, -CH2CH2CH2OCH2CH3, and the like.

[0374] "Alkoxyalkoxyalkyl" refers to an alkoxyalkyl group, as defined herein, in which one of the hydrogen atoms of the alkoxy group is replaced by a second alkoxy group. In some embodiments, the alkoxyalkoxyalkyl group is a (C1-C6 alkoxy)-(C1-C6 alkoxy)-C1-C6 alkyl group, which can also be viewed as a (C1-C6 alkyl)-O-(C1-C6 alkyl)-O-(C1-C6 alkyl)-group. In some embodiments, the alkoxyalkoxyalkyl group is a (C1-C4 alkoxy)-(C1-C4 alkoxy)-C1-C6 alkyl group, which can also be viewed as a (C1-C4 alkyl)-O-(C1-C4 alkyl)-O-(C1-C6 alkyl)-group. Typical alkoxyalkoxyalkyl groups include, but are not limited to, -CH2OCH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH2CH2CH2OCH2CH2OCH3, -CH2CH2CH2OCH2CH2OCH3, -CH2OCH2CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH2CH2CH2OCH2CH2OCH3, -CH2CH2CH2OCH2CH2OCH3, -CH2OCH2CH2OCH2CH2OCH3, -CH2CH2OCH2CH2OCH2CH3, -CH2OCH2CH2OCH2CH3, -CH2CH2OCH2CH2OCH2CH3, -CH2CH2OCH2CH2OCH2CH3, -CH2CH2OCH2CH2OCH2CH3, -CH2CH2OCH2CH2OCH2CH3, -CH2CH2OCH2CH2OCH2CH3 , -CH2CH2CH2OCH2CH2CH2OCH2CH3, -CH2CH2CH2CH2OCH2CH2CH2OCH2CH3, etc.

[0375] "Alkoxyalkoxy" refers to an alkoxy group, as defined herein, in which one of the hydrogen atoms is replaced by an alkoxy group. In some embodiments, the alkoxyalkoxy group is a (C1-C6 alkoxy)-C1-C6 alkoxy group, which may also be viewed as a (C1-C6 alkyl)-O-(C1-C6 alkyl)-O- group. In some embodiments, the alkoxyalkyl group is a (C1-C4 alkoxy)-C1-C6 alkoxy group, which may also be viewed as a (C1-C4 alkyl)-O-(C1-C6 alkyl)-O- group. Typical alkoxyalkyl groups include, but are not limited to, -OCH2CH2OCH3, -OCH2CH2CH2OCH3, -OCH2CH2CH2CH2OCH3, -OCH2OCH2CH3, -OCH2CH2OCH2CH3, -OCH2CH2OCH2CH3, -OCH2CH2CH2OCH2CH3, and the like.

[0376] As used herein, alone or in combination, the term "amino" refers to -NRR', wherein R and R' are independently selected from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which itself may be optionally substituted. Additionally, R and R' may combine to form heterocycloalkyl, any of which may be optionally substituted. In one aspect, as used herein, "amino" refers to a -NH2 group.

[0377] As used herein, alone or in combination, the term "alkylamino" refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups can be monoalkylated or dialkylated to form groups such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino, and the like. In some embodiments, the term "alkylamino" refers to -N(alkyl) x H y In some embodiments, the term "alkylamino" refers to an -NH(alkyl) group, and the term "dialkylamino" refers to an N(alkyl) group. In some embodiments, the alkylamino group is a C1-C6 alkylamino group, which refers to an -NH(C1-C6 alkyl) group. In some embodiments, the dialkylamino group is a di-(C1-C6 alkyl)-amino group, which refers to an -N(C1-C6 alkyl) group.

[0378] As used herein, alone or in combination, the term "alkylthio" refers to an alkylthioether (RS-) group, wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized. Examples of suitable alkylthioether groups include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, methylsulfonyl, ethylsulfinyl, and the like. In some embodiments, the term "alkylthio" refers to an -S-(alkyl) group. In some embodiments, an alkylthio group is a C1-C6 alkylthio group, which refers to an -S-(C1-C6 alkyl) group.

[0379] As used herein, alone or in combination, the term "alkynyl" refers to a straight or branched hydrocarbon group having one or more triple bonds and containing 2 to 20 carbon atoms. In certain embodiments, the alkynyl group comprises 2 to 6 carbon atoms. In other embodiments, the alkynyl group comprises 2 to 4 carbon atoms. In one embodiment, the alkynyl group has the formula -C≡CR, wherein R refers to the remainder of the alkynyl group. In some embodiments, R is H or an alkyl group. In some embodiments, the alkynyl group is selected from ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH3, -C≡CCH2CH3, -CH2C≡CH. The term "alkynylene" refers to a carbon-carbon triple bond (-C:::C-, -C≡C-) attached to two positions such as ethynylene. Examples of alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, etc. Unless otherwise specified, the term "alkynyl" may include "alkynylene".

[0380] As used herein, alone or in combination, the terms "amido" and "carbamyl" refer to an amino group attached to the parent molecular moiety through a carbonyl group, or vice versa, as described below. As used herein, alone or in combination, the term "C-amido" refers to a -C(=O)N(RR') group having R and R' as defined herein or as indicated by a specifically enumerated "R" group. As used herein, alone or in combination, the term "N-amido" refers to a RC(=O)N(R')- group having R and R' as defined herein or as indicated by a specifically enumerated "R" group. As used herein, alone or in combination, the term "amido" encompasses an acyl group attached to the parent moiety through an amino group. An example of an "amido" group is acetamido (CH3C(=O)NH-).

[0381] The term "aromatic" refers to a planar ring having a delocalized π electron system containing 4n+2 π electrons, where n is an integer. The term "aromatic" includes both carbocyclic aromatic ("aryl," e.g., phenyl) and heterocyclic aromatic (or "heteroaryl" or "heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings that share adjacent pairs of carbon atoms) groups.

[0382] The term "carbocyclic" or "carbocycle" refers to a ring or ring system in which the atoms forming the backbone of the ring are all carbon atoms. This term thus distinguishes carbocycle from a "heterocyclic" ring or "heterocycle" in which the ring backbone contains at least one atom other than carbon. In some embodiments, at least one of the two rings of a bicyclic carbocycle is aromatic. In some embodiments, both rings of a bicyclic carbocycle are aromatic. Carbocycles include aryl and cycloalkyl groups.

[0383] As used herein, alone or in combination, the term "aryl" means a carbocyclic aromatic system containing one, two, or three rings, wherein such polycyclic systems are fused together. The term "aryl" encompasses aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthrenyl. In one aspect, aryl is phenyl or naphthyl. In some embodiments, aryl is phenyl. In some embodiments, aryl is phenyl, naphthyl, indanyl, indenyl, or tetrahydronaphthyl. In some embodiments, aryl is C6-C 10 Depending on the structure, an aryl group is a monoradical or a diradical (ie, an arylene group).

[0384]

[0066] The term "arylalkenyl" or "aralkenyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.

[0385]

[0066] The term "arylalkoxy" or "aralkoxy," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.

[0386]

[0046] The term "arylalkyl" or "aralkyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.

[0387]

[0066] The term "arylalkynyl" or "aralkynyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.

[0388] The term "arylalkanoyl" or "aralkanoyl" or "aroyl," as used herein, alone or in combination, refers to an acyl group derived from an aryl-substituted alkanoic acid, such as benzoyl, naphthoyl, phenylacetyl, 3-phenylpropionyl(hydrocinnamoyl), 4-phenylbutanoyl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.

[0389] As used herein, alone or in combination, the term aryloxy refers to an aryl group attached to the parent molecular moiety through an oxy group. In some embodiments, as used herein, aryloxy refers to an aryl-O- group. In some embodiments, aryloxy is a phenoxy or phenyl-O- group.

[0390] As used herein, the term "benzo" refers to a fused bicyclic or polycyclic ring system with benzene as one of the rings. Examples include benzofuran, benzothiophene, and benzimidazole.

[0391] As used herein, alone or in combination, the term "cycloalkyl" refers to a saturated or partially saturated monocyclic, bicyclic, or tricyclic alkyl group, wherein each cyclic moiety contains 3 to 12 carbon atom ring members and which may optionally be a benzo-fused ring system that is optionally substituted as defined herein. In some embodiments, cycloalkyl groups include groups having 3 to 10 ring atoms. In certain embodiments, the cycloalkyl group will contain 5 to 7 carbon atoms. In certain embodiments, the cycloalkyl group will contain 3 to 6 carbon atoms. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl, and the like. As used herein, "bicyclic" and "tricyclic" are intended to include both fused ring systems (such as decahydronaphthalene, octahydronaphthalene) and polycyclic (multi-center) saturated or partially unsaturated types. The latter isomers are generally exemplified by bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane. In some embodiments, the cycloalkyl group is a C3-C6 cycloalkyl group. In some embodiments, the cycloalkyl group is a C3-C4 cycloalkyl group.

[0392] As used herein, alone or in combination, the term "cycloalkyloxy" refers to a cycloalkyl group attached to a parent molecule through an oxy group. In some embodiments, the cycloalkyloxy group is a C3-C6 cycloalkyloxy group, which refers to a (C3-C6 cycloalkyl)-O- group.

[0393] "Cycloalkylalkyl" refers to an alkyl group as defined herein in which one hydrogen atom is replaced by a cycloalkyl group. In some embodiments, the cycloalkylalkyl group is (C3-C6 cycloalkyl)-C1-C6 alkyl.

[0394] "Cycloalkoxyalkyl" refers to an alkyl group, as defined herein, in which one hydrogen atom is replaced by a cycloalkoxy group. In some embodiments, the cycloalkoxyalkyl group is (C3-C6 cycloalkoxy)-C1-C6 alkyl, which refers to a (C3-C6 cycloalkyl)-O-(C1-C6 alkyl)-group.

[0395] "Cycloalkylalkoxy" refers to an alkoxy group, as defined herein, in which one hydrogen atom is replaced by a cycloalkyl group. In some embodiments, cycloalkylalkoxy is (C3-C6 cycloalkyl)-C1-C6 alkoxy, which refers to a (C3-C6 cycloalkyl)-(C1-C6 alkyl)-O- group.

[0396] The term "heterocycle" or "heterocyclic" refers to heteroaromatic rings (also referred to as heteroaryl) and heterocycloalkyl rings containing one to four heteroatoms in the ring, wherein each heteroatom in the ring is selected from O, S, and N, wherein each heterocyclyl has 3 to 10 atoms in its ring system, and provided that any ring does not contain two adjacent O or S atoms. Non-aromatic heterocyclyls (also referred to as heterocycloalkyls) include rings having 3 to 10 atoms in their ring system, and aromatic heterocyclyls include rings having 5 to 10 atoms in their ring system. Heterocyclic groups include benzo-fused ring systems. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, oxazolidinone, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thiooxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolemorpholinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolane, pyrazomorpholinyl, dioxol ... Thianyl, dithiolanyl (dithiolanyl), dihydropyranyl, dihydrothiophenyl, dihydrofuranyl, pyrazolidinyl, imidazomorpholinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, 3H-indolyl, indolin-2-onyl, isoindolin-1-onyl, isoindolin-1,3-dionyl, 3,4-dihydroisoquinolin-1(2H)-onyl, 3,4-dihydroquinolin-2(1H)-onyl, isoindolin-1,3-disulfinyl, benzo[d]oxazol-2(3H)-onyl, 1H-benzo[d]imidazol-2(3H)-onyl, benzo[d]thiazol-2(3H)-onyl and quinolizinyl. Examples of aromatic heterocyclic groups are pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, pyrazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, The aforementioned groups are C-attached (or C-linked) or N-attached where possible. For example, groups derived from pyrrole include both pyrrole-1-yl (N-attached) and pyrrole-3-yl (C-attached). In addition, groups derived from imidazole include imidazol-1-yl or imidazol-3-yl (all N-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-attached). Heterocyclic groups include benzo-fused ring systems. Non-aromatic heterocycles are optionally substituted with one or two oxo (=O) moieties, such as pyrrolidin-2-one. In some embodiments, at least one of the two rings of the bicyclic heterocycle is aromatic. In some embodiments, both rings of the bicyclic heterocycle are aromatic.

[0397] The term "heteroaryl" or alternatively "heteroaromatic" refers to an aromatic group that includes one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, as used herein alone or in combination, the term "heteroaryl" refers to a 3- to 15-membered unsaturated heteromonocyclic ring or a fused monocyclic, bicyclic, or tricyclic ring system containing at least one atom selected from N, O, and S, wherein at least one of the fused rings is an aromatic ring. In certain embodiments, the heteroaryl group will contain 1 to 4 heteroatoms as ring members. In other embodiments, the heteroaryl group will contain 1 to 2 heteroatoms as ring members. In certain embodiments, the heteroaryl group will contain 5 to 7 atoms. The term also encompasses fused polycyclic groups in which a heterocyclic ring is fused to an aryl ring, in which a heteroaryl ring is fused to another heteroaryl ring, in which a heteroaryl ring is fused to a heterocycloalkyl ring, or in which a heteroaryl ring is fused to a cycloalkyl ring. Examples of heteroaryl groups include pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, triazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuranyl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl, and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzindolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, quinazolyl ...

[0398] "Heterocycloalkyl" refers to a cycloalkyl group comprising at least one heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, as used herein alone or in combination, the term "heterocycloalkyl" refers to a saturated, partially unsaturated, or fully unsaturated (but non-aromatic) monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each of the heteroatoms can be independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, the heterocycloalkyl group will contain 1 to 4 heteroatoms as ring members. In other embodiments, the heterocycloalkyl group will contain 1 to 2 heteroatoms as ring members. In certain embodiments, the heterocycloalkyl group will contain 3 to 8 ring members in each ring. In other embodiments, the heterocycloalkyl group will contain 3 to 7 ring members in each ring. In other embodiments, the heterocycloalkyl group will contain 5 to 6 ring members in each ring. "Heterocycloalkyl" and "heterocycle" are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic and benzofused ring systems; in addition, both terms also include systems in which a heterocycle is fused to an aryl group as defined herein, or an additional heterocyclic group. Examples of heterocyclic groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinomorpholinyl, dihydro 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolane, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. Unless specifically prohibited, heterocyclyl groups may be optionally substituted. In one aspect, heterocyclyl is C2-C 10 In another aspect, the heterocycloalkyl group is C4-C 10 Heterocycloalkyl. In some embodiments, the heterocycloalkyl is a monocyclic or bicyclic ring. In some embodiments, the heterocycloalkyl is a monocyclic ring with 3, 4, 5, 6, 7, or 8 members. In some embodiments, the heterocycloalkyl is a monocyclic ring with 3, 4, 5, or 6 members. In some embodiments, the heterocycloalkyl is a monocyclic ring with 3 or 4 members. In some embodiments, the heterocycloalkyl contains 0-2 N atoms in the ring. In some embodiments, the heterocycloalkyl contains 0-2 N atoms, 0-2 O atoms, and 0-1 S atoms in the ring.

[0399] The term "carbamate," as used herein, alone or in combination, refers to an ester of carbamic acid (-NHCOO-), which can be attached to the parent molecular moiety from either the nitrogen or the acid terminus, and which can be optionally substituted as defined herein.

[0400] The term "O-carbamyl," as used herein, alone or in combination, refers to a -OC(=O)NRR' group, where R and R' are as defined herein.

[0401] The term "N-carbamyl," as used herein, alone or in combination, refers to a ROC(=O)NR'- group, where R and R' are as defined herein.

[0402] As used herein, the term "carbonyl" includes formyl [-C(=O)H] when used alone and in combination as a -C(=O)- group.

[0403] As used herein, the term "carboxyl" or "carboxy" refers to -C(=O)OH or the corresponding "carboxylate" anion, such as in a carboxylate salt. "O-carboxyl" refers to a RC(=O)O- group, where R is as defined herein. "C-carboxyl" refers to a -C(=O)OR group, where R is as defined herein.

[0404]

[0046] The term "cyano," as used herein, alone or in combination, refers to -CN.

[0405]

[00146] The term "ester," as used herein, alone or in combination, refers to a carboxyl group bridging two moieties linked at carbon atoms.

[0406]

[0066] The term "ether," as used herein, alone or in combination, refers to an oxy group bridging two moieties attached at carbon atoms.

[0407] As used herein, the term "halo" or "halogen," alone or in combination, refers to fluoro, chloro, bromo, or iodo. In some embodiments, halo is fluoro, chloro, or bromo.

[0408] As used herein alone or in combination, the term "haloalkyl" refers to an alkyl group having the meaning as defined above, wherein one or more hydrogens are replaced by halogen. Monohaloalkyl, dihaloalkyl, and polyhaloalkyl are particularly encompassed. Monohaloalkyl, for example, can contain iodine, bromine, chlorine, or fluorine atoms within the group. Dihaloalkyl and polyhaloalkyl can have a combination of two or more identical halogen atoms or different halo groups. Examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl. "haloalkylene" refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (-CFH-), difluoromethylene (-CF2-), chloromethylene (-CHCl-), etc. In one aspect, haloalkyl is a C1-C6 haloalkyl group. In another aspect, the haloalkyl is a C1-C4 haloalkyl.

[0409] As used herein, alone or in combination, the term "haloalkoxy" refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom. In one aspect, a haloalkoxy group is a C1-C6 haloalkoxy group, which refers to a (C1-C6 haloalkyl)-O- group. In another aspect, a haloalkoxy group is a C1-C4 haloalkoxy group, which refers to a (C1-C4 haloalkyl)-O- group.

[0410] "Haloalkoxyalkyl" refers to an alkyl group, as defined herein, in which one hydrogen atom is replaced by a haloalkoxy group. In some embodiments, the haloalkoxyalkyl group is a (C1-C6 haloalkoxy)-C1-C6 alkyl group, which may also be viewed as a (C1-C6 haloalkyl)-O-(C1-C6 alkyl)-group. In some embodiments, the alkoxyalkyl group is a (C1-C4 haloalkoxy)-C1-C6 alkyl group, which may also be viewed as a (C1-C4 haloalkyl)-O-(C1-C6 alkyl)-group. Typical haloalkoxyalkyl groups include, but are not limited to, -CH2OCF3, -CH2CH2OCF3, -CH2CH2CH2OCF3, -CH2CH2CH2CH2OCF3, -CH2OCH2CF3, -CH2CH2OCH2CF3, -CH2CH2CH2OCH2CF3, -CH2CH2CH2OCH2CF3, and the like.

[0411] As used herein, alone or in combination, the term "heteroalkyl" refers to a stable straight or branched chain, or combinations thereof, that is fully saturated or contains from 1 to 3 degrees of unsaturation, consisting of the specified number of carbon atoms and one to three heteroatoms selected from N, O, and S, wherein the N and S atoms may be optionally oxidized and the N heteroatom may be optionally quaternized. The heteroatom may be located at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as -CH2-NH-OCH3.

[0412]

[0066] The term "hydrazino," as used herein, alone or in combination, refers to two amino groups linked by a single bond, ie, -NN-.

[0413]

[0046] The terms "hydroxy" or "hydroxyl," as used herein, alone or in combination, refer to -OH.

[0414] As used herein, alone or in combination, the term "hydroxyalkyl" refers to a hydroxy group attached to the parent molecular moiety through an alkyl group. In some embodiments, the hydroxyalkyl group is a C1-C4 hydroxyalkyl group. Typical hydroxyalkyl groups include, but are not limited to, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, and the like.

[0415] The term "imino," as used herein, alone or in combination, refers to =N-.

[0416] The term "iminohydroxy," as used herein, alone or in combination, refers to =N(OH) and =NO-.

[0417] The phrase "in the backbone" refers to the longest continuous or adjacent chain of carbon atoms starting at the point of attachment of a group to a compound of any one of the formulations disclosed herein.

[0418] The term "isocyanato" refers to an -NCO group.

[0419] The term "isothiocyanato" refers to a -NCS group.

[0420] The phrase "linear chain of atoms" refers to the longest straight chain of atoms independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur.

[0421] As used herein, alone or in combination, unless expressly defined otherwise, the term "lower" means containing from 1 to 6 and including 6 carbon atoms (ie, C1-C6 alkyl).

[0422] The term "lower aryl," as used herein, alone or in combination, means phenyl or naphthyl, which may be optionally substituted as provided.

[0423] As used herein, the term "lower heteroaryl," alone or in combination, means any of the following: 1) a monocyclic heteroaryl containing five or six ring members, wherein between one and four of said members may be heteroatoms selected from N, O, and S; or 2) a bicyclic heteroaryl, wherein each of the fused rings contains five or six ring members containing one to four heteroatoms selected from N, O, and S.

[0424] As used herein, alone or in combination, the term "lower cycloalkyl" means a monocyclic cycloalkyl group having three to six ring members (i.e., a C3-C6 cycloalkyl group). Lower cycloalkyl groups may be unsaturated. Examples of lower cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0425] As used herein, alone or in combination, the term "lower heterocycloalkyl" means a monocyclic heterocycloalkyl having between three and six ring members, of which between one and four ring members may be heteroatoms selected from N, O, and S (i.e., C3-C6 heterocycloalkyl). Examples of lower heterocycloalkyl groups include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl. Lower heterocycloalkyl groups may be unsaturated.

[0426] The term "lower amino," as used herein, alone or in combination, refers to -NRR', wherein R and R' are independently selected from hydrogen and lower alkyl, either of which may be optionally substituted.

[0427]

[0046] The term "mercaptyl," as used herein, alone or in combination, refers to an RS- group, where R is as defined herein.

[0428]

[0046] The term "nitro," as used herein, alone or in combination, refers to -NO2.

[0429]

[0066] The term "oxy" or "oxa," as used herein, alone or in combination, refers to -O-.

[0430] The term "oxo," as used herein, alone or in combination, refers to =0.

[0431] The term "perhaloalkoxy" refers to an alkoxy group in which all of the hydrogen atoms are replaced by halogen atoms.

[0432]

[0046] The term "perhaloalkyl," as used herein, alone or in combination, refers to an alkyl group in which all of the hydrogen atoms are replaced by halogen atoms.

[0433] As used herein, alone or in combination, as sulfonic acids are used in salt formation, the terms "sulfonate," "sulfonic acid," and "sulfonic" refer to the -SO3H group and its anion.

[0434]

[00146] The term "thio," as used herein, alone or in combination, refers to -S-.

[0435]

[00146] The term "sulfinyl," as used herein, alone or in combination, refers to -S(=O)-.

[0436] The term "sulfonyl," as used herein, alone or in combination, refers to a -S(=O)2-, -S(=O)2R, or -S(=O)2R- group, where R is as defined herein.

[0437] As used herein, alone or in combination, the term "sulfonylamino" includes both N-sulfonylamino and S-sulfonylamino. The term "N-sulfonylamino" refers to a RS(=O)2NR'- or -S(=O)2NR'- group, where R and R' are as defined herein. The term "S-sulfonylamino" refers to a -S(=O)2NRR' or -S(=O)2NR- group, where R and R' are as defined herein.

[0438] As used herein, the terms "thia" and "thio," alone or in combination, refer to an -S- group or an ether wherein the oxygen is replaced by sulfur. Oxygenated derivatives of thio, i.e., sulfinyl and sulfonyl, are included in the definitions of thia and thio.

[0439] The term "thiol," as used herein, alone or in combination, refers to a -SH group.

[0440] As used herein, the term "thiocarbonyl" when used alone includes a thiocarbonyl -C(S)H group and in combination is a -C(S)- group.

[0441] The term "N-thiocarbamyl" refers to a ROC(S)NR'- group, where R and R' are as defined herein.

[0442] The term "O-thiocarbamyl" refers to a -OC(S)NRR' group, where R and R' are as defined herein.

[0443] The term "thiocyanato" refers to a -CNS group.

[0444] The term "trihalomethanesulfonylamino" refers to a X3CS(=O)2NR- group, where X is a halogen and R is as defined herein.

[0445] The term "trihalomethanesulfonyl" refers to a X3CS(=O)2- group where X is a halogen.

[0446] The term "trihalomethoxy" refers to a X3CO- group where X is a halogen.

[0447] As used herein, the term "trisubstituted silyl" alone or in combination, refers to a silicone group substituted in its three free valences with groups as listed below under the definition of substituted amino. Examples include trimethylsilyl, tert-butyldimethylsilyl, triphenylsilyl, and the like.

[0448] Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is the element to which the parent moiety is attached. For example, the composite group alkylamido would represent an alkyl group attached to the parent molecule via an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule via an alkyl group.

[0449] When a group is defined as "empty", it means that the group does not exist.

[0450] The term "optionally substituted" means that the preceding group may be substituted or unsubstituted. When substituted, the substituents of the "optionally substituted" group may include, but are not limited to, one or more substituents independently selected from the following groups or the specifically specified groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower The substituents may be substituted with alkyl, alkyl, or alkylamino groups, such as ... Optionally substituted groups may be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at any level between fully substituted and monosubstituted (e.g., -CH2CF3). When a substituent is described without reciting a qualification regarding substitution, both substituted and unsubstituted forms are encompassed. Where a substituent is defined as "substituted," the substituted form is particularly desirable. In addition, different sets of optional substituents for a particular moiety may be defined as required; in these cases, the optional substitutions are as defined, typically immediately following the phrase "optionally substituted."

[0451] In some embodiments, the term "optionally substituted" or "substituted" means that the referenced group is optionally substituted with one or more additional groups individually and independently selected from the group consisting of halogen, -CN, -NH2, -NH(alkyl), -N(alkyl)2, -OH, -C02H, -C02alkyl, -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl)2, -S(=O)2NH2, -S(=O)2NH(alkyl), -S(=O)2N(alkyl)2, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone. In some other embodiments, the optional substituents are independently selected from halogen, -CN, -NH2, -NH(CH3), -N(CH3)2, -OH, -CO2H, -CO2(C1-C4 alkyl), -C(=O)NH2, -C(=O)NH(C1-C4 alkyl), -C(=O)N(C1-C4 alkyl)2, -S(=O)2NH2, -S(=O)2NH(C1-C4 alkyl), -S(=O)2N(C1-C4 alkyl)2, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 fluoroalkyl, C1-C4 heteroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -SC1-C4 alkyl, -S(=O)C1-C4 alkyl and -S(=O)2C1-C4 alkyl. In some embodiments, the optional substituents are independently selected from halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -CH3, -CH2CH3, -CHF2, -CF3, -OCH3, -OCHF2, and -OCF3. In some embodiments, the substituted groups are substituted with one or both of the preceding groups. In some embodiments, the optional substituents on aliphatic carbon atoms (acyclic or cyclic) include oxo (=O).

[0452] Unless otherwise defined, the term R or the term R', when appearing alone and without a number, refers to a moiety selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycloalkyl, any of which may be optionally substituted. Such R and R' groups are understood to be optionally substituted as defined herein. Regardless of whether the R group has a number designation, each R group (including R, R', and R') is optionally substituted. n, where n = (1, 2, 3 ... n)), each substituent and each term should be understood to be independent of each other in terms of selection from the group. If any variable, substituent or term (e.g., aryl, heterocycle, R, etc.) occurs more than once in a formula or general structure, its definition at each occurrence is independent of its definition at every other occurrence. Those skilled in the art will further recognize that certain groups can be attached to the parent molecule or can occupy a position in the chain of elements from either end as written. For example, an asymmetric group such as -C(=O)N(R)- can be attached to the parent moiety at either carbon or nitrogen.

[0453] Asymmetric centers are present in the compounds disclosed herein. These centers are represented by the symbols "R" or "S," depending on the configuration of the substituents surrounding the chiral carbon atom. It should be understood that the present invention encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and l-isomers and mixtures thereof. Individual stereoisomers of a compound can be prepared by synthesis from commercially available starting materials containing a chiral center, or by preparing a mixture of enantiomeric products followed by separation, such as conversion to a diastereomeric mixture followed by separation or recrystallization, chromatography, direct separation of enantiomers on a chiral chromatographic column, or any other suitable method known in the art. Starting compounds of a specific stereochemistry are commercially available or can be prepared and resolved by techniques known in the art. In addition, the compounds disclosed herein may exist as geometric isomers. The present invention includes all cis, trans, syn, anti, E (entgegen), and Z (zusammen) isomers and suitable mixtures thereof. In addition, the compounds may exist as tautomers; all tautomeric isomers are provided by the present invention. In addition, the compounds disclosed herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, etc. In general, the solvated forms are considered equivalent to the unsolvated forms.

[0454] The term "bond" refers to a covalent bond between two atoms, or between two moieties when the atoms connected by the bond are considered to be part of a larger substructure. Unless otherwise specified, a bond can be a single bond, a double bond, or a triple bond. A dashed line between two atoms in a molecular diagram indicates that an additional bond may or may not be present at that position.

[0455] As used herein, the term "disease" is generally intended to be synonymous with and interchangeable with the terms "disorder," "syndrome," and "condition" (as in medical conditions) because they all reflect an abnormal condition of the human or animal body or one of its parts that impairs normal function, is usually manifested by prominent signs and symptoms, and results in a shortened survival or reduced quality of life for the human or animal.

[0456] The term "combination therapy" means the administration of two or more therapeutic agents to treat the therapeutic conditions or disorders described in this disclosure. Such administration encompasses the co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple separate capsules for each active ingredient. In addition, such administration also encompasses the use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide a beneficial effect of the drug combination in treating the conditions or disorders described herein.

[0457] "GLUT9 inhibitor" is used herein to refer to an inhibitor that exhibits an IC of no more than about 100 μM for GLUT9 activity. 50 and more typically no more than about 50 μM of the compound as measured in the GLUT9 assay generally described herein. 50 " is the concentration of inhibitor that reduces the activity of an enzyme (e.g., GLUT9) to half the maximal level. Certain compounds disclosed herein have been found to exhibit inhibition against GLUT9. In certain embodiments, the compounds will exhibit an EC of no more than about 2 μM with respect to GLUT9. 50 In yet other embodiments, the compound will exhibit an EC of no more than about 1 μM with respect to GLUT9. 50 In yet other embodiments, the compound will exhibit an EC of no more than about 500 nM with respect to GLUT9. 50 , as measured in the GLUT9 assay described herein.

[0458] The phrase "therapeutically effective" is intended to qualify the amount of active ingredient used to treat a disease or disorder or achieve a clinical endpoint.

[0459] The term "pharmaceutically acceptable" refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) that are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, commensurate with a reasonable benefit / risk ratio, and effective for their intended use.

[0460] As used herein, "treating / treatment" and the like means to alleviate a disease, so as to reduce, improve or eliminate one or more of its cause, its progression, its severity or its symptoms, or otherwise advantageously change the disease of the subject. In certain embodiments, reference to "treating / treatment" of a subject at risk of developing a disease or at risk of the disease progressing to a worse state is intended to include prevention. Preventing a disease may involve complete protection from the disease, such as in the case of preventing infection with a pathogen, or may involve preventing the progression of a disease, such as preventing prediabetes from progressing to diabetes. For example, preventing a disease may not mean completely excluding the possibility of any effect associated with the disease at any level, but may mean preventing the symptoms of the disease at a clinically significant or detectable level. Preventing a disease may also mean preventing the disease from progressing to a late stage of the disease.

[0461] The term "patient" is generally synonymous with the term "subject" and includes all mammals, including humans. Examples of mammals include humans, livestock (such as cattle, goats, sheep, pigs and rabbits) and companion animals (such as dogs, cats, rabbits and horses). Preferably, the patient or subject or mammal is a human.

[0462] The term "prodrug" refers to a compound that has increased activity in vivo. Certain compounds disclosed herein may also exist in prodrug form, as described in: Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA Journal, Zurich, Switzerland 2003; T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Volume 14 of the ACS Symposium Series; and Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, 1987). The prodrug of the compound described herein is a structurally modified form of the compound that is easily subjected to chemical changes under physiological conditions to provide a compound. In addition, the prodrug can be converted into a compound in an ex vivo environment by chemical or biochemical methods. For example, when the prodrug is placed in a transdermal patch reservoir together with a suitable enzyme or chemical reagent, it can be slowly converted into a compound. Prodrugs are generally applicable because in some cases they are easier to administer than the compound or the parent drug. It can be, for example, bioavailable by oral administration, while the parent drug is not. Prodrugs can also have improved solubility compared to the parent drug in a pharmaceutical composition. Various prodrug derivatives are known in the art, such as those that rely on the hydrolytic cleavage or oxidative activation of the prodrug. Examples of prodrugs are, but not limited to, administered in the form of an ester ("prodrug"), but then metabolically hydrolyzed to a carboxylic acid, i.e., a compound of an active entity. Other examples include peptidyl derivatives of the compound.

[0463] The compounds disclosed herein may exist in the form of pharmaceutically acceptable salts. The present invention includes the compounds listed above in salt form, including acid addition salts. Suitable salts include salts formed from organic and inorganic acids. Such acid addition salts will generally be pharmaceutically acceptable. However, in the preparation and purification of the compounds in question, salts that are not pharmaceutically acceptable salts may have utility. Base addition salts may also be formed and are pharmaceutically acceptable. A more comprehensive discussion of the preparation and selection of salts can be found in Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).

[0464] As used herein, the term "pharmaceutically acceptable salt" refers to a salt or zwitterionic form of a compound disclosed herein that is water or oil soluble or dispersible and pharmaceutically acceptable as defined herein. Salts can be prepared during the final separation and purification of the compound, or separately prepared by reacting the appropriate compound in the form of a free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (benzenesulfonate / besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (hydroxyethyl sulfonate), lactate, maleic acid

[0014] The compounds disclosed herein include quaternary ammonium salts of: methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, dodecyl, tetradecyl, and sterol chlorides, bromides, and iodides; and benzyl and phenethyl bromides.

[0465] The compounds provided herein may optionally exist as pharmaceutically acceptable salts, including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Representative acids include, but are not limited to, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, dichloroacetic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, etc.

[0466] Examples of inorganic acids that can be used to form pharmaceutically acceptable addition salts include hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid. Examples of organic acids that can be used to form pharmaceutically acceptable addition salts include oxalic acid, maleic acid, succinic acid, and citric acid. Salts can also be formed by coordination of the compounds with alkali metal or alkaline earth metal ions. Thus, the present invention encompasses sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein.

[0467] Base addition salts can be prepared during the final isolation and purification of the compound by reacting the carboxyl group with a suitable base (such as a hydroxide, carbonate or bicarbonate of a metal cation) or with ammonia or an organic primary, secondary or tertiary amine. The cation of the pharmaceutically acceptable salt includes lithium, sodium, potassium, calcium, magnesium and aluminum, and non-toxic quaternary ammonium cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylphenoline, dicyclohexylamine, procaine, benzhydrylamine, N,N-benzhydrylphenethylamine, 1-diphenylhydroxymethylamine and N,N'-benzhydrylethylenediamine. Other representative organic amines that can be used to form base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine and piperazine.

[0468] Certain compounds provided herein containing carboxylic acid functional groups may optionally exist in the form of pharmaceutically acceptable salts containing pharmaceutically acceptable non-toxic metal cations and cations derived from organic bases. Representative metals include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and the like. In some embodiments, the pharmaceutically acceptable metal is sodium. Representative organic bases include, but are not limited to, benzathine (N 1 ,N 2

[0014] Pharmaceutically acceptable salts include 2-(diethylamino)ethyl 4-(chloroamino)benzoate, choline, diethanolamine, ethylenediamine, meglumine ((2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentanol), procaine (2-(diethylamino)ethyl 4-aminobenzoate), and the like. Certain pharmaceutically acceptable salts are listed in Berge et al., Journal of Pharmaceutical Sciences, 66:1-19 (1977).

[0469] Salts of compounds can be prepared by reacting the appropriate compound in its free base form with a suitable acid.

[0470] Acid addition salts can be obtained as direct products of compound synthesis. Alternatively, the free base can be dissolved in a suitable solvent containing an appropriate acid and the salt can be isolated by evaporating the solvent or otherwise separating the salt from the solvent. The compounds provided herein can form solvates with standard low molecular weight solvents using methods known to those skilled in the art.

[0471] Additionally, the compounds described herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, etc. The solvated forms of the compounds presented herein are also considered to be disclosed herein.

[0472] It should be understood that reference to pharmaceutically acceptable salts includes solvent addition forms. In some embodiments, solvates contain stoichiometric or non-stoichiometric amounts of solvent and are formed during separation or crystallization processes with pharmaceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein are optionally present in unsolvated as well as solvated forms.

[0473] In some embodiments, sites on the organic radicals (e.g., alkyl, aromatic rings) of the compounds described herein are susceptible to different metabolic reactions. Incorporating suitable substituents into the organic radicals will reduce, minimize, or eliminate these metabolic pathways. In certain embodiments, suitable substituents that reduce or eliminate the susceptibility of the aromatic ring to metabolic reactions are, for example, halogens, deuterium, alkyls, haloalkyls, or deuterated alkyls.

[0474] In another embodiment, the compounds described herein are isotopically labeled (e.g., with a radioactive isotope) or labeled by another other means. The compounds described herein include isotopically labeled compounds that are identical to those listed in the various formulas and structures presented herein, but in practice one or more atoms are replaced by an atom having an atomic mass or mass number different from that normally found in nature. Examples of isotopes that can be incorporated into the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine, iodine, phosphorus, such as 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 35 S. 18 F. 36 Cl, 123 I 、124 I. 125 I. 131 In one aspect, isotopically labeled compounds described herein (e.g., wherein there is a 3 H and 14 Radioisotopes of deuterium (such as those containing deuterium) are useful in drug and / or substrate tissue distribution assays. In one aspect, substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.

[0475] In some embodiments, the compounds described herein have one or more stereocenters, and each stereocenter exists independently in either the R or S configuration. In some embodiments, the compounds exist in the R configuration. In some embodiments, the compounds exist in the S configuration. The compounds presented herein include all diastereoisomers, single enantiomers, configurational isomers, and epimeric forms, as well as suitable mixtures thereof. The compounds and methods provided herein include all cis, trans, iso, para, E, and Z isomers, as well as suitable mixtures thereof.

[0476] If desired, a single stereoisomer is obtained by methods such as stereoselective synthesis and / or separation of stereoisomers by chiral chromatographic columns, or separation of diastereoisomers by crystallization and recrystallization of achiral or chiral chromatographic columns or in a suitable solvent or mixture of solvents. In certain embodiments, the compound is prepared as a single stereoisomer by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomeric compounds / salts, separating the diastereoisomers and recovering an optically pure single enantiomer. In some embodiments, single enantiomers are resolved using covalent diastereomeric derivatives of the compounds described herein. In another embodiment, diastereoisomers are separated by separation / resolution techniques based on differences in solubility. In other embodiments, stereoisomers are separated by chromatography or by forming diastereomeric salts and by recrystallization or chromatographic separation or any combination thereof. Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981. In some embodiments, stereoisomers are obtained by stereoselective synthesis.

[0477] Pharmaceutical compositions and formulations

[0478] The formulations can be prepared by any suitable method, generally by uniformly admixing the active compound with liquid or finely divided solid carriers, or both, in the desired proportions, and then, if necessary, shaping the resulting mixture into the desired presentation.

[0479] Conventional excipients, such as adhesives, fillers, acceptable wetting agents, tableting lubricants and disintegrants, can be used in tablets and capsules for oral administration. Liquid preparations for oral administration can be in the form of solutions, emulsions, aqueous or oily suspensions and syrups. Alternatively, oral preparations can be in the form of dry powders, which can be reconstituted with water or other suitable liquid vehicles before use. Additional additives such as suspending agents or emulsifiers, non-aqueous vehicles (including edible oils), preservatives and flavorings and colorants can be added to the liquid preparation. Parenteral dosage forms can be prepared by dissolving the compound provided herein in a suitable liquid vehicle and filtering and sterilizing the solution before filling and sealing a suitable vial or ampoule. These methods are only several examples of many appropriate methods for preparing dosage forms well known in the art.

[0480] The compounds of the invention can be formulated into pharmaceutical compositions using techniques well known to those skilled in the art. Suitable pharmaceutically acceptable carriers (except those mentioned herein) are known in the art; for example, see Remington, The Science and Practice of Pharmacy, 20th ed., 2000, Lippincott Williams & Wilkins, (Editors: Gennaro et al.).

[0481] While possible for prophylactic or therapeutic use, the compounds provided herein may alternatively be administered as the raw or pure chemical, however, it is preferable to present the compound or active ingredient as a pharmaceutical formulation or composition additionally comprising a pharmaceutically acceptable carrier.

[0482] Drug formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for use by suction, insufflation or by transdermal patch administration. Transdermal patches distribute the drug at a controlled rate by presenting the drug for absorption in an effective manner with minimum drug degradation. Typically, transdermal patches comprise an impermeable backing layer, a single pressure-sensitive adhesive and a removable protective layer with a drug release liner. Those of ordinary skill in the art will appreciate and understand the technology suitable for manufacturing the required effective transdermal patch based on the needs of the technician.

[0483] Therefore, the compounds provided herein, together with conventional adjuvants, carriers or diluents, can be made into pharmaceutical formulations and their unit dosage forms, and in this form can be used as solids such as tablets or filled capsules for oral use, or liquids such as solutions, suspensions, emulsions, elixirs, gels or capsules filled therewith; suppositories for rectal administration; or as sterile injection solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and their unit dosage forms can contain conventional ingredients in conventional proportions, with or without additional active compounds or ingredients, and such unit dosage forms can contain any suitable effective amount of active ingredients comparable to the daily dose range to be adopted.

[0484] For oral administration, the pharmaceutical composition can be in the form of, for example, tablets, capsules, suspensions or liquids. The pharmaceutical composition is preferably prepared in the form of a dosage unit containing a specific amount of the active ingredient. Examples of such dosage units are capsules, tablets, powders, granules or suspensions with conventional additives such as lactose, mannitol, corn starch or potato starch; binders such as crystalline cellulose, cellulose derivatives, gum arabic, corn starch or gelatin; disintegrants such as corn starch, potato starch or sodium carboxymethylcellulose; and lubricants such as talc or magnesium stearate. The active ingredient can also be administered by injection using, for example, saline, dextrose or water as a composition suitable for pharmaceutically acceptable carriers.

[0485] The compounds provided herein, or salts, solvates or hydrates thereof, can be used as active ingredients in pharmaceutical compositions, particularly as GLUT9 transporter modulators or inhibitors. The term "active ingredient," as defined in the context of a "pharmaceutical composition," refers to a component of a pharmaceutical composition that provides the primary pharmacological effect, as opposed to an "inactive ingredient" that is generally identified as not providing a pharmaceutical benefit.

[0486] The dosage when using the compound provided herein can vary within a wide range and, due to customary use and being known to doctors or other clinicians, it is customized for individual conditions in each case. This depends on, for example, the nature and severity of the disease to be treated, the patient's condition, the compound used, whether to treat acute or chronic disease conditions or to prevent or to administer other active compounds in addition to the compound provided herein. Representative dosages include, but are not limited to, about 0.001 mg to about 5000 mg, about 0.001 mg to about 2500 mg, about 0.001 mg to about 1000 mg, about 0.001 mg to about 500 mg, about 0.001 mg to about 250 mg, about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg, and about 0.001 mg to about 25 mg. Multiple doses can be administered during one day, especially when it is considered that a relatively large amount is needed, such as 2, 3 or 4 doses. Depending on the individual and as a health care provider, it may be necessary to deviate upward or downward from the dosage described herein.

[0487] The amount of the active ingredient or its active salt or derivative required for treatment will vary not only with the specific salt selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient and will ultimately be handled at the discretion of the attending physician or clinician. In general, one skilled in the art understands how to extrapolate in vivo data obtained in a model system, typically an animal model, to another model such as a human. In some cases, these extrapolations can be based solely on the weight of the animal model compared to another model such as a mammal, preferably a human, but more generally, these extrapolations are not simply based on weight, but rather on a combination of various factors. Representative factors include the type, age, weight, sex, diet, and medical condition of the patient; the severity of the disease; the route of administration; pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicological profile of the specific compound employed, whether a drug delivery system is utilized, whether acute or chronic disease conditions are treated or prevented, or whether other active compounds are administered in addition to the compounds provided herein and as part of a drug combination. The dosage regimen for treating disease conditions using the compounds and / or compositions provided herein is selected based on various factors as cited above. Thus, the actual dosage regimen employed may vary widely and therefore may deviate from the preferred dosage regimen, and one skilled in the art will recognize that doses and dosage regimens outside of these typical ranges may be tested and, where appropriate, used in the methods provided herein.

[0488] The desired dose can be conveniently presented as a single dose or multiple doses (e.g., sub-doses twice, three times, four times or more per day) administered at appropriate intervals. The sub-doses themselves can be further divided into, for example, a number of loosely spaced discrete administrations. The daily dose can be administered in several portions (e.g., two, three, or four parts), especially when administered in relatively large quantities as needed. Where appropriate, it may be necessary to deviate upward or downward from the specified daily dose, depending on individual behavior.

[0489] The compounds provided herein can be administered in a wide variety of oral and parenteral dosage forms. It will be apparent to those skilled in the art that the dosage form can comprise a compound provided herein or a pharmaceutically acceptable salt, hydrate or solvate of a compound provided herein as an active ingredient.

[0490] To prepare pharmaceutical compositions from the compounds provided herein, suitable pharmaceutically acceptable carriers are selected that can be solid, liquid, or a mixture of the two. Solid form formulations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances that can also act as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, preservative, tablet disintegrant, or encapsulating material.

[0491] In powders, the carrier is a finely divided solid which is in admixture with the finely divided active component.

[0492] In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

[0493] Powders and tablets may contain varying percentages of the active compound. A typical amount in a powder or tablet may contain 0.5 to about 90 percent of the active compound; however, skilled artisans will recognize when amounts outside this range are necessary. Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low-melting waxes, cocoa butter, and the like. The term "prepared" refers to formulating the active compound with an encapsulating material as a carrier to provide a capsule in which the active ingredient, with or without a carrier, is surrounded by the carrier and thus bound to the carrier. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges may be used in solid forms suitable for oral administration.

[0494] To prepare suppositories, a low melting point wax (such as a mixture of fatty acid glycerides or cocoa butter) is first melted and the active ingredient is dispersed uniformly therein (e.g., by stirring). The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

[0495] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0496] Liquid form preparations include solutions, suspensions and emulsions, such as water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in polyethylene glycol aqueous solutions. Suitable dispersants or wetting agents and suspending agents can be used to prepare injectable preparations, such as sterile injectable aqueous or oily suspensions, according to known techniques. Sterile injectable preparations can also be sterile injectable solutions or suspensions in non-toxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butanediol. Among acceptable vehicles and solvents, water, Ringer's solution and isotonic sodium chloride solution can be used. In addition, sterile fixed oils can be used as solvents or suspension media conventionally. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid can be used to prepare injectables.

[0497] The compounds provided herein can therefore be formulated for parenteral administration (e.g., by injection, such as bolus injection or continuous infusion) and can be presented in unit dosage form in ampoules, prefilled syringes, small volume infusers, or multiple dose containers with added preservatives. The pharmaceutical composition can be in the form of a suspension, solution, or emulsion in an oily or aqueous vehicle and can contain formulations such as suspending agents, stabilizers, and / or dispersants. Alternatively, the active ingredient can be in powder form, which is obtained by aseptic isolation of sterile solids or by lyophilization from a solution and reconstituted with a suitable vehicle (e.g., sterile, pyrogen-free water) before use.

[0498] Aqueous formulations suitable for oral use can be prepared by dissolving or suspending the active component in water and adding suitable colorants, flavorings, stabilizers, and thickening agents as desired.

[0499] Aqueous suspensions suitable for oral use can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.

[0500] Also included are solid form preparations that are converted into liquid form preparations for oral administration immediately before use. Such liquid forms include solutions, suspensions, and emulsions. In addition to the active ingredient, these preparations may contain colorants, flavorings, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

[0501] For topical administration to the epidermis, the compounds provided herein may be formulated as ointments, creams or lotions, or as a transdermal patch.

[0502] Ointments and creams may be formulated, for example, with an aqueous or oily base with the addition of suitable thickeners and / or gelling agents. Lotions may be formulated with an aqueous or oily base and will generally also contain one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners or colorants.

[0503] Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; tablets comprising the active ingredient in an inert basis such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0504] The solution or suspension is administered directly to the nasal cavity by conventional means, for example, with a dropper, pipette or sprayer. The formulation can be provided in single or multiple doses. In the latter case of a dropper or pipette, this can be achieved by administering an appropriate predetermined volume of the solution or suspension to the patient. In the case of a sprayer, this can be achieved, for example, by a metered atomizing spray pump.

[0505] It is also possible to provide an aerosol formulation in a pressurized package with an active ingredient and a suitable propellant to achieve administration to the respiratory tract. If the compound provided herein or a pharmaceutical composition comprising the compound is administered in the form of an aerosol (e.g., nasal aerosol) or by inhalation, it can be performed, for example, using a sprayer, a nebulizer, a pump nebulizer, an inhalation device, a metered dose inhaler, or a dry powder inhaler. The pharmaceutical form for administering the compound provided herein in an aerosol can be prepared by methods well known to those skilled in the art. Regarding its preparation, for example, conventional additives such as benzyl alcohol or other suitable preservatives, absorption enhancers for increasing bioavailability, solubilizers, dispersants, and other conventional propellants, including carbon dioxide, CFCs such as dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, etc., can be used to utilize a solution or dispersion of the compound provided herein in water, a water / alcohol mixture, or a suitable physiological saline solution. The aerosol also conveniently contains a surfactant such as lecithin. The drug dosage can be controlled by providing a metering valve.

[0506] In formulations to be administered to the respiratory tract (including intranasal formulations), the compound will generally have a small particle size, for example, about 10 microns or less. Such particle sizes can be obtained by means known in the art, for example, by micronization. Where desired, formulations suitable for providing sustained release of the active ingredient may be employed.

[0507] Alternatively, the active ingredient may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives (such as hydroxypropylmethylcellulose) and polyvinylpyrrolidone (PVP). The powder carrier should preferably form a gel in the nasal cavity. The powder composition may be presented in unit dosage form, for example in capsules or cartridges of, for example, gelatin, or in blister packs, and the powder may be administered by inhaler.

[0508] The pharmaceutical formulation is preferably in unit dosage form. In such form, the formulation is subdivided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form can be a packaged formulation containing discrete quantities of the preparation, such as packaged tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, tablet, cachet, or lozenge itself, or it can be an appropriate number of any of these unit dosage forms in packaged form.

[0509] Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.

[0510] Some embodiments include methods of producing a pharmaceutical composition for "combination therapy" comprising admixing at least one compound according to any of the compound embodiments disclosed herein with at least one known agent and a pharmaceutically acceptable carrier.

[0511] Indications and methods of treatment

[0512] Also provided herein are methods for treating a GLUT9-mediated disorder in a human or animal subject in need of such treatment, comprising administering to the subject an amount of a compound disclosed herein effective to reduce or prevent the disorder in the subject, and at least one additional agent known in the art for treating the disorder. In a related aspect, certain embodiments provide therapeutic compositions for treating a GLUT9-mediated disorder, comprising at least one compound disclosed herein and one or more additional agents.

[0513] GLUT9 inhibitors are considered to be agents for treating or preventing pathological conditions involving high blood uric acid levels; specifically, hyperuricemia, gout (e.g., gouty arthritis, gouty kidney, and tophi), etc. In addition, they are believed to have the potential to be suitable agents for treating or preventing the following pathological conditions, which are generally known to have complications associated with hyperuricemia and are particularly shown to be associated with high uric acid; specifically, chronic kidney disease (CKD), hypertension, diabetes, heart disease (e.g., cardiovascular disease, heart failure, and atrial fibrillation), arteriosclerotic disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), psoriasis, etc.

[0514] Specific diseases to be treated by the compounds, compositions, and methods disclosed herein include hyperuricemia and gout.

[0515] In addition to being useful in human therapy, certain compounds and formulations disclosed herein are also useful in veterinary treatment of companion animals, exotic animals, and farm animals, including mammals, rodents, etc. More preferred animals include horses, dogs, and cats.

[0516] Thus, the present invention also relates to a method for inhibiting at least one GLUT9 function, comprising the step of contacting GLUT9 with a compound as described herein. Cell phenotype, cell proliferation, GLUT9 activity, changes in biochemical output produced by active GLUT9, expression of GLUT9, or binding of GLUT9 to a natural binding partner can be monitored. Such methods can be therapeutic modalities for the disease, bioassays, cell assays, biochemical assays, and the like.

[0517] Also provided herein is a method for treating a GLUT9-mediated disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound as disclosed herein or a salt thereof.

[0518] GLUT9 inhibitors are considered to be agents for treating or preventing pathological conditions involving high blood uric acid levels; specifically, hyperuricemia, gout (e.g., gouty arthritis, gouty kidney, and tophi), etc. In addition, they are believed to have the potential to be suitable agents for treating or preventing the following pathological conditions, which are generally known to have complications associated with hyperuricemia and are particularly shown to be associated with high uric acid; specifically, chronic kidney disease (CKD), hypertension, diabetes, heart disease (e.g., cardiovascular disease, heart failure, and atrial fibrillation), arteriosclerotic disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), psoriasis, etc.

[0519] In one embodiment, the disease is selected from hyperuricemia, gout and uncontrolled gout, including comorbidities and related diseases.

[0520] In certain embodiments, the disease is selected from hyperuricemia and gout.

[0521] Also provided herein are compounds as disclosed herein for use as medicaments.

[0522] Also provided herein is a compound as disclosed herein, which is suitable for use as a medicament for treating GLUT9-mediated diseases.

[0523] Also provided are compounds as disclosed herein for use as medicaments.

[0524] Also provided are uses of the compounds as disclosed herein as medicaments for the treatment of GLUT9-mediated diseases.

[0525] Also provided is a compound as disclosed herein for use in the manufacture of a medicament for treating a GLUT9-mediated disease.

[0526] Also provided is a use of a compound as disclosed herein for treating a GLUT9-mediated disease.

[0527] Also provided herein is a method of inhibiting GLUT9, comprising contacting GLUT9 with a compound as disclosed herein or a salt thereof.

[0528] Also provided herein is a method for achieving an effect in a patient comprising administering to the patient a therapeutically effective amount of a compound as disclosed herein or a salt thereof, wherein the effect is selected from cognitive enhancement.

[0529] In certain embodiments, the GLUT9-mediated disease is selected from hyperuricemia and gout.

[0530] Also provided herein is a method for achieving an effect in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein, wherein the effect is lowering blood uric acid levels.

[0531] Also provided is a method of modulating GLUT9-mediated function in a subject comprising administering a therapeutically effective amount of a compound as disclosed herein.

[0532] Also provided is a pharmaceutical composition comprising a compound as disclosed herein and a pharmaceutically acceptable carrier.

[0533] In certain embodiments, pharmaceutical compositions are formulated for oral administration.

[0534] In certain embodiments, the oral pharmaceutical composition is selected from tablets and capsules.

[0535] Combination therapy

[0536] In some cases, it is appropriate to administer at least one of the compounds described herein (or a pharmaceutically acceptable salt, ester, or prodrug thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient after receiving one of the compounds herein is hypertension, it may be appropriate to administer an antihypertensive agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administering an adjuvant (i.e., the adjuvant itself may have only minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Or, by way of example only, the benefit experienced by the patient may be increased by administering one of the compounds described herein together with another therapeutic agent (which also includes a treatment regimen) that also has a therapeutic benefit. By way of example only, in the treatment of diabetes involving the administration of one of the compounds described herein, an increased therapeutic benefit may be generated by also providing the patient with another therapeutic agent for diabetes. In any case, regardless of the disease, disorder, or condition being treated, the total benefit experienced by the patient may simply be additive of the two therapeutic agents, or the patient may experience a synergistic benefit.

[0537] Specific non-limiting examples of possible combination therapies include the use of certain compounds of the present invention together with uric acid synthesis inhibitors, uricosuric drugs, and uric acid catabolists.

[0538] In one embodiment, the uricosuric drug is selected from probenecid, lesinade, benzbromarone and sulfinpyrazone.

[0539] In one embodiment, the uric acid synthesis inhibitor is selected from allopurinol and febuxostat.

[0540] In one embodiment, the uric acid catabolism agent is pegloticase.

[0541] In one embodiment, the other agent is colchicine.

[0542] In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein) can be administered in any order or even simultaneously. If administered simultaneously, the multiple therapeutic agents can be provided in a single unified form or in multiple forms (by way of example only, in a single pill form or in two separate pill forms). One of the therapeutic agents can be given in multiple doses, or both can be given in multiple doses. If not given simultaneously, the time between multiple doses can be any duration ranging from a few minutes to four weeks.

[0543] General synthetic scheme

[0544] The following protocols can be used to practice the present invention.

[0545] Solution 1

[0546]

[0547] Option 2

[0548]

[0549] Option 3

[0550]

[0551] Option 4

[0552]

[0553] Option 5

[0554]

[0555] Option 6

[0556]

[0557] Option 7

[0558]

[0559] Option 8

[0560]

[0561] Option 9

[0562]

[0563] Plan 10

[0564]

[0565] Examples

[0566] The present invention is further illustrated by the following examples.All IUPAC names were generated using CambridgeSoft's ChemDraw Ultra 11.0.1 or CambridgeSoft's ChemDraw Ultra 20.0.0.41.

[0567] I. Chemical Synthesis

[0568] List of commonly used abbreviations

[0569] g (gram); mg (milligram);

[0570] L (liter); mL (milliliter); μL (microliter);

[0571] psi (pounds per square inch);

[0572] M (molar concentration); mM (millimolar concentration); μM (micromolar concentration);

[0573] MHz (megahertz);

[0574] mol (mole); mmol (millimole);

[0575] rt (room temperature);

[0576] hr(hours);

[0577] min(minutes);

[0578] TLC (thin layer chromatography);

[0579] mp (melting point);

[0580] THF (tetrahydrofuran);

[0581] TFA (trifluoroacetic acid);

[0582] TFAA (trifluoroacetic anhydride);

[0583] Et3N (triethylamine);

[0584] NMP (N-methyl-2-pyrrolidine)

[0585] CDCl3 (deuterated chloroform);

[0586] N2(g) (nitrogen)

[0587] DMSO (dimethyl sulfoxide);

[0588] SOCl2( Thionyl chloride)

[0589] SiO2 (silicon dioxide);

[0590] atm (atmospheric pressure);

[0591] EtOAc (ethyl acetate);

[0592] CHCl 3( chloroform);

[0593] HCl (hydrochloric acid);

[0594] Ac (acetyl);

[0595] DMF (N,N-dimethylformamide);

[0596] Me (methyl);

[0597] Et(ethyl);

[0598] t-Bu (tert-butyl);

[0599] Pr(propyl);

[0600] i-Pr(isopropyl);

[0601] Cs2CO3 (cesium carbonate);

[0602] EtOH (ethanol);

[0603] MeOH (methanol);

[0604] CD3OD (deuterated methanol);

[0605] p-TsOH (p-toluenesulfonic acid);

[0606] CDI (1,1′-carbonyldiimidazole);

[0607] NaHCO3 (sodium bicarbonate);

[0608] DCM (dichloromethane);

[0609] DCE (1,2-dichloroethane);

[0610] K2CO3 (potassium carbonate);

[0611] Na2CO3 (sodium carbonate);

[0612] ACN or CH3CN (acetonitrile);

[0613] PE (petroleum ether);

[0614] MTBE (methyl tert-butyl ether);

[0615] Hex (hexane);

[0616] H2SO4 (sulfuric acid);

[0617] HCl (hydrochloric acid);

[0618] TMSBr (bromotrimethylsilane);

[0619] Na2SO4 (sodium sulfate);

[0620] Boc (tert-butoxycarbonyl);

[0621] DIPEA (diisopropylethylamine);

[0622] IPA (isopropyl alcohol);

[0623] HMDS (hexamethyldisilazane);

[0624] NH4Cl (ammonium chloride);

[0625] K3PO4 (tripotassium phosphate);

[0626] (NH4)HCO3 (ammonium bicarbonate);

[0627] EDCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide);

[0628] NaOH (sodium hydroxide);

[0629] DMAP (4-dimethylaminopyridine);

[0630] TMSCl (chlorotrimethylsilane);

[0631] NIS (N-iodosuccinimide);

[0632] NCS (N-chlorosuccinimide);

[0633] CuI (copper(I) iodide);

[0634] KOAc (potassium acetate);

[0635] KF (potassium fluoride);

[0636] CsF (cesium fluoride);

[0637] NaN3 (sodium azide);

[0638] TMP (2,2,6,6-tetramethylpiperidine);

[0639] K2OsO 4( potassium osmate);

[0640] NaIO4 (sodium metaperiodate);

[0641] DAST (diethylaminosulfur trifluoride);

[0642] Pd(OAc)2(palladium acetate);

[0643] BF3·(OEt)2 (boron trifluoride diethyl ether);

[0644] CS2 (carbon disulfide);

[0645] Tf2O (trifluoromethanesulfonic anhydride);

[0646] TMSCN (trimethylsilyl cyanide);

[0647] CDI (1,1′-carbonyldiimidazole);

[0648] LiAlH4 (lithium aluminum hydride);

[0649] TMSN3 (trimethylsilyl azide);

[0650] DMA (N,N-dimethylacetamide);

[0651] FA (formic acid);

[0652] NH2OH·HCl (hydroxylamine hydrochloride);

[0653] DEAD (diethyl azodicarboxylate);

[0654] PyBOP (benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate);

[0655] Pd(PPh3)2Cl2 (bis(triphenylphosphine)palladium chloride);

[0656] Pd(dppf)Cl2([1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II));

[0657] Pd(dppf)Cl2·CH2Cl2 ([1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct);

[0658] Pd(PPh3)4(tetrakis(triphenylphosphine)palladium(0).

[0659] Synthesis method

[0660] The following intermediates and examples can be synthesized using the general synthetic procedures described in Schemes 1-10.

[0661] Intermediate 1. (E)-5-(But-1-en-1-yl)-3-chloropyrazin-2-amine

[0662]

[0663] To a mixture of 3-chloro-5-iodo-pyrazin-2-amine (18.0 g, 70.47 mmol, 1.0 eq) and 2-[(E)-but-1-enyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (15.0 g, 82.39 mmol, 1.2 eq) in H2O (90 mL) and 1,4-dioxane (270 mL) at room temperature was added Pd(dppf)Cl2·CH2Cl2 (5.75 g, 7.05 mmol, 0.1 eq) and Cs2CO3 (68.88 g, 211.40 mmol, 3.0 eq). The resulting reaction mixture was heated to 80°C and stirred for 12 hours. The reaction mixture was then cooled to room temperature, diluted with H2O (300 mL), and then extracted with EtOAc (2×400 mL). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 3:1) to give (E)-5-(but-1-en-1-yl)-3-chloropyrazin-2-amine (22.4 g, 86% yield) as a yellow solid. 1 C8H 10 LCMS calculated value for ClN3: m / z=183; found: m / z=184 (M+H).

[0664] Intermediate 2. Methyl (E)-1-(3-amino-6-(but-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[0665]

[0666] To a solution of (E)-5-(but-1-en-1-yl)-3-chloropyrazin-2-amine (Intermediate 1) (4.0 g, 21.78 mmol, 1.0 equiv) in NMP (80 mL) at room temperature was added methyl piperidine-4-carboxylate (31.19 g, 217.82 mmol, 10.0 equiv). The resulting reaction mixture was heated at 160°C for 3 h. The reaction mixture was cooled to room temperature, diluted with H2O (100 mL), and then extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (1 x 10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford crude methyl (E)-1-(3-amino-6-(but-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate (approximately 2 g). The aqueous phase was adjusted to pH 5 with a saturated aqueous solution of citric acid (5 mL), and then extracted with EtOAc (2 × 10 mL). The combined organic layer was washed with brine (1 × 10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give (E) -1- (3-amino-6- (but-1-ene-1-yl) pyrazine-2-yl) piperidine-4-carboxylic acid (5 g, crude material) as a yellow oil. The crude acid was dissolved in MeOH (500 mL), and the resulting solution was treated with SOCl2 (6.46 g, 54.28 mmol, 3.94 mL, 3.0 equivalents). The resulting reaction mixture was heated to 70 ° C and stirred for 1 hour. The reaction mixture was cooled to room temperature and treated with a saturated aqueous solution of NaHCO3 (50 mL), and the resulting mixture was extracted with EtOAc (2 × 10 mL). The combined organic layers were washed with brine (1×10 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give additional crude (E)-methyl 1-(3-amino-6-(but-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate, which was combined with the material obtained above and purified by silica gel column chromatography (PE:EtOAc=50:1 to 15:1) to give pure (E)-methyl 1-(3-amino-6-(but-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate (3.5 g, 58% yield) as a yellow solid. 1 H NMR (400MHz, CD3OD) δ7.44(s,1H),6.57(m,1H),6.28(d,J=15.6,1H),3.72(s,3H),3.56(m, 2H),2.58(m,1H),2.36(m,2H),2.23(m,2H),2.09(m,2H),1.93(m,2H),1.10(t,J=7.2,3H); C 15 H 22 LCMS calculated value for N4O2: m / z=290; found: m / z=291 (M+H).

[0667] Intermediate 3. Methyl 1-(3-amino-6-butylpyrazin-2-yl)piperidine-4-carboxylate

[0668]

[0669] Pd / C (2.0 g, 10% weight) was added to a solution of (E)-1-(3-amino-6-(but-1-ene-1-yl)pyrazine-2-yl)piperidine-4-carboxylic acid methyl ester (intermediate 2) (6.0 g, 20.66 mmol, 1.0 equivalent) in MeOH (50 mL) at room temperature. The resulting reaction mixture was degassed under vacuum and purged with H2(g) several times. The reaction mixture was then stirred at room temperature under H2(15 psi) for 12 hours. The reaction mixture was then purged with N2(g) several times, filtered through a pad of celite to remove the Pd catalyst, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 20: 1 to 1: 1) to give 1-(3-amino-6-butylpyrazine-2-yl)piperidine-4-carboxylic acid methyl ester (4.3 g, 71% yield) as a yellow solid. 1 HNMR(400MHz, CDCl3)δ7.47(s,1H),4.50(s,br,2H),3.69(s,3H)3.51(m,2H),2.83(m,3H),2 .55(t,J=7.6,2H),2.02(m,2H),1.85(m,2H),1.60(m,2H),1.33(m,2H),0.91(t,J=7.2,3H); C 15 H 24 LCMS calculated value for N4O2: m / z = 292; found: m / z = 293 (M+H).

[0670] Intermediate 4. Methyl 1-(3-bromo-6-butylpyrazin-2-yl)piperidine-4-carboxylate

[0671]

[0672] To a solution of methyl 1-(3-amino-6-butylpyrazin-2-yl)piperidine-4-carboxylate (Intermediate 3) (0.45 g, 1.54 mmol, 1.0 equiv) in dibromomethane (30 mL) at room temperature under N2(g) was added isoamyl nitrite (198 mg, 1.69 mmol, 228 μL, 1.1 equiv) followed by a solution of TMSBr (259 mg, 1.69 mmol, 220 μL, 1.1 equiv) in dibromomethane (15 mL) at room temperature. The resulting reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was treated with H2O (10 mL) and then extracted with EtOAc (2×10 mL). The combined organic layers were washed with brine (1×10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative thin layer chromatography (PE:EtOAc=8:1) to give methyl 1-(3-bromo-6-butylpyrazin-2-yl)piperidine-4-carboxylate (0.6 g, 55% yield) as a yellow oil. 15 H 22 LCMS calculated value for BrN3O2: m / z=355; found: m / z=356 (M+H).

[0673] Intermediate 5. 5-Butyl-3-chloropyrazin-2-amine

[0674]

[0675] Under N2(g), PtO2(370mg, 1.63mmol, 0.1 equivalent) was added to a solution of (E)-5-(but-1-ene-1-yl)-3-chloropyrazine-2-amine (intermediate 1) (3.0g, 16.34mmol, 1.0 equivalent) in EtOAc (120mL) at room temperature. The suspension was degassed in vacuo and purged with H2 several times. The resulting reaction mixture was stirred at room temperature for 3 hours under H2(g) (15psi). The reaction mixture was purged with N2(g) several times, then filtered to remove the catalyst and concentrated under reduced pressure to give 5-butyl-3-chloropyrazine-2-amine (3.0g, crude material) as a yellow liquid. CH 12 LCMS calculated value for ClN3: m / z=185; found: m / z=186 (M+H).

[0676] Intermediate 6. 2-Bromo-5-butyl-3-chloropyrazine

[0677]

[0678] To a solution of crude 5-butyl-3-chloropyrazin-2-amine (Intermediate 5) (3.0 g, 16.16 mmol, 1.0 equiv) in dibromomethane (18 mL) at room temperature under an N2(g) atmosphere was added isoamyl nitrite (3.79 g, 32.32 mmol, 4.35 mL, 2.0 equiv) in one portion, followed by a solution of TMSBr (4.95 g, 32.32 mmol, 4.19 mL, 2.0 equiv) in dibromomethane (27 mL). The resulting reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then poured into H2O (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 2-bromo-5-butyl-3-chloropyrazine (3.1 g, 78% yield) as a yellow liquid. 1 H NMR: (400MHz, CD3OD) δ8.24 (s, 1H), 2.76 (t, J = 7.6, 2H), 1.69 (m, 2H), 1.38 (m, 2H), 0.94 (t, J = 7.6, 3H); C8H 1o LCMS calculated for BrClN2: m / z=249; found: m / z=250 (M+H).

[0679] Intermediate 7. 5-Butyl-3-chloro-2-(4-methoxyphenyl)pyrazine

[0680]

[0681] To a mixture of 2-bromo-5-butyl-3-chloropyrazine (Intermediate 6) (2.5 g, 10.02 mmol, 1.0 equiv) and (4-methoxyphenyl)boronic acid (1.37 g, 9.02 mmol, 0.9 equiv) in dioxane (25 mL) and H2O (5 mL) at room temperature under N2(g) atmosphere was added Pd(dppf)Cl2.CH2Cl2 (818 mg, 1.00 mmol, 0.1 equiv) and K2CO3 (2.77 g, 20.04 mmol, 2.0 equiv). The resulting reaction mixture was heated to 80°C and stirred for 12 hours. The reaction mixture was cooled to room temperature, diluted with H2O (100 mL), and then extracted with EtOAc (2×100 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 5-butyl-3-chloro-2-(4-methoxyphenyl)pyrazine (2.3 g, 83% yield) as a yellow oil. 1H NMR (400MHz, CD3OD) δ8.48(s,1H),7.73(d,J=8.4,2H),7.05(d,J=8.8,2H),3. 88(s,3H),2.84(t,J=8.0,2H),1.77(m,2H),1.44(m,2H),1.00(t,J=7.2,3H); C 15 H 17 LCMS calculated for ClN2O: m / z = 276; found: m / z = 277 (M+H).

[0682] Intermediate 8. Ethyl 1-(6-chloropyrazin-2-yl)piperidine-4-carboxylate

[0683]

[0684] To a solution of 2,6-dichloropyrazine (20.00 g, 134.25 mmol, 1.0 eq) and ethyl piperidine-4-carboxylate (22.16 g, 140.96 mmol, 1.1 eq) in 1,4-dioxane (600 mL) at room temperature was added EtN (14.94 g, 147.64 mmol, 1.1 eq). The resulting reaction mixture was heated to 100 ° C. for 12 hours under an N (g) atmosphere with stirring. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove most of the 1,4-dioxane. The residue was poured into H O (700 mL) and extracted with EtOAc (1400 mL). The organic phase was washed with brine (100 mL), dried over anhydrous Na SO, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 5:1) to give ethyl 1-(6-chloropyrazin-2-yl)piperidine-4-carboxylate (29.50 g, 74% yield) as a yellow oil. 1 C 12 H 16 LCMS calculated value for ClN3O2: m / z=269; found: m / z=270 (M+H).

[0685] Intermediate 9. Ethyl 1-(6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0686]

[0687] To a mixture of Zn (16.82 g, 257.23 mmol, 3.0 eq) in THF (180 mL) at room temperature under N2 (g) atmosphere, 1,2-dibromoethane (3.16 g, 16.81 mmol, 1.27 mL, 0.2 eq) was added. The resulting reaction mixture was heated to 80 ° C and stirred for 5 min, then recooled to room temperature. This heating-cooling cycle was repeated three times. Next, TMSCl (547 mg, 5.04 mmol, 0.06 eq) was added to the mixture, and the resulting reaction mixture was stirred at room temperature for 10 min. The reaction mixture was then cooled to 0 ° C, and a solution of 1,1,1-trifluoro-4-iodobutane (20 g, 84.04 mmol, 1.0 eq) in THF (180 mL) was added dropwise to the mixture over 15 minutes. The resulting reaction mixture was warmed to room temperature and stirred for 15 min. Next, a solution of ethyl 1-(6-chloropyrazine-2-yl)piperidine-4-carboxylate (intermediate 8) (9.56 g, 35.43 mmol, 1.0 eq) in THF (300 mL) was added to the reaction mixture. The reaction mixture was degassed and purged 3 times with N2(g), followed by addition of Pd(dppf)Cl2.CH2Cl2 (2.89 g, 3.54 mmol, 0.1 eq). The resulting reaction mixture was heated to 60 ° C and stirred for 12 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove THF. The reaction mixture was poured into H2O (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic phases were washed with brine (400 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=5:1 to 1:1) to give ethyl 1-(6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (14 g, 60% yield) as a brown oil. 1 HNMR (400MHz, CDCl3) δ = 8.13 (s, 1H), 7.68 (s, 1H), 4.26 (d, J = 13.6, 2H), 4.13 (q, J = 7.2, 2H), 3.12 (m ,2H),2.73(t,J=7.6,2H),2.61(m,1H),2.16(m,2H),2.05(m,4H),1.76(m,2H),1.29(t,J=7.2,3H); C 16 H 22 LCMS calculated value for F3N3O2: m / z=345; found: m / z=346 (M+H).

[0688] Intermediate 10. Ethyl 1-(5-iodo-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0689]

[0690] To a solution of ethyl 1-(6-(4,4,4-trifluorobutyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 9) (74 g, 214.26 mmol, 1.0 eq) in DMF (1000 mL) at room temperature was added TFA (24.44 g, 214.26 mmol, 1.0 eq) and NIS (62.66 g, 278.56 mmol, 1.3 eq). The resulting reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then adjusted to pH = 8 with a saturated aqueous solution of NaHCO3, and the reaction mixture was then extracted with EtOAc (3 × 500 mL). The combined organic layers were washed with brine (1000 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 5:1) to give ethyl 1-(5-iodo-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (49 g, 45% yield) as a brown oil. 1 HNMR (400MHz, CDCl3) δ = 7.77 (s, 1H), 4.19 (m, 4H), 3.05 (m, 2H), 2.83 (t, J = 7.4, 2H),2.57(m,1H),2.19(m,2H),2.01(m,4H),1.73(m,2H),1.27(t,J=7.2,3H); C 16 H 21 LCMS calculated value for F3IN3O2: m / z=471; found: m / z=472 (M+H).

[0691] Intermediate 11. Ethyl 1-(3-chloro-5-iodo-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0692]

[0693] To a solution of 1-(5-iodo-6-(4,4,4-trifluorobutyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 10) (44 g, 93.36 mmol, 1.0 eq) in DMF (500 mL) at room temperature was added NCS (18.70 g, 140.06 mmol, 1.5 eq) and TFA (10.64 g, 93.36 mmol, 1.0 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 1 hour. The reaction mixture was then cooled to room temperature and adjusted to pH = 8 with a saturated aqueous solution of NaHCO3, and the resulting mixture was extracted with EtOAc (3 × 500 mL). The combined organic layer was washed with brine (400 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 5:1) to give ethyl 3-(3-chloro-5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)-3-azabicyclo[3.1.1]heptane-6-carboxylate (49 g, 93% yield) as a yellow oil. 16 H 20 LCMS calculated value of ClF3IN3O2: m / z=489; found: m / z=506 (M+H).

[0694] Intermediate 12. Ethyl 1-(3-chloro-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0695]

[0696] To a solution of 1-(3-chloro-5-iodo-6-(4,4,4-trifluorobutyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 11) (36g, 73.19mmol, 1.0eq) in EtOH (300mL) at room temperature under N2(g) atmosphere is added 10% Pd / C (30g). The resulting suspension is degassed and purged 3 times with H2(g). The resulting reaction mixture is stirred at room temperature under H2(g) atmosphere (30psi) for 12 hours. Then, the mixture is purged three times with N2(g) and then filtered through diatomaceous earth to remove the catalyst. The filtrate is concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 3:1) to give ethyl 1-(3-chloro-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (13 g, 45% yield) as a yellow oil. 1H NMR(400MHz, CDCl3)δ=7.72(s,1H),4.17(q,J=7.2,2H),3.95(d,J=13.6,2H),2.96(m,2H),2 .75(t,J=7.2,2H),2.54(m,1H),2.18(m,2H),2.02(m,4H),1.90(m,2H),1.29(t,J=7.2,3H); C 16 H 21 LCMS calculated value for ClF3N3O2: m / z=379; found: m / z=380 (M+H).

[0697] Intermediate 13. Ethyl 1-(6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate

[0698]

[0699] 2,2,2-trifluoroethanol (37.36 g, 373.44 mmol, 3.0 eq) was added to a slurry of NaH (14.94 g, 373.44 mmol, 60% purity, 3.0 eq) in THF (1125 mL) at 0 ° C. The reaction mixture was warmed to room temperature and stirred for 1 hour. Then, the reaction mixture was recooled to 0 ° C. and potassium trifluoro((2,2,2-trifluoroethoxy)methyl)borate (25.00 g, 124.48 mmol, 1.0 eq) was added. The reaction mixture was warmed to room temperature and stirred for 11 hours. The reaction mixture was cooled to 0 ° C. and quenched with potassium bifluoride (200 mL, 4.5 M), and the reaction mixture was stirred for 30 min. The suspension was concentrated under reduced pressure to obtain a residue. The residue was ground with MTBE (2 × 600 mL) at room temperature for 30 min. The slurry was filtered, and the solid was collected and dried in vacuo. The crude product was ground with acetonitrile (200 mL) at room temperature for 30 min. The resulting slurry was filtered and the filtrate was concentrated in vacuo to give (2,2,2-trifluoroethoxymethyl) potassium trifluoroborate (27.00 g, crude material) as a white solid. Next, to 1- (6-chloropyrazine-2-yl) piperidine-4-carboxylic acid ethyl ester (intermediate 8) (10.00 g, 37.07 mmol, 1.0 eq) and (2,2,2-trifluoroethoxymethyl) potassium trifluoroborate (12.23 g, 55.61 mmol, 1.5 eq) in 1,4-dioxane (100 mL) and H2O (20 mL) in a solution of Pd (dppf) Cl2 CH2Cl2 (1.51 g, 1.85 mmol, 0.05 eq) and Cs2CO3 (36.24 g, 111.22 mmol, 3.0 eq). The obtained reaction mixture was heated to 110 DEG C and stirred for 12 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove most of the dioxanes. The residue was poured into H2O (300mL) and extracted with EtOAc (3 × 300mL). The combined organic phase was washed with brine (100mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 1: 1) to give ethyl 1- (6- ((2,2,2- trifluoroethoxy) methyl) pyrazine-2-yl) piperidine-4-carboxylate (9.5g, 73% yield) as a yellow solid. 1H NMR (400MHz, CDCl3) δ8.02(s,1H),7.85(s,1H),4.58(s,2H),4.18(m,2H),4.07(m,2H),3.90( q,J=8.8,2H),2.97(m,2H),2.51(m,1H),1.96(m,3H),1.68(m,2H),1.22-1.73(t,J=8.8,3H).

[0700] Intermediate 14. Ethyl 1-(5-chloro-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate

[0701]

[0702] To a solution of ethyl 1-(6-((2,2,2-trifluoroethoxy)methyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 13) (1.50 g, 4.32 mmol, 1.0 eq) in DMF (15 mL) at room temperature under an N2(g) atmosphere was added NCS (519 mg, 3.89 mmol, 0.9 eq) and TFA (49 mg, 431 μmol, 0.1 eq). The resulting reaction mixture was then heated at 60 ° C and stirred for 1 hour. The reaction mixture was then cooled to room temperature. The residue was poured into H2O (50 mL) and extracted with EtOAc (3×50 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 3:1) to give ethyl 1-(5-chloro-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate (720 mg, 43% yield) as a white solid. 15 H 19 LCMS calculated value of ClF3N3O3: m / z=381; found: m / z=382 (M+H).

[0703] Intermediate 15. Ethyl 1-(5-chloro-3-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate

[0704]

[0705] To a solution of ethyl 1-(5-chloro-6-((2,2,2-trifluoroethoxy)methyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 14) (620 mg, 1.62 mmol, 1.0 eq) in CHCl (10 mL) at room temperature under an N2(g) atmosphere was added NIS (730 mg, 3.25 mmol, 2.0 eq) and TFA (18 mg, 162 μmol, 12 μL, 0.1 eq). The resulting reaction mixture was then heated at 80 ° C and stirred for 0.5 hours. The reaction mixture was cooled to room temperature and then poured into H2O (30 mL) and extracted with EtOAc (3×30 mL). The combined organic phases were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 5:1) to give ethyl 1-(5-chloro-3-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate (780 mg, 94% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ4.68 (s, 2H), 4.10 (q, J = 7.2, 2H), 3.94 (dd, J = 8.4, 16.8, 2H), 3 .74(m,2H),2.88(m,2H),2.42(m,1H),1.98(m,2H),1.88(m,2H),1.21(t,J=7.2,3H).

[0706] Intermediate 16. Ethyl 1-(6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0707]

[0708] Over 5min, 1,2-dibromoethane (2.06g, 10.95mmol, 0.2eq) was added to a suspension of Zn (10.74g, 164.25mmol, 3.0eq) in THF (45mL) at room temperature under an N2(g) atmosphere. After the addition was complete, the resulting reaction mixture was heated to 80°C and stirred for 5min, and the reaction mixture was then cooled to room temperature. This heating-cooling cycle was repeated three more times. Next, TMSCl (356mg, 3.29mmol, 0.1eq) was added to the mixture at room temperature, and the resulting reaction mixture was stirred for 10min. The reaction mixture was cooled to 0°C, and a solution of 1,1,1,2,2-pentafluoro-4-iodo-butane (15g, 54.75mmol, 1.0eq) in THF (45mL) was then added dropwise over 10min. The resulting reaction mixture was warmed to room temperature and stirred for 15min. Next, ethyl 1-(6-chloropyrazine-2-yl)piperidine-4-carboxylate (intermediate 8) (7.50 g, 27.81 mmol, 1.0 eq) was added, followed by Pd(dppf)Cl2·CH2Cl2 (2.30 g, 2.78 mmol, 0.1 eq). The resulting reaction mixture was heated to 60 ° C and stirred for 12 hours. The reaction mixture was then cooled to room temperature and poured into H2O (100 mL) and extracted with EtOAc (2×100 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 15: 1 to 1: 1) to give ethyl 1-(6-(3,3,4,4,4-pentafluorobutyl)pyrazine-2-yl)piperidine-4-carboxylate (10.5 g, 38% yield) as a yellow liquid. 16 H 20 LCMS calculated value for F5N3O2: m / z=381; found: m / z=382 (M+H).

[0709] Intermediate 17. Ethyl 1-(5-iodo-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0710]

[0711] To a mixture of ethyl 1-(6-(3,3,4,4,4-pentafluorobutyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 16) (11.00 g, 28.85 mmol, 1.0 eq) in DMF (110 mL) at room temperature was added NIS (7.79 g, 34.61 mmol, 1.2 eq) and TFA (3.29 g, 28.85 mmol, 1.0 eq). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by adding a saturated aqueous solution of NH4Cl (100 mL). The mixture was then diluted with H2O (300 mL) and extracted with EtOAc (3 × 400 mL). The combined organic phases were washed with brine (400 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 5:1) to give ethyl 1-(5-iodo-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (11.00 g, 77% yield) as a brown solid. 1 C 16 H 19 LCMS calculated value for F5IN3O2: m / z=507; found: m / z=508 (M+H).

[0712] Intermediate 18. Ethyl 1-(3-chloro-5-iodo-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0713]

[0714] To a mixture of ethyl 1-(5-iodo-6-(3,3,4,4,4-pentafluorobutyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 17) (10.00 g, 19.71 mmol, 1.0 eq) in DMF (100 mL) at room temperature was added NCS (3.42 g, 25.63 mmol, 1.3 eq) and TFA (2.25 g, 19.71 mmol, 1.0 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 1 hour. The reaction mixture was then cooled to room temperature and quenched by adding a saturated aqueous solution of NH4Cl (80 mL). The resulting solution was diluted with H2O (300 mL) and extracted with EtOAc (3×400 mL). The combined organic phases were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 5:1) to give ethyl 1-(3-chloro-5-iodo-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (9.11 g, 96% yield) as a yellow liquid. 16 H 18 LCMS calculated value of ClF5IN3O2: m / z=541; found: m / z=542 (M+H).

[0715] Intermediate 19. Ethyl 1-(3-chloro-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0716]

[0717] To a solution of 1-(3-chloro-5-iodo-6-(3,3,4,4,4-pentafluorobutyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 18) (2.00, 3.69mmol, 1.0eq) in MeOH (80mL) at room temperature under N2(g) atmosphere, Pd / C (0.60g, 10% weight) is added. The resulting suspension is degassed in vacuo and purged three times with H2(g). The resulting reaction mixture is stirred at room temperature under H2(g) atmosphere (30psi) for 12 hours. The reaction mixture is then purged with N2(g), filtered through a pad of celite to remove the catalyst, and the filtrate is concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=30:1 to 1:1) to give ethyl 1-(3-chloro-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (1.67 g, crude) as a yellow solid. 1C 16 H 19 LCMS calculated value for ClF5N3O2: m / z=415; found: m / z=416 (M+H).

[0718] Intermediate 20. Ethyl 1-(5-chloro-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0719]

[0720] To a solution of ethyl 1-(6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl}piperidine-4-carboxylate (Intermediate 16) (2.50 g, 6.56 mmol, 1.0 eq) in DMF (10 mL) at room temperature was added NCS (875 mg, 6.56 mmol, 1.0 eq). The resulting reaction mixture was heated to 60° C. and stirred for 7 hours. The reaction mixture was then cooled to room temperature. The residue was poured into H 2 O The product was added into the mixture of 4-nitro-1- pyrrolidone (5-nitro-2- pyrrolidone) and 4-nitro-1- pyrrolidone (5-nitro-1- pyrrolidone) (70 mL) and extracted with EtOAc (3 × 15 mL). The combined organic phases were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 20: 1 to 10: 1) to give ethyl 1-(5-chloro-6-(3,3,4,4,4-pentafluorobutyl) pyrazin-2-yl) piperidine-4-carboxylate (1.5 g, 55% yield) as a yellow solid. 1 C 16 H 19 LCMS calculated value for ClF5N3O2: m / z=415; found: m / z=416 (M+H).

[0721] Intermediate 21. Ethyl 1-(5-chloro-3-iodo-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0722]

[0723] To a solution of ethyl 1-(5-chloro-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 20) (1.00 g, 2.41 mmol, 1.0 eq) in CHCl (5 mL) at room temperature was added NIS (1.08 g, 4.81 mmol, 2.0 eq) and TFA (27 mg, 240 μmol, 0.1 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 1.5 hours. The reaction mixture was then cooled to room temperature. The residue was poured into H2O (15 mL) and extracted with DCM (2×5 mL). The combined organic phases were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(5-chloro-3-iodo-6-(3,3,4,4,4-pentafluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (0.9 g, 70% yield) as a yellow solid. 16 H 18 LCMS calculated value of ClF5IN3O2: m / z=541; found: m / z=542 (M+H).

[0724] Intermediate 22. Ethyl 1-(6-(cyclopropylethynyl)pyrazin-2-yl)piperidine-4-carboxylate

[0725]

[0726] To a solution of ethyl 1-(6-chloropyrazine-2-yl)piperidine-4-carboxylate (intermediate 8) (10.00 g, 37.07 mmol, 1.0 eq) in DMA (40 mL) at room temperature was added CuI (706 mg, 3.71 mmol, 0.1 eq), DIPEA (47.92 g, 370.75 mmol, 10.0 eq), Pd(PPh ) Cl (2.60 g, 3.71 mmol, 0.1 eq) and ethynylcyclopropane (12.25 g, 185.37 mmol, 5.0 eq). The resulting reaction mixture was heated at 60° C. under an N (g) atmosphere and stirred for 12 hours. The reaction mixture was cooled to room temperature and then poured into H O (400 mL) and extracted with EtOAc (800 mL). The organic phase was washed with brine (100 mL), dried over anhydrous Na SO , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=15:1 to 10:1) to give ethyl 1-(6-(cyclopropylethynyl)pyrazin-2-yl)piperidine-4-carboxylate (18 g, 81% yield) as a yellow solid. 1H NMR (400MHz, CD3OD) δ8.07(s,1H),7.73(s,1H),4.26(m,2H),4.12(q,J=7.2,2H),3.07(m,2H),2. 65(m,1H),2.00(m,2H),1.69(m,2H),1.53(m,1H),1.26(t,J=7.2,3H),0.95(m,2H),0.86(m,2H); C 17 H 21 LCMS calculated value for N3O2: m / z=299; found: m / z=300 (M+H).

[0727] Intermediate 23. Ethyl 1-(6-(2-cyclopropylethyl)pyrazin-2-yl)piperidine-4-carboxylate

[0728]

[0729] To a solution of ethyl 1-(6-(cyclopropylethynyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 22) (2.00 g, 6.68 mmol, 1.0 eq) in MeOH (100 mL) at room temperature under an N2(g) atmosphere was added 10% Pd / C (1.00 g). The resulting suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under an H2(g) atmosphere (15 psi) for 12 hours. The reaction mixture was then purged with N2(g), filtered through a pad of celite to remove the catalyst, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(6-(2-cyclopropylethyl)pyrazine-2-yl)piperidine-4-carboxylate (2 g, crude material) as a yellow solid. 17 H 25 LCMS calculated value for N3O2: m / z=303; found: m / z=304 (M+H).

[0730] Intermediate 24. Ethyl 1-(6-(2-cyclopropylethyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0731]

[0732] To a solution of ethyl 1-(6-(2-cyclopropylethyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 23) (10.00 g, 32.96 mmol, 1.0 eq) in DMF (100 mL) at room temperature was added NIS (9.64 g, 42.85 mmol, 1.3 eq) and TFA (1.88 g, 16.48 mmol, 0.5 eq). The resulting reaction mixture was stirred at room temperature under an N2(g) atmosphere for 1 hour. The reaction mixture was quenched by slowly adding a saturated aqueous solution of NaHCO3 (200 mL), poured into H2O (500 mL) and extracted with EtOAc (1000 mL). The organic phase was washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(6-(2-cyclopropylethyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (9.52 g, 67%) as a yellow oil. 17 H 24 LCMS calculated for IN 3 O 2 : m / z = 429; found: m / z = 430 (M+H).

[0733] Intermediate 25. Ethyl 1-(3-chloro-6-(2-cyclopropylethyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0734]

[0735] To a solution of 1-(6-(2-cyclopropylethyl)-5-iodopyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 24) (10.00 g, 23.29 mmol, 1.0 eq) in DMF (100 mL) at room temperature was added TFA (1.33 g, 11.65 mmol, 0.5 eq) and NCS (3.42 g, 25.62 mmol, 1.1 eq). The resulting reaction mixture was heated to 100 ° C under an N (g) atmosphere and stirred for 1 hour. The reaction mixture was cooled to room temperature and quenched by slowly adding a saturated aqueous solution of NaHCO (100 mL), poured into H O (300 mL) and extracted with EtOAc (700 mL). The organic phase was washed with brine (400 mL), dried over anhydrous Na SO , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 15:1) to give ethyl 1-(3-chloro-6-(2-cyclopropylethyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (6.8 g, 63%) as a yellow oil. 1HNMR(400MHz,CD3OD)δ4.16(q,J=6.8,2H),3.96(m,2H),3.04-2.80(m,4H),2.61(m,1H),2.01(m, 2H),1.87-1.59(m,4H),1.40(m,1H),1.28(t,J=6.8,3H),0.98(m,1H),0.80(m,1H),0.46(m,2H).

[0736] Intermediate 26. Ethyl 1-(3-chloro-6-(2-cyclopropylethyl)pyrazin-2-yl)piperidine-4-carboxylate

[0737]

[0738] To a solution of 1-(3-chloro-6-(2-cyclopropylethyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 25) (1.00 g, 2.16 mmol, 1.0 eq) in MeOH (100 mL) at room temperature under N2(g) atmosphere was added 10% Pd / C (700 mg). The resulting suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under H2(g) atmosphere (30 psi) for 2 hours. The reaction mixture was then purged with N2(g), filtered through a celite pad to remove the catalyst, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE: EtOAc = 20: 1 to 15: 1) to give 1-(3-chloro-6-(2-cyclopropylethyl)pyrazin-2-yl)piperidine-4-carboxylic acid ethyl ester (0.6 g, 83%) as a yellow oil. 17 H 24 LCMS calculated value for ClN3O2: m / z=337; found: m / z=338 (M+H).

[0739] Intermediate 27. Ethyl 1-(5-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate

[0740]

[0741] To a solution of ethyl 1-(6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 13) (15.00 g, 43.19 mmol, 1.0 eq) in DMF (150 mL) at room temperature under an N2(g) atmosphere was added NIS (12.63 g, 56.14 mmol, 1.3 eq) and TFA (4.92 g, 43.19 mmol, 1.0 eq). The resulting reaction mixture was stirred for 1 hour. The reaction mixture was poured into H2O (1000 mL) and extracted with EtOAc (3×300 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 15:1) to give ethyl 1-(5-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate (30 g, 75% yield). 1 H NMR(400MHz, CDCl3)δ7.99(s,1H),4.71(s,2H),4.31(m,2H),4.25-4.05(m,4 H),3.11(m,2H),2.71(m,1H),2.01(m,2H),1.73(m,2H),1.27(t,J=7.2,3H).

[0742] Intermediate 28. Ethyl 1-(3-chloro-5-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate

[0743]

[0744] To a solution of ethyl 1-(5-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 27) (8.00 g, 16.91 mmol, 1.0 eq) in DMF (80 mL) at room temperature under an N2(g) atmosphere was added NCS (2.93 g, 21.98 mmol, 1.3 eq) and TFA (1.93 mg, 16.91 mmol, 1.0 eq). The resulting reaction mixture was then heated at 90 ° C and stirred for 1 hour. The reaction mixture was cooled to room temperature. The reaction mixture was then poured into H2O (200 mL) and extracted with EtOAc (3×200 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 1:1) to give ethyl 1-(3-chloro-5-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate (8.00 g, 93% yield) as a yellow oil.15 H 18 LCMS calculated value of ClF3IN3O3: m / z=507; found: m / z=508 (M+H).

[0745] Intermediate 29. Ethyl 1-(3-chloro-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate

[0746]

[0747] To a solution of 1-(3-chloro-5-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 28) (5.00 g, 9.85 mmol, 1.0 eq) in MeOH (100 mL) at room temperature under N2(g) atmosphere was added 10% Pd / C (600 mg). The resulting suspension was degassed in vacuo and purged three times with H2(g). The resulting reaction mixture was stirred at room temperature under H2(g) atmosphere (30 psi) for 1 hour. The reaction mixture was then purged with N2(g), filtered through a pad of celite to remove the catalyst, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=40:1 to 15:1) to give ethyl 1-(3-chloro-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carboxylate (2.20 g, 54% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.94 (s, 1H), 4.72 (s, 2H), 4.13 (q, J = 7.2, 2H), 3.96 (m, 4H), 2.94 (m, 2H), 2.53 (m, 1H), 2.01 (m, 2H), 1.88 (m, 2H), 1.25 (t, J = 7.2, 3H).

[0748] Intermediate 30. Ethyl 1-(6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0749]

[0750] To a solution of ethyl 1-(6-chloropyrazin-2-yl)piperidine-4-carboxylate (Intermediate 8) (2.00 g, 7.41 mmol, 1.0 eq) and potassium trifluoro(3,3,3-trifluoropropyl)borate (1.81 g, 8.90 mmol, 1.2 eq) in 1,4-dioxane (30 mL) and H2O (6 mL) at room temperature under an N2(g) atmosphere was added Pd(dppf)Cl2·CH2Cl2 (605 mg, 741 μmol, 0.1 eq) and Cs2CO3 (7.25 g, 22.24 mmol, 3.0 eq). The resulting reaction mixture was heated to 110°C and stirred for 12 hours. The reaction mixture was cooled to room temperature, diluted with H2O (300 mL), and then extracted with EtOAc (2×300 mL). The combined organic phases were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (2.09 g, 85% yield) as a yellow liquid. 1 H NMR (400MHz, CDCl3) δ7.97 (s, 1H), 7.69 (s, 1H), 4.24 (m, 2H), 4.13 (q, J = 7.2, 2H), 3 .03(m,2H),2.84(m,2H),2.53(m,3H)1.99(m,2H)1.74(m,5H)1.25(t,J=7.2,3H); C 15 H 20 LCMS calculated value for F3N3O2: m / z=331; found: m / z=332 (M+H).

[0751] Intermediate 31. Ethyl 1-(5-chloro-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0752]

[0753] To a solution of ethyl 1-(6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (intermediate 30) (300 mg, 905 μmol, 1.0 eq) in DMF (2 mL) at room temperature was added NCS (121 mg, 905 μmol, 1.0 eq). The resulting reaction mixture was heated to 60 ° C under an N2(g) atmosphere and stirred for 1 hour. The reaction mixture was cooled to room temperature, poured into H2O (100 mL), and extracted with EtOAc (3×100 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(5-chloro-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (170 mg, 51% yield) as a white solid. 1 C 15 H 19 LCMS calculated value of ClF3N3O2: m / z=365; found: m / z=366 (M+H).

[0754] Intermediate 32. Ethyl 1-(5-chloro-3-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0755]

[0756] To a solution of ethyl 1-(5-chloro-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 31) (150 mg, 410 μmol, 1.0 eq) in CHCl (5 mL) at room temperature was added NIS (92 mg, 410 μmol, 1.0 eq) and TFA (46 mg, 410 μmol, 1.0 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 1 hour. The reaction mixture was cooled to room temperature, poured into H2O (100 mL), and extracted with EtOAc (3×100 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(5-chloro-3-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (172 mg) as an oily yellow liquid.15 H 18 LCMS calculated value of ClF3IN3O2: m / z=491; found: m / z=492 (M+H).

[0757] Intermediate 33. Ethyl 1-(5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0758]

[0759] To a solution of ethyl 1-(6-(3,3,3-trifluoropropyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 30) (10.00 g, 30.18 mmol, 1.0 eq) in DMF (100 mL) at room temperature was added TFA (344 mg, 3.02 mmol, 0.1 eq) and NIS (6.79 g, 30.18 mmol, 1.0 eq). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by the addition of a saturated aqueous solution of NaHCO (70 mL), and the reaction mixture was then diluted with H2O (300 mL) and extracted with EtOAc (3 × 300 mL). The combined organic phases were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (10.30 g) as a yellow solid. 15 H 19 LCMS calculated value for F3IN3O2: m / z=457; found: m / z=458 (M+H).

[0760] Intermediate 34. Ethyl 1-(3-chloro-5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0761]

[0762] To a solution of ethyl 1-(5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (intermediate 33) (4.65 g, 10.17 mmol, 1.0 eq) in DMF (45 mL) at room temperature was added TFA (1.16 g, 10.17 mmol, 0.1 eq) and NCS (1.63 g, 12.20 mmol, 1.2 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 2 hours. The reaction mixture was then cooled to room temperature and quenched by the addition of a saturated aqueous solution of NaHCO3 (50 mL), diluted with H2O (300 mL) and extracted with EtOAc (3×400 mL). The combined organic phases were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(3-chloro-5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (4.65 g) as a yellow solid. 15 H 18 LCMS calculated value of ClF3IN3O2: m / z=491; found: m / z=492 (M+H).

[0763] Intermediate 35. Ethyl 1-(3-chloro-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0764]

[0765] To a solution of 1-(3-chloro-5-iodo-6-(3,3,3-trifluoropropyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 34) (1.30 g, 2.64 mmol, 1.0 eq) in MeOH (50 mL) at room temperature under N2 (g) atmosphere was added 10% Pd / C (0.50 g). The suspension was degassed in vacuo and purged three times with H2 (g). The resulting reaction mixture was stirred at room temperature under H2 (g) atmosphere (30 psi) for 12 hours. The reaction mixture was then purged with N2 (g), filtered through a celite pad to remove the catalyst, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give ethyl 1-(3-chloro-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carboxylate (0.73 g, 76%) as a yellow liquid. 1C 15 H 18 LCMS calculated value of ClF3N3O2: m / z=365; found value: m / z=366 (M+H).

[0766] Intermediate 36. 1-(6-chloropyrazin-2-yl)piperidine-4-carbonitrile

[0767]

[0768] To a solution of 2,6-dichloropyrazine (5.00 g, 33.56 mmol, 1.0 eq) and piperidinium-4-carbonitrile hydrochloride (5.12 g, 34.90 mmol, 1.1 eq) in 1,4-dioxane (50 mL) at room temperature was added Et3N (3.74 g, 36.92 mmol, 1.1 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 12 hours. The reaction mixture was then cooled to room temperature, diluted with H2O (200 mL), and then extracted with EtOAc (3×200 mL). The combined organic phases were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 20: 1 to 10: 1) to give 1- (6-chloropyrazine-2-yl) piperidine-4-carbonitrile (3.24 g, 43% yield) as a yellow solid. 10 H 11 LCMS calculated value for ClN4: m / z = 222; found: m / z = 223 (M+H).

[0769] Intermediate 37. 1-(6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0770]

[0771] To a solution of 1-(6-chloropyrazin-2-yl)piperidine-4-carbonitrile (Intermediate 36) (3.00 g, 13.47 mmol, 1.0 eq) and potassium trifluoro((2,2,2-trifluoroethoxy)methyl)borate (4.44 g, 20.21 mmol, 1.5 eq) in H2O (4 mL) and 1,4-dioxane (20 mL) at room temperature under N2(g) atmosphere was added Pd(dppf)Cl2·CH2Cl2 (1.10 g, 1.35 mmol, 0.1 eq) and Cs2CO3 (13.17 g, 40.41 mmol, 3.0 eq). The resulting reaction mixture was heated to 110°C and stirred for 12 hours. The reaction mixture was cooled to room temperature, diluted with H2O (200 mL), and extracted with EtOAc (2×300 mL). The combined organic phases were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 1-(6-(2,2,2-trifluoroethoxymethyl)pyrazin-2-yl)piperidine-4-carbonitrile (1.3 g, 32% yield) as a white solid. 13 H 15 LCMS calculated value for F3N4O: m / z=300; found: m / z=301 (M+H).

[0772] Intermediate 38. 1-(5-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0773]

[0774] To a solution of 1-(6-(2,2,2-trifluoroethoxymethyl)pyrazine-2-yl)piperidine-4-carbonitrile (intermediate 37) (6.00 g, 19.98 mmol, 1.0 eq) in DMF (40 mL) at room temperature was added TFA (2.28 g, 19.98 mmol, 1.0 eq) and NIS (5.84 g, 25.98 mmol, 1.3 eq), and the resulting reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched at room temperature by adding a saturated aqueous solution of NaHCO3 (100 mL), diluted with H2O (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 1-(5-iodo-6-(2,2,2-trifluoroethoxymethyl)pyrazin-2-yl)piperidine-4-carbonitrile (4.5 g, 55% yield) as a yellow solid. 13 H 14LCMS calculated value for F3IN4O: m / z=426; found: m / z=427 (M+H).

[0775] Intermediate 39. 1-(3-chloro-5-iodo-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0776]

[0777] To a solution of 1-(5-iodo-6-(2,2,2-trifluoroethoxymethyl)pyrazin-2-yl)piperidine-4-carbonitrile (intermediate 38) (3.5 g, 8.21 mmol, 1.0 eq) in DMF (35 mL) at room temperature was added TFA (936 mg, 8.21 mmol, 1.0 eq) and NCS (1.43 g, 10.68 mmol, 1.3 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 3 hours. The reaction mixture was then cooled to room temperature. The reaction mixture was quenched at room temperature by the addition of a saturated aqueous solution of NaHCO3 (50 mL), diluted with H2O (200 mL) and extracted with EtOAc (3×200 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 1-(3-chloro-5-iodo-6-(2,2,2-trifluoroethoxymethyl)pyrazin-2-yl)piperidine-4-carbonitrile (3.24 g, 86% yield) as a yellow solid. 13 H 13 LCMS calculated value of ClF3IN4O: m / z=460; found: m / z=461 (M+H).

[0778] Intermediate 40. 1-(3-chloro-6-((2,2,2-trifluoroethoxy)methyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0779]

[0780] Under N2(g) atmosphere, to a solution of 1-(3-chloro-5-iodo-6-(2,2,2-trifluoroethoxymethyl)pyrazine-2-yl)piperidine-4-carbonitrile (intermediate 39) (1.00g, 2.17mmol, 1.0eq) in MeOH (50mL) at room temperature, Pd / C (0.50g, 10% weight) was added. The suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under H2(g) atmosphere (30psi) for 12 hours. The reaction mixture was then purged with N2(g), filtered through a pad of celite to remove the catalyst, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 1-(3-chloro-6-(2,2,2-trifluoroethoxymethyl)pyrazin-2-yl)piperidine-4-carbonitrile (600 mg, 82% yield) as a yellow liquid. 13 H 14 LCMS calculated value for ClF3N4O: m / z=334; found: m / z=335 (M+H).

[0781] Intermediate 41. 2-(7-fluorobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0782]

[0783] To a solution of 5-bromo-7-fluoro-benzofuran (7.0 g, 32.56 mmol, 1.0 eq) and bispinacolatodiborane (13.23 g, 52.09 mmol, 1.6 eq) in 1,4-dioxane (98 mL) at room temperature under an N2(g) atmosphere was added Pd(dppf)Cl2·CH2Cl2 (5.32 g, 6.51 mmol, 0.2 eq) and KOAc (6.39 g, 65.11 mmol, 2.0 eq). The resulting reaction mixture was heated to 100°C and stirred for 12 hours. The reaction mixture was then cooled to room temperature, diluted with H2O (500 mL), and then extracted with EtOAc (2×500 mL). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 15:1) to give 2-(7-fluorobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.35 g, 91%) as a white solid. 1 H NMR (400MHz, CD3OD) δ7.84 (d, J = 2.0, 2H), 7.38 (d, J = 11.2, 1H), 6.95 (m, 1H), 1.38 (s, 12H).

[0784] Intermediate 42. 1-(6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0785]

[0786] To a solution of 1-(6-chloropyrazin-2-yl)piperidine-4-carbonitrile (Intermediate 36) (3.00 g, 13.47 mmol, 1.0 eq) and potassium trifluoro(3,3,3-trifluoropropyl)borate (3.02 g, 14.82 mmol, 1.1 eq) in 1,4-dioxane (30 mL) and H2O (6 mL) at room temperature under N2(g) atmosphere was added Pd(dppf)Cl2·CH2Cl2 (1.10 g, 1.35 mmol, 0.1 eq) and Cs2CO3 (13.17 g, 40.42 mmol, 3.0 eq). The resulting reaction mixture was heated to 110°C and stirred for 12 hours. The reaction mixture was then cooled to room temperature, diluted with H2O (200 mL), and extracted with EtOAc (2×300 mL). The combined organic phases were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc = 20:1 to 5:1) to give 1-(6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile (3.7 g, 96% yield) as a brown liquid. 13 H 15 LCMS calculated value of F3N4: m / z=284; found value: m / z=285 (M+H).

[0787] Intermediate 43. 1-(5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0788]

[0789] To a suspension of 1-(6-(3,3,3-trifluoropropyl)pyrazine-2-yl)piperidine-4-carbonitrile (intermediate 42) (3.20 g, 11.26 mmol, 1.0 eq) in DMF (32 mL) at room temperature was added NIS (3.29 g, 14.63 mmol, 1.3 eq) and TFA (1.28 g, 11.26 mmol, 1.0 eq), and the resulting reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with a saturated aqueous solution of NaHCO (50 mL), diluted with H2O (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 1-(5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile (2.3 g, 50% yield) as a yellow oil. 13 H 14 LCMS calculated value for F3IN4: m / z = 410; found: m / z = 411 (M+H).

[0790] Intermediate 44. 1-(3-chloro-5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0791]

[0792] To a solution of 1-(5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile (intermediate 43) (2.00 g, 4.88 mmol, 1.0 eq) in DMF (20 mL) at room temperature was added TFA (556 mg, 4.88 mmol, 1.0 eq) and NCS (846 mg, 6.34 mmol, 1.3 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 3 hours. The reaction mixture was then cooled to room temperature. The reaction mixture was quenched by adding a saturated aqueous solution of NaHCO3 (50 mL), diluted with H2O (200 mL) and extracted with EtOAc (3×200 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 1-(3-chloro-5-iodo-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile (1.9 g, 88% yield) as a yellow solid. 13 H 13 LCMS calculated value of ClF3IN4: m / z=443; found: m / z=444 (M+H).

[0793] Intermediate 45. 1-(3-chloro-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0794]

[0795] Under N2(g) atmosphere, 10% Pd / C (1.00g) was added to a solution of 1-(3-chloro-5-iodo-6-(3,3,3-trifluoropropyl)pyrazine-2-yl)piperidine-4-carbonitrile (intermediate 44) (1.80g, 4.05mmol, 1.0eq) in MeOH (100mL) at room temperature. The suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under H2(g) atmosphere (30psi) for 12 hours. The reaction mixture was then purged with N2(g), filtered through a celite pad to remove the catalyst, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 10:1) to give 1-(3-chloro-6-(3,3,3-trifluoropropyl)pyrazin-2-yl)piperidine-4-carbonitrile (1.23 g, 95% yield) as an oily yellow liquid. 13 H 14 LCMS calculated value of ClF3N4: m / z=317; found: m / z=318 (M+H).

[0796] Intermediate 46. Ethyl 1-(6-vinylpyrazin-2-yl)piperidine-4-carboxylate

[0797]

[0798] To a solution of ethyl 1-(6-chloropyrazin-2-yl)piperidine-4-carboxylate (Intermediate 8) (20.0 g, 74.15 mmol, 1.0 eq) and potassium trifluoro(vinyl)borate (11.92 g, 88.98 mmol, 1.2 eq) in THF (200 mL) and H2O (40 mL) at room temperature was added Pd(dppf)Cl2.CH2Cl2 (3.03 g, 3.71 mmol, 0.05 eq) and K2CO3 (20.50 g, 148.30 mmol, 2.0 eq). The resulting reaction mixture was heated at 80°C under an N2(g) atmosphere and stirred for 12 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to remove most of the THF. The residue was poured into H2O (700 mL) and extracted with EtOAc (2×700 mL). The combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 10: 1 to 5: 1) to give ethyl 1-(6-vinylpyrazin-2-yl)piperidine-4-carboxylate (16.8 g, 86% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ8.03(s,1H),7.80(s,1H),6.67(dd,J=10.8,17.2,1H),6.29(dd,J=2.0,17.2,1H),5.48(dd,J=2.0 C 14 H 19 LCMS calculated value for N3O2: m / z=261; found: m / z=262 (M+H).

[0799] Intermediate 47. Ethyl 1-(6-formylpyrazin-2-yl)piperidine-4-carboxylate

[0800]

[0801] To a solution of ethyl 1-(6-vinylpyrazin-2-yl)piperidine-4-carboxylate (Intermediate 46) (10.0 g, 38.27 mmol, 1.0 eq) in THF (100 mL) and H2O (20 mL) at 0°C was added KOsO4 (2.82 g, 7.65 mmol, 0.2 eq) followed by NaIO4 (24.56 g, 114.80 mmol, 3.0 eq). The resulting reaction mixture was then warmed to room temperature and stirred for 12 hours. The reaction mixture was poured into H2O (700 mL) and extracted with EtOAc (2 x 700 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 2:1) to give ethyl 1-(6-formylpyrazin-2-yl)piperidine-4-carboxylate (3.00 g, 29% yield) as a yellow oil. 1 H NMR(400MHz, CDCl3)δ9.96(s,1H),8.38(s,1H),8.33(s,1H),4.34(m,2H),4.14(q,J =7.2,2H),3.16(m,2H),2.62(m,1H),2.08(m,2H),1.81(m,2H),1.29(t,J=7.2,3H); C 13 H 17 LCMS calculated value for N3O3: m / z=263; found: m / z=264 (M+H).

[0802] Intermediate 48. Ethyl (E)-1-(6-(5,5,5-trifluoropent-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[0803]

[0804] To a mixture of ethyl 1-(6-formylpyrazin-2-yl)piperidine-4-carboxylate (Intermediate 47) (2.50 g, 9.50 mmol, 1.0 eq) and triphenyl-(4,4,4-trifluorobutyl)phosphonium iodide (prepared by heating a solution of 1,1,1-trifluoro-4-iodobutane (5.00 g, 21.01 mmol, 1.0 eq) and PPh3 (5.51 g, 21.01 mmol, 1.0 eq) in toluene (50 mL) at 85°C for 12 hours) (7.25 g, 14.43 mmol, 1.52 eq) in isopropyl acetate (25 mL) was added K2CO3 (2.10 g, 15.19 mmol, 1.6 eq) at room temperature. The resulting reaction mixture was heated to 80°C and stirred for 12 hours. The reaction mixture was cooled to room temperature, diluted with H2O (400 mL) and extracted with EtOAc (2×400 mL). The combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 8: 1 to 2: 1) to give (E)-1-(6-(5,5,5-trifluoropent-1-en-1-yl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (2.83 g) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ8.01(s,1H),7.73(s,1H),6.33(d,J=11.6,1H),5.88(m,1H),4.17(m, 4H),3.11(m,4H),2.58(m,1H),2.31(m,2H),2.05(m,2H),1.80(m,2H),1.30(t,J=7.2,3H); C 17 H 22 LCMS calculated value for F3N3O2: m / z=357; found: m / z=358 ​​(M+H).

[0805] Intermediate 49. Ethyl 1-(6-(5,5,5-trifluoropentyl)pyrazin-2-yl)piperidine-4-carboxylate

[0806]

[0807] To a solution of (E)-1-(6-(5,5,5-trifluoropent-1-en-1-yl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 48) (1.20 g, 3.36 mmol, 1.0 eq) in MeOH (100 mL) at room temperature was added 10% Pd / C (800 mg). The suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under an H2(g) atmosphere (15 psi) for 3 hours. The reaction mixture was then purged with N2(g) three times and filtered through a celite pad to remove the catalyst. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 5:1) to give 1-(6-(5,5,5-trifluoropentyl)pyrazine-2-yl]piperidine-4-carboxylic acid ethyl ester (0.91 g, 76% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.97(s,1H),7.70(s,1H),4.27(m,2H),4.16(q,J=7.2,2H),3.04(dt,J=2.4,11.2,2H) ,2.64(t,J=7.2,2H),2.53(m,1H),2.16(m,2H),2.03(m,2H),1.80(m,4H),1.63(m,2H),1.29(t,J=7.2,3H); 17 H 24 LCMS calculated value for F3N3O2: m / z=359; found: m / z=360 (M+H).

[0808] Intermediate 50. Ethyl 1-(5-iodo-6-(5,5,5-trifluoropentyl)pyrazin-2-yl)piperidine-4-carboxylate

[0809]

[0810] To a solution of ethyl 1-(6-(5,5,5-trifluoropentyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 49) (2.00 g, 5.57 mmol, 1.0 eq) in DMF (20 mL) at room temperature was added NIS (1.38 g, 6.12 mmol, 1.1 eq) and TFA (63 mg, 556 μmol, 0.1 eq). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by slowly adding a saturated aqueous solution of NaHCO (20 mL), and the reaction mixture was then poured into H2O (200 mL) and extracted with EtOAc (400 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=15:1 to 10:1) to give ethyl 1-(5-iodo-6-(5,5,5-trifluoropentyl)pyrazin-2-yl)piperidine-4-carboxylate (2.3 g, 85% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.76 (s, 1H), 4.19 (m, 4H), 3.03 (dt, J = 2.4, 11.2, 2H), 2.79 (t, J = 7 .2,2H),2.57(m,1H),2.19-1.98(m,4H),1.78(m,4H),1.69(m,2H),1.27(t,J=7.2,3H); C 17 H 23 LCMS calculated value for F3IN3O2: m / z=485; found: m / z=486 (M+H).

[0811] Intermediate 51. Ethyl 1-(3-chloro-5-iodo-6-(5,5,5-trifluoropentyl)pyrazin-2-yl)piperidine-4-carboxylate

[0812]

[0813] To a solution of ethyl 1-(5-iodo-6-(5,5,5-trifluoropentyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 50) (2.50 g, 5.15 mmol, 1.0 eq) in DMF (25 mL) at room temperature was added NCS (894 mg, 6.70 mmol, 1.3 eq) and TFA (58 mg, 515 μmol, 0.1 eq). The resulting reaction mixture was heated at 100 ° C and stirred for 2 hours. The reaction mixture was cooled to room temperature, poured into H2O (200 mL) and extracted with EtOAc (2×200 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=15:1 to 12:1) to give ethyl 1-(3-chloro-5-iodo-6-(5,5,5-trifluoropentyl)pyrazin-2-yl)piperidine-4-carboxylate (2.5 g, 93% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ4.16(q,J=7.2,2H),3.95(m,2H),3.01(dt,J=2.4,11.2,2H),2.83(t,J=7.2, 2H),2.54(m,1H),2.18(m,2H),2.04(m,2H),1.92-1.76(m,4H),1.66(m,2H),1.27(t,J=7.2,3H); 17 H 22 LCMS calculated value of ClF3IN3O2: m / z=519; found: m / z=520 (M+H).

[0814] Intermediate 52. Ethyl 1-(3-chloro-6-(5,5,5-trifluoropentyl)pyrazin-2-yl)piperidine-4-carboxylate

[0815]

[0816] To a solution of 1-(3-chloro-5-iodo-6-(5,5,5-trifluoropentyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 51) (1.00 g, 1.92 mmol, 1.0 eq) in MeOH (100 mL) at room temperature was added 10% Pd / C (600 mg). The suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under an H2(g) atmosphere (30 psi) for 0.5 hours. The reaction mixture was then purged with N2(g) and filtered through a celite pad to remove the catalyst. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 15: 1 to 10: 1) to give 1-(3-chloro-6-(5,5,5-trifluoropentyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (900 mg, 79% yield) as a yellow oil. 1 HNMR (400MHz, CDCl3) δ7.71 (s, 1H), 4.16 (q, J = 7.2, 2H), 3.93 (m, 2H), 2.99 (dt, J = 2.4, 11.2, 2H), 2.69 (t,J=7.2,2H),2.53(m,1H),2.16-2.01(m,4H),1.95-1.75(m,4H),1.62(m,2H),1.28(t,J=7.2,3H); C 17 H 23 LCMS calculated value for ClF3N3O2: m / z=393; found: m / z=394 (M+H).

[0817] Intermediate 53. Ethyl 1-(6-(3-hydroxybut-1-yn-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[0818]

[0819] By 1- (6- iodopyrazine -2- bases) piperidine -4- ethyl formate (intermediate 76) (15.0g, 41.53mmol, 1.0eq), but -3- yn-2-ol (8.73g, 124.59mmol, 3.0eq), PPh (2.18g, 8.31mmol, 0.2eq), CuI (1.58g, 8.31mmol, 0.2eq) and Et N (21.01g, 208mmol, 5.0eq) in ACN (200mL) mixture was purged three times with N (g). Next, Pd (dppf) Cl (3.04g, 4.15mmol, 0.1eq) was added, and the resulting reaction mixture was heated to 60 DEG C and stirred under N (g) atmosphere for 12 hours. The reaction mixture was cooled to room temperature, diluted with H O (200mL) and extracted with EtOAc (3 × 200mL). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc = 3:1 to 1:1) to give ethyl 1-(6-(3-hydroxybut-1-yn-1-yl)pyrazin-2-yl)piperidine-4-carboxylate (12.0 g, 83% yield) as a brown oil. 16 H 21 LCMS calculated value for N3O3: m / z=303; found: m / z=304 (M+H).

[0820] Intermediate 54. Ethyl 1-(6-(3-hydroxybutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0821]

[0822] Under N2(g) atmosphere, 20% Pd(OH)2 / C (1.5g, 50.11mmol, 1.0eq) was added to a solution of 1-(6-(3-hydroxybutyl-1-yn-1-yl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 53) (15.2g, 50.11mmol, 1.0eq) in MeOH (40mL). The suspension was degassed and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under H2(g) atmosphere (30psi) for 4 hours. The reaction mixture was then purged with N2(g) and filtered through a celite pad to remove the catalyst. The filtrate was concentrated in vacuo to give crude 1-(6-(3-hydroxybutyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (9.6g, 55% yield) as a yellow oil. 1H NMR(400MHz, CDCl3)δ7.99(s,1H),7.73(s,1H),4.18(m,4H),3.88(m,1H),3.04(m,2H), 2.78(t,J=7.2,2H),2.56(m,1H),2.02(m,2H),1.93-1.71(m,4H),1.27(t,J=7.0,3H); C 16 H 21 LCMS calculated value for N3O3: m / z=307; found: m / z=308 (M+H).

[0823] Intermediate 55. Ethyl 1-(6-(3-oxobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0824]

[0825] To a solution of ethyl 1-(6-(3-hydroxybutyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 54) (9.60 g, 31.23 mmol, 1.0 eq) in DCM (120 mL) at room temperature was added Dess-Martin periodinanae (26.49 g, 62.46 mmol, 2.0 eq). The resulting reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then concentrated under reduced pressure to remove DCM. The residue was diluted with a saturated aqueous solution of NaHCO (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (150 mL), dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=3:1 to 1:1) to give ethyl 1-(6-(3-oxobutyl)pyrazin-2-yl)piperidine-4-carboxylate (6.20 g, 53% yield) as a brown oil. 16 H 23 LCMS calculated value for N3O3: m / z=305; found: m / z=306 (M+H).

[0826] Intermediate 56. Ethyl 1-(6-(3,3-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0827]

[0828] To a solution of ethyl 1-(6-(3-oxobutyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 55) (3.00 g, 9.82 mmol, 1.0 eq) in DCE (30 mL) at room temperature was added DAST (43.47 g, 196.48 mmol, 20.0 eq). The resulting reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then cooled to 0°C and adjusted to pH = 8 with a saturated aqueous solution of NaHCO (100 mL). The reaction mixture was diluted with H2O (100 mL), extracted with EtOAc (3 x 200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=5:1 to 2:1) to give ethyl 1-(6-(3,3-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (1.20 g, 33% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.99(s,1H),7.73(s,1H),4.27(m,2H),4.17(q,J=7.2,2H),3.04(t,J=8.8,2H),2.8 8(m,2H),2.57(m,1H),2.29(m,2H),2.02(m,2H),1.80(m,2H),1.65(t,J=18.4,3H),1.28(t,J=7.2,3H); 16 H 23 LCMS calculated value for F2N3O2: m / z=327; found: m / z=328 (M+H).

[0829] Intermediate 57. Ethyl 1-(6-(3,3-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0830]

[0831] To a solution of ethyl 1-(6-(3,3-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 56) (1.7 g, 5.19 mmol, 1.0 eq) in DMF (15 mL) at room temperature was added TFA (593 mg, 5.19 mmol, 1.0 eq) and NIS (1.52 g, 6.75 mmol, 1.3 eq). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was adjusted to pH = 8 with a saturated aqueous solution of NaHCO3 (30 mL) and then extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=5:1 to 3:1) to give ethyl 1-(6-(3,3-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (1.8 g, 76% yield) as a yellow oil. 16 H 22 LCMS calculated value for F2IN3O2: m / z=453; found: m / z=454 (M+H).

[0832] Intermediate 58. Ethyl 1-(3-chloro-6-(3,3-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0833]

[0834] To a solution of 1-(6-(3,3-difluorobutyl)-5-iodo-pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 57) (1.5 g, 3.31 mmol, 1.0 eq) in DMF (20 mL) at room temperature was added TFA (378 mg, 3.31 mmol, 1.0 eq) and NCS (663 mg, 4.96 mmol, 1.5 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 1 hour. The reaction mixture was then cooled to room temperature and adjusted to pH = 8 with a saturated aqueous solution of NaHCO3 (30 mL) and then extracted with EtOAc (3 × 20 mL). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 4:1) to give ethyl 1-(3-chloro-6-(3,3-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (1.5 g, 77% yield) as a yellow oil. 1H NMR (400MHz, CDCl3) δ4.18 (q, J = 7.0, 2H), 3.94 (m, 2H), 2.98 (m, 4H), 2.54 (m, 1H), 2.31(m,2H),2.02(m,2H),1.88(m,2H),1.69(t,J=18.4,3H),1.28(t,J=7.2,3H).

[0835] Intermediate 59. Ethyl 1-(3-chloro-6-(3,3-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0836]

[0837] To a solution of ethyl 1-(3-chloro-6-(3,3-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (intermediate 58) (1.2 g, 2.46 mmol, 1.0 eq) in EtOH (30 mL) was added 10% Pd / C (2.5 g, 2.46 mmol, 1.0 eq). The suspension was degassed and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under H2(g) (15 psi) for 12 hours. The reaction mixture was then purged with N2(g) and filtered through a pad of celite to remove the catalyst. The filtrate was concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=0:1 to 3:1) to give ethyl 1-(3-chloro-6-(3,3-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (920 mg, 83% yield) as a yellow oil. 16 H 22 LCMS calculated value for ClF2N3O2: m / z=361; found: m / z=362 (M+H).

[0838] Intermediate 60. Ethyl (E)-1-(6-(4-methoxybut-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[0839]

[0840] To a solution of ethyl 1-(6-formylpyrazin-2-yl)piperidine-4-carboxylate (Intermediate 47) (3.21 g, 12.19 mmol, 1.0 eq) in isopropyl acetate (45 mL) at room temperature was added (3-methoxypropyl)triphenylphosphonium bromide (6.33 g, 15.24 mmol, 1.3 eq) followed by K2CO3 (2.02 g, 14.63 mmol, 1.2 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 48 hours. The reaction mixture was then cooled to room temperature, diluted with H2O (400 mL) and extracted with EtOAc (2×150 mL). The organic layers were combined, washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc=3:1 to 2:1) to give (E)-ethyl 1-(6-(4-methoxybut-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate (3.60 g, 92% yield) as a pale yellow oil. 1 H NMR (400MHz, CDCl3) δ7.97(s,1H),7.77(s,1H),6.34(d,J=11.8,1H),6.01(m,1H),4.27(m,2H),4.17(q,J=8.0, C 17 H 25 LCMS calculated value for N3O3: m / z=319; found: m / z=320 (M+H).

[0841] Intermediate 61. Ethyl 1-(6-(4-methoxybutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0842]

[0843] Under N2(g) atmosphere, 10% Pd / C (1.87 g) was added to a solution of (E)-1-(6-(4-methoxybutyl-1-ene-1-yl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 60) (1.87 g, 5.85 mmol, 1.0 eq) in EtOH (20 mL) at room temperature. The resulting suspension was degassed and purged three times with H2, and the mixture was then stirred at room temperature under H2(g) atmosphere (15 psi) for 2 hours. The reaction mixture was then purged with N2(g), filtered through a pad of celite to remove the catalyst, and the filtrate was concentrated under reduced pressure to give 1-(6-(4-methoxybutyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (3.65 g, 97% yield) as a light yellow oil. 1 H NMR (400MHz, CDCl3) δ7.95(s,1H),7.70(s,1H),4.26(m,2H),4.16(q,J=8.0,2H),3.41(t,J=6.0,2H),3.33(s,3 C 17 H 27 LCMS calculated value for N3O3: m / z=321; found: m / z=322 (M+H).

[0844] Intermediate 62. Ethyl 1-(5-iodo-6-(4-methoxybutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0845]

[0846] To a solution of ethyl 1-(6-(4-methoxybutyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 61) (3.45 g, 10.73 mmol, 1.0 eq) in DMF (75 mL) at room temperature was added NIS (3.02 g, 13.42 mmol, 1.2 eq). The resulting reaction mixture was heated to 60 ° C and stirred for 2 hours under an N2(g) atmosphere in the absence of light. The reaction mixture was then cooled to room temperature, quenched by the addition of a saturated aqueous solution of Na2SO3 (10 mL), and then diluted with EtOAc (200 mL) and H2O (200 mL). The aqueous layer was extracted with EtOAc (3×150 mL). The organic layers were combined, washed with brine (2×150 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=4:1 to 2:1) to give ethyl 1-(5-iodo-6-(4-methoxybutyl)pyrazin-2-yl)piperidine-4-carboxylate (3.57 g, 74% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.73 (s, 1H), 4.19 (m, 2H), 4.15 (q, J = 8.0, 2H), 3.42 (t, J = 6.0, 2H), 3.34 (s, 3H), 3. 01(m,2H),2.77(t,J=6.0,2H),2.54(m,1H),2.01(m,2H),1.76(m,4H),1.68(m,2H),1.26(t,J=6.0,3H); C 17 H 26 LCMS calculated value for IN3O3: m / z=447; found: m / z=448 (M+H).

[0847] Intermediate 63. Ethyl 1-(3-chloro-5-iodo-6-(4-methoxybutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0848]

[0849] To a solution of ethyl 1-(5-iodo-6-(4-methoxybutyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 62) (2.37 g, 5.30 mmol, 1.0 eq) in DMF (23 mL) at room temperature was added NCS (707 mg, 5.30 mmol, 1.0 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 4 hours under an N2(g) atmosphere in the absence of light. The reaction mixture was then cooled to room temperature and quenched by adding a saturated aqueous solution of Na2SO3 (20 mL). The mixture was then diluted with EtOAc (300 mL) and H2O (300 mL). The aqueous layer was extracted with EtOAc (2×300 mL). The organic layers were combined, washed with brine (2×200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=9:1 to 4:1) to give ethyl 1-(3-chloro-5-iodo-6-(4-methoxybutyl)pyrazin-2-yl)piperidine-4-carboxylate (2.13 g, 83% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ4.16(q,J=8.0,2H),3.95(m,2H),3.43(t,J=8.0,2H),3.35(s,3H),2.98(m,2H),2. 83(t,J=8.0,2H),2.54(m,1H),2.04(m,2H),1.90(m,2H),1.77(m,2H),1.67(m,2H),1.28(t,J=6.0,3H); C 17 H 25 LCMS calculated value for ClIN3O3: m / z=481; found: m / z=482 (M+H).

[0850] Intermediate 64. Ethyl 1-(3-chloro-6-(4-methoxybutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0851]

[0852] To a suspension of 10% Pd / C (2.81 g, 2.65 mmol) in EtOH (140 mL) at room temperature was added ethyl 1-(3-chloro-5-iodo-6-(4-methoxybutyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 63) (2.81 g, 5.83 mmol, 1.0 eq) under a N2(g) atmosphere. The suspension was degassed and purged with H2(g) three times. The mixture was stirred at room temperature under a H2(g) atmosphere (30 psi) for 4 hours. The reaction mixture was then purged with N2(g), filtered through a pad of celite to remove the catalyst, and the filtrate was concentrated under reduced pressure to remove EtOH. The residue was partitioned between H2O (200 mL) and EtOAc (150 mL). The aqueous layer was extracted with EtOAc (3×150 mL). The organic layers were combined, dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=9:1 to 4:1) to give ethyl 1-(3-chloro-6-(4-methoxybutyl)pyrazin-2-yl)piperidine-4-carboxylate (1.57 g, 76% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ7.71(s,1H),4.17(q,J=8.0,2H),3.93(m,2H),3.40(t,J=8.0,2H),3.33(s,3H),2.94(m,2 C 17 H 26 LCMS calculated value for ClN3O3: m / z=355; found: m / z=356 (M+H).

[0853] Intermediate 65. Ethyl 1-(6-(4-hydroxybut-1-yn-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[0854]

[0855] To a mixture of ethyl 1-(6-iodopyrazin-2-yl)piperidine-4-carboxylate (Intermediate 76) (15.0 g, 41.53 mmol, 1.0 eq), but-3-yn-1-ol (4.37 g, 62.30 mmol, 4.72 mL, 1.5 eq), CuI (1.58 g, 8.31 mmol, 0.2 eq), PPh (2.18 g, 8.31 mmol, 0.2 eq), and EtN (21.01 g, 207.65 mmol, 28.90 mL, 5.0 eq) in ACN (150 mL) at room temperature under N(g) atmosphere was added Pd(dppf)Cl (3.04 g, 4.15 mmol, 0.1 eq). The resulting reaction mixture was heated to 80° C. and stirred for 12 h. The reaction mixture was cooled to room temperature, diluted with H2O (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine (2 × 200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 3: 1 to 1: 2) to give ethyl 1- (6- (4-hydroxybut-1-yn-1-yl) pyrazine-2-yl) piperidine-4-carboxylate (11.0 g, 73% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ8.03(s,1H),7.89(s,1H),4.23(m,2H),4.15(q,J=7.2,2H),3.85(m,2H),3 .02(m,2H),2.73(t,J=6.4,2H),2.55(m,1H),2.01(m,2H),1.77(m,2H),1.26(t,J=7.2Hz,3H); C 16 H 21 LCMS calculated value for N3O3: m / z=303; found: m / z=304 (M+H).

[0856] Intermediate 66. Ethyl 1-(6-(4-oxobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0857]

[0858] To a suspension of 20% Pd(OH)2 (15.0 g, 21.36 mmol) in EtOH (100 mL) at room temperature under N2(g) atmosphere was added 1-(6-(4-hydroxybut-1-yn-1-yl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 65) (9.00 g, 29.67 mmol, 1.0 eq). The resulting reaction mixture was degassed in vacuo and purged with H2(g) several times, then stirred at room temperature under H2(g) atmosphere (30 psi) for 96 hours. The reaction mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure to give crude 1-(6-(4-hydroxybutyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (8.00 g, crude material) as a yellow oil. In a separate culture flask, a solution of oxalyl chloride (8.67 g, 68.32 mmol, 5.98 mL, 3.0 eq) in DCM (80 mL) was treated dropwise with DMSO (8.90 g, 113.86 mmol, 8.90 mL, 5.0 eq) for 5 min at -78 ° C under an N2 (g) atmosphere, and the resulting reaction mixture was stirred for 0.5 hours. Next, a solution of the crude 1- (6- (4-hydroxybutyl) pyrazin-2-yl) piperidine-4-carboxylic acid ethyl ester prepared above in DCM (20 mL) was added dropwise over 10 min, and the resulting reaction mixture was stirred at -78 ° C for 1 hour. Et3N (18.43 g, 182.18 mmol, 25.36 mL, 8.0 eq) was then added dropwise over 5 min, and the resulting reaction mixture was stirred at -78 ° C for 0.5 hours. The mixture was allowed to warm to room temperature, diluted with H2O (50 mL) and extracted with DCM (3×30 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 5: 1 to 1: 1) to give ethyl 1-(6-(4-oxobutyl)pyrazin-2-yl)piperidine-4-carboxylate (3.60 g, 52%) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ9.79(s,1H),7.99(s,1H),7.71(s,1H),4.26(m,2H),4.17(q,J=7.2,2H),3.05(m,2H) ,2.67(t,J=7.2,2H),2.60(m,1H),2.51(m,2H),2.08(m,2H),2.02(m,2H),1.76(m,2H),1.28(t,J=7.2,3H).

[0859] Intermediate 67. Ethyl 1-(6-(4,4-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0860]

[0861] To a solution of ethyl 1-(6-(4-oxobutyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 66) (3.20 g, 10.48 mmol, 1.0 eq) in DCM (30 mL) at -78 ° C was added DAST (4.64 g, 20.96 mmol, 4.59 mL, 2.0 eq). The resulting reaction mixture was warmed to room temperature and stirred for 3 hours. The reaction mixture was diluted with a saturated aqueous solution of NaHCO3 (50 mL) and then extracted with DCM (3×30 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 5: 1 to 1: 1) to give ethyl 1-(6-(4,4-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (1.90 g, 55% yield) as a yellow oil. 16 H 23 LCMS calculated value for F2N3O2: m / z=327; found: m / z=328 (M+H).

[0862] Intermediate 68. Ethyl 1-(6-(4,4-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0863]

[0864] A solution of 1-(6-(4,4-difluorobutyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 67) (2.00 g, 6.11 mmol, 1.0 eq), TFA (696 mg, 6.11 mmol, 452 μL, 1.0 eq) and NIS (1.79 g, 7.94 mmol, 1.3 eq) in DMF (20 mL) was degassed and purged with N2(g) three times at room temperature, and the resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with a saturated aqueous solution of NaHCO3 (30 mL) and then extracted with EtOAc (3 × 50 mL). The combined organic layer was washed with brine (2 × 50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=30:1 to 10:1) to give ethyl 1-(6-(4,4-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (2.16 g, 78% yield) as a yellow oil. 16 H 22 LCMS calculated value for F2IN3O2: m / z=453; found: m / z=454 (M+H).

[0865] Intermediate 69. Ethyl 1-(3-chloro-6-(4,4-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0866]

[0867] A solution of 1-(6-(4,4-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 68) (2.20 g, 4.85 mmol, 1.0 eq), NCS (842 mg, 6.31 mmol, 1.3 eq), TFA (553 mg, 4.85 mmol, 359 μL, 1.0 eq) in DMF (20 mL) at room temperature was degassed and purged three times with N2(g), and the resulting reaction mixture was heated to 100 ° C and stirred for 1 hour. The reaction mixture was cooled to room temperature, diluted with a saturated aqueous solution of NaHCO3 (30 mL), and extracted with EtOAc (2×50 mL). The combined organic layer was washed with brine (2×50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 10:1) to give ethyl 1-(3-chloro-6-(4,4-difluorobutyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (1.62 g, 68% yield) as a yellow oil. 16 H 21 LCMS calculated value for ClF2IN3O2: m / z=487; found: m / z=488 (M+H).

[0868] Intermediate 70. Ethyl 1-(3-chloro-6-(4,4-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate

[0869]

[0870] To a solution of 1-(3-chloro-6-(4,4-difluorobutyl)-5-iodopyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 69) (1.50 g, 3.08 mmol, 1.0 eq) in EtOH (15 mL) at room temperature under N2 (g) atmosphere, 10% Pd / C (3.00 g) was added. The resulting suspension was degassed in vacuo and purged several times with H2 (g). The resulting reaction mixture was stirred at room temperature under H2 (g) atmosphere (15 psi) for 48 hours. The reaction mixture was purged several times with N2 (g) and then filtered through a celite pad to remove the catalyst. The filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=30:1 to 10:1) to give ethyl 1-(3-chloro-6-(4,4-difluorobutyl)pyrazin-2-yl)piperidine-4-carboxylate (975 mg, 87% yield) as a yellow oil.16 H 22 LCMS calculated value for ClF2N3O2: m / z=361; found: m / z=362 (M+H).

[0871] Intermediate 71. 1-(6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0872]

[0873] To a mixture of zinc (6.44 g, 76.35 mmol, 3.0 eq) in THF (75 mL) at room temperature under N2 (g) atmosphere, 1,2-dibromoethane (1.18 g, 6.30 mmol, 0.2 eq) was added. The resulting reaction mixture was heated to 80 ° C and stirred for 5 min. The reaction mixture was then cooled to room temperature. This heating and cooling cycle was repeated four times, and then TMSCl (205 mg, 1.89 mmol, 0.06 eq) was added to the mixture, and the resulting mixture was stirred at room temperature for 10 min and then cooled to 0 ° C. Next, a solution of 1,1,1-trifluoro-3-iodo-propane (7.50 g, 31.51 mmol, 1.0 eq) in THF (75 mL) was added dropwise to the reaction mixture over 10 min, and the resulting reaction mixture was stirred at 0 ° C for 15 min. Next, 5mL THF containing 1- (6-chloropyrazine-2-yl) piperidine-4-carbonitrile (intermediate 36) (3.50g, 15.72mmol, 1.0eq) was added, followed by Pd (dppf) Cl2·CHCl2 (1.28g, 1.57mmol, 0.1eq). The resulting reaction mixture was heated at 60°C under stirring for 12 hours. The reaction mixture was cooled to room temperature and then poured into H2O (300mL) and extracted with EtOAc (2 × 300mL). The combined organic phases were washed with brine (300mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 1 to 0: 1) to obtain 1- (6- (4,4,4-trifluorobutyl) pyrazine-2-yl) piperidine-4-carbonitrile (4.1g, 87%) as a black oil. 1 H NMR (400MHz, CDCl3) δ7.94(s,1H),7.69(s,1H),3.79(m,2H),3.52(m,2H),2.84(m,1H),2.64(t,J=7.2,2H),2.07(m,2H),1.92(m,6H).

[0874] Intermediate 72. 1-(5-iodo-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0875]

[0876] To a solution of 1-(6-(4,4,4-trifluorobutyl)pyrazine-2-yl)piperidine-4-carbonitrile (intermediate 71) (3.10 g, 10.39 mmol, 1.0 eq) in DMF (30 mL) at room temperature under an N2(g) atmosphere was added NIS (3.04 g, 13.51 mmol, 1.3 eq) and TFA (1.18 g, 10.39 mmol, 1 eq). The resulting reaction mixture was then stirred at room temperature for 1 hour. The reaction mixture was quenched by a saturated aqueous solution of NaHCO3 (60 mL), poured into H2O (100 mL) and extracted with EtOAc (2×140 mL). The combined organic phases were washed with brine (150 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 4:1) to give 1-(5-iodo-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carbonitrile (3.6 g, 81% yield) as a yellow oil. 1 HNMR (400MHz, CDCl3) δ7.72(s,1H),3.74(m,2H),3.51(m,2H),2.80(m,1H),2.72(m,2H),2.09(m,2H),1.94(m,6H).

[0877] Intermediate 73. 1-(3-chloro-5-iodo-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0878]

[0879] To a solution of 1-(5-iodo-6-(4,4,4-trifluorobutyl)pyrazine-2-yl)piperidine-4-carbonitrile (intermediate 72) (3.30 g, 7.78 mmol, 1.0 eq) in DMF (30 mL) at room temperature under N2(g) atmosphere was added NCS (1.14 g, 8.56 mmol, 1.1 eq) and TFA (887 mg, 7.78 mmol, 1.0 eq). The resulting reaction mixture was heated at 100 ° C and stirred for 2 hours. The reaction mixture was cooled to room temperature and then quenched with a saturated aqueous solution of NaHCO3 (50 mL), poured into H2O (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic phase was washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 6:1) to give 1-(3-chloro-5-iodo-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carbonitrile (3.1 g, 85% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ3.59(m,2H),3.32(m,2H),2.84(m,3H),2.16(m,2H),1.98(m,6H).

[0880] Intermediate 74. 1-(3-chloro-6-(4,4,4-trifluorobutyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0881]

[0882] To a solution of 1- (3- chloro -5- iodo -6- (4,4,4- trifluorobutyl) pyrazine -2- bases) piperidine -4- carbonitrile (2.00 g, 4.36 mmol, 1.0 eq) in MeOH (150 mL) at room temperature was added 10% Pd / C (1.00 g). The suspension was degassed in vacuo and purged with H2 (g) three times. The resulting reaction mixture was stirred at room temperature under an H2 (g) atmosphere (30 psi) for 12 hours. The reaction mixture was then purged with N2 (g) three times and filtered through a celite pad to remove the catalyst. The filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 15: 1 to 5: 1) to obtain 1- (3- chloro -6- (4,4,4- trifluorobutyl) pyrazine -2- bases) piperidine -4- carbonitrile (1.2 g, 80% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.70(s,1H),3.59(m,2H),3.31(m,2H),2.83(m,1H),2.70(m,2H),2.01(m,8H).

[0883] Intermediate 75.2,6-Diiodopyrazine

[0884]

[0885] To a solution of 2,6-dichloropyrazine (50.00 g, 335 mmol, 1.0 eq) in HI (250 mL, 48% purity) at room temperature was added sodium iodide (65.40 g, 436 mmol, 1.3 eq). The resulting reaction mixture was heated to 100°C and stirred for 1 hour. The mixture was then cooled to room temperature, diluted with H2O (500 mL) and extracted with MTBE (3×500 mL). The combined organic layers were washed sequentially with saturated aqueous NaHCO3 (500 mL), Na2S2O3 (500 mL) and brine (500 mL), then dried over Na2SO4, filtered and concentrated under reduced pressure to give 2,6-diiodopyrazine (102 g, crude) as a white solid. 1H NMR (400MHz, DMSO-d6) δ8.91 (s, 2H).

[0886] Intermediate 76. Ethyl 1-(6-iodopyrazin-2-yl)piperidine-4-carboxylate

[0887]

[0888] To a solution of 2,6-diiodopyrazine (intermediate 75) (60 g, 180 mmol, 1.0 eq) in dioxane (800 mL) at room temperature was added EtN (27.44 g, 271 mmol, 37.8 mL, 1.5 eq) and ethyl piperidine-4-carboxylate (42.63 g, 271 mmol, 41.8 mL, 1.5 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 12 hours. The mixture was then cooled to room temperature, diluted with H O (500 mL) and extracted with EtOAc (3×500 mL). The combined organic layers were washed with brine (500 mL), dried over Na SO , filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 10:1) to give ethyl 1-(6-iodopyrazin-2-yl)piperidine-4-carboxylate (66 g, 96% yield) as a yellow oil. 1 C 12 H 16LCMS calculated value for IN3O2: m / z=361; found: m / z=362 (M+H).

[0889] Intermediate 77. Ethyl 1-(6-(3-hydroxyprop-1-yn-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[0890]

[0891] To a solution of ethyl 1-(6-iodopyrazine-2-yl)piperidine-4-carboxylate (intermediate 76) (10 g, 28 mmol, 1.00 eq) in ACN (100 mL) at room temperature was added prop-2-yn-1-ol (3.35 g, 61 mmol, 2.20 eq), CuI (1.05 g, 5.6 mmol, 0.20 eq), PPh (1.45 g, 5.6 mmol, 0.20 eq), Pd(dppf)Cl (1.01 g, 1.4 mmol, 0.05 eq) and EtN (14.01 g, 138.5 mmol, 19 mL, 5.00 eq). The resulting reaction mixture was degassed and purged three times with N (g), and the reaction mixture was then heated to 60 ° C and stirred under a N (g) atmosphere for 12 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove most of the ACN. The residue was diluted with H2O (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 1: 1) to give ethyl 1-(6-(3-hydroxyprop-1-yn-1-yl)pyrazin-2-yl)piperidine-4-carboxylate (7.50 g, 90% yield) as a brown oil. 1 H NMR(400MHz, CDCl3)δ8.07(s,1H),7.95(s,1H),4.51(s,2H),4.23(m,2H),4.12(q,J =7.2,2H),3.04(m,2H),2.56(m,1H),2.01(m,2H),1.77(m,2H),1.28(t,J=7.2,3H); C 15 H 19 LCMS calculated value for N3O3: m / z=289; found: m / z=290 (M+H).

[0892] Intermediate 78. Ethyl 1-(6-(3-hydroxypropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0893]

[0894] To a solution of 1-(6-(3-hydroxyprop-1-ynyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 77) (12 g, 41.48 mmol, 1.0 eq) in EtOH (100 mL) at room temperature was added 20% Pd(OH) / C (15.0 g). The resulting suspension was degassed in vacuo and purged with H(g) several times. The reaction mixture was stirred at room temperature under an H(g) atmosphere (15 psi) for 12 hours. The reaction mixture was then purged with N(g) several times. The reaction mixture was filtered, and the filtrate was concentrated to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 1: 1) to give 1-(6-(3-hydroxypropyl)pyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (6.75 g, 55% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ8.00(s,1H),7.73(s,1H),4.21(m,2H),4.14(q,J=7.2,2H),3.71(t,J=6.0,2H),3. 03(m,2H),2.77(t,J=7.2,2H),2.58(m,1H),2.02(m,2H),1.96(m,2H),1.80(m,2H),1.27(t,J=7.2,3H); C 15 H 23 LCMS calculated value for N3O3: m / z=293; found: m / z=294 (M+H).

[0895] Intermediate 79. Ethyl 1-(6-(3-hydroxypropyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0896]

[0897] To a solution of ethyl 1-(6-(3-hydroxypropyl)pyrazin-2-yl)piperidine-4-carboxylate (intermediate 78) (2.30 g, 8 mmol, 1.0 eq) and NIS (2.29 g, 10 mmol, 1.3 eq) in DMF (30 mL) at room temperature was added TFA (179 mg, 1.57 mmol, 116 μL, 0.2 eq). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with a saturated aqueous solution of NaHCO₃ (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 3: 1) to give ethyl 1-(6-(3-hydroxypropyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (1.8 g, 55% yield) as a yellow solid. 1HNMR (400MHz, CDCl3) δ7.77 (s, 1H), 4.16 (m, 4H), 3.71 (t, J = 7.2, 2H), 3.04 (m, 2H), 2. 90(t,J=7.2,2H),2.56(m,1H),2.07-1.93(m,5H),1.76(m,2H),1.27(t,J=7.2,3H);C 15 H 22 LCMS calculated value for IN3O3: m / z=419; found: m / z=420 (M+H).

[0898] Intermediate 80. Ethyl 1-(3-chloro-6-(3-hydroxypropyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0899]

[0900] To a solution of ethyl 1-(6-(3-hydroxypropyl)-5-iodo-pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 79) (1.3 g, 3 mmol, 1 eq) and NCS (497 mg, 3.72 mmol, 1.2 eq) in DMF (20 mL) at room temperature was added TFA (71 mg, 620 μmol, 46 μL, 0.2 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 1 hour. The mixture was then cooled to room temperature, diluted with H2O (30 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 3:1) to give ethyl 1-(3-chloro-6-(3-hydroxypropyl)-5-iodo-pyrazin-2-yl)piperidine-4-carboxylate (1.0 g, 71% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ4.18(q,J=7.2,2H),3.94(m,2H),3.72(t,J=6.4,2H),3. 04-2.88(m,4H),2.53(m,1H),2.02(m,4H),1.89(m,2H),1.28(t,J=7.2,3H);C 15 H 21 LCMS calculated value for ClIN3O3: m / z=453; found: m / z=454 (M+H).

[0901] Intermediate 81. Ethyl 1-(3-chloro-6-(3-hydroxypropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0902]

[0903] To a solution of 1- (3- chloro-6- (3- hydroxypropyl) -5- iodo- pyrazine-2-yl) piperidine-4-carboxylic acid ethyl ester (intermediate 80) (1.1 g, 2.42 mmol, 1.0 eq) in EtOH (10 mL) was added 10% Pd / C (2.42 mmol, 1 eq). The resulting suspension was degassed in vacuo and purged with H2(g) several times. The reaction mixture was stirred at room temperature under an H2(g) atmosphere (15 psi) for 16 hours. The reaction mixture was then purged with N2(g). The reaction mixture was filtered, and the filtrate was concentrated to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 2: 1) to give 1- (3- chloro- 6- (3- hydroxypropyl) pyrazine-2-yl) piperidine-4-carboxylic acid ethyl ester (500 mg, 63% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.76 (s, 1H), 4.18 (q, J = 7.2, 2H), 3.93 (m, 2H), 3.71 (m, 2H), 3.00-2.92 (m, 2 H),2.81(t,J=7.2,2H),2.53(m,1H),2.27(m,1H),2.07(m,2H),1.94(m,4H),1.29(t,J=7.2,3H); C 15 H 22 LCMS calculated value for ClN3O3: m / z=327; found: m / z=328 (M+H).

[0904] Intermediate 82. Ethyl 1-(3-chloro-6-(3-oxopropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0905]

[0906] A solution of oxalyl chloride (465mg, 3.66mmol, 320 μL, 3eq) in DCM (5mL) is cooled to -78 ° C. To this solution, DMSO (477mg, 6.10mmol, 476 μL, 5eq) is added, and the resulting reaction mixture is stirred at -78 ° C for 30min. Next, a solution of 1- (3- chloro- 6- (3- hydroxypropyl) pyrazine-2-yl) piperidine-4-carboxylic acid ethyl ester (intermediate 81) (400mg, 1.22mmol, 1eq) in DCM (5mL) is added dropwise to the reaction mixture over 5min, and the resulting reaction mixture is stirred at -78 ° C for 1 hour. Then, at -78 ° C, EtN (988mg, 9.76mmol, 1.36mL, 8eq) is added dropwise over 5min, and the resulting reaction mixture is stirred for 30min, then warmed to room temperature and stirred for another 15min. The reaction mixture was diluted with H2O (30 mL) and extracted with DCM (3 × 30 mL). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 1: 1) to give ethyl 1- (3-chloro-6- (3-oxopropyl) pyrazine-2-yl) piperidine-4-carboxylate (380 mg, 69% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ9.89 (s, 1H), 7.77 (s, 1H), 4.18 (q, J = 7.2, 2H), 3.92 (m, 2H), 3.05 ( m,2H),2.99-2.84(m,4H),2.53(m,1H),2.03(m,2H),1.90(m,2H),1.29(t,J=7.2,3H); C 15 H 20 LCMS calculated value for ClN3O3: m / z=325; found: m / z=326 (M+H).

[0907] Intermediate 83. Ethyl 1-(3-chloro-6-(4,4-difluorobut-3-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[0908]

[0909] To a mixture of ethyl 1-(3-chloro-6-(3-oxopropyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 82) (911 mg, 2.80 mmol, 1.5 eq), 2-((difluoromethyl)sulfonyl)pyridine (360 mg, 1.86 mmol, 1.0 eq) and CsF (566 mg, 3.73 mmol, 138 μL, 2.0 eq) in DMF (15 mL) at room temperature under N2(g) atmosphere was added bis(trimethylsilyl)amine (871 mg, 3.73 mmol, 2 eq). The resulting reaction mixture was stirred at room temperature for 11.5 hours. The mixture was cooled to 0°C, and then saturated aqueous NH4Cl solution (100 mg, 1.86 mmol, 1 eq) and HCl (2 M, 13.98 mL, 15 eq) were added sequentially to the reaction mixture, and the resulting reaction mixture was heated to 50°C and stirred for 30 min. The reaction mixture was cooled to room temperature, diluted with H2O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 5: 1) to give 1- (3-chloro-6- (4,4-difluorobut-3-ene-1-yl) pyrazine-2-yl) piperidine-4-carboxylic acid ethyl ester (420 mg, 61% yield) as a yellow oil. 1 H NMR(400MHz, CDCl3)δ7.63(s,1H),4.11(m,3H),3.87(m,2H),2.90(m,2H),2.66(t, J=7.6,2H),2.46(m,1H),2.34(m,2H),1.97(m,),1.85(m,2H),1.21(t,J=7.2,3H); C 16 H 20 LCMS calculated value for ClF2N3O2: m / z=359; found: m / z=360 (M+H).

[0910] Intermediate 84. 5-Bromo-2-chloro-3-(methoxymethoxy)pyridine

[0911]

[0912] Over 10 min, to a solution of NaH (2.49 g, 62.37 mmol, 60% purity, 1.30 eq) in DMF (50 mL) at room temperature under an N2 (g) atmosphere was dropwise added DMF (50 mL) containing 5-bromo-2-chloropyridine-3-ol (10.00 g, 47.98 mmol, 1.00 eq). The resulting reaction mixture was stirred at room temperature for 30 min, and then MOMCl (4.83 g, 59.99 mmol, 4.56 mL, 1.25 eq) was added. The resulting reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with a saturated aqueous solution of NaHCO3 (100 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layer was washed with brine (2 × 100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 5:1) to give 5-bromo-2-chloro-3-(methoxymethoxy)pyridine (10.0 g, 81% yield) as a white solid.

[0913] Intermediate 85. 3-(6-chloro-5-(methoxymethoxy)pyridin-3-yl)prop-2-yn-1-ol

[0914]

[0915] By 3-methoxyprop-1-yne (12.21g, 174.26mmol, 14.37mL, 2.00eq), 5-bromo-2-chloro-3-(methoxymethoxy) pyridine (intermediate 84) (22.00g, 87.13mmol, 1.00eq), CuI (1.66g, 8.71mmol, 0.10eq), [2-(2-aminophenyl) phenyl] palladium (1+); bis(1-adamantyl)-butyl-phosphine; a mixture of methanesulfonate (CataCXium A PdG3) (3.17g, 4.36mmol, 0.05eq) and Cs2CO3 (85.17g, 261.39mmol, 3.00eq) in ACN (400mL) was degassed in vacuo and purged three times with N2(g), and the reaction mixture was then heated to 100°C and stirred for 12 hours. The reaction mixture was cooled to room temperature and filtered through a pad of celite. The filtrate was diluted with H2O (300 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine (2 × 200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 50: 1 to 10: 1) to give 2-chloro-3-(methoxymethoxy)-5-(3-methoxyprop-1-yn-1-yl)pyridine (17.0 g, 80% yield) as a yellow solid. 1C 11 H 12 LCMS calculated value for ClNO3: m / z=241; found: m / z=242 (M+H).

[0916] Intermediate 86. 2-chloro-3-(methoxymethoxy)-5-(3-methoxypropyl)pyridine

[0917]

[0918] To a solution of 2-chloro-3-(methoxymethoxy)-5-(3-methoxyprop-1-ynyl)pyridine (13.00 g, 53.79 mmol, 1.0 eq) in MeOH (10 mL) at room temperature under an N2(g) atmosphere was added 5% Rh / C (6.00 g). The resulting suspension was degassed in vacuo and purged three times with H2(g). The reaction mixture was stirred at room temperature under H2(g) (15 psi) for 8 h. The reaction mixture was then purged three times with N2(g), filtered through a celite pad, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 30: 1 to 10: 1) to give 2-chloro-3-(methoxymethoxy)-5-(3-methoxypropyl)pyridine (10.00 g, 75% yield) as a yellow oil. 11 H 16 LCMS calculated value for ClNO3: m / z=245; found: m / z=246 (M+H).

[0919] Intermediate 87. 6-Bromo-4-fluorobenzo[d][1,3]dioxole

[0920]

[0921] To a solution of 5-bromo-3-fluoro-benzene-1,2-diol (200 mg, 966 μmol, 1.0 eq) and bromo(chloro)methane (375 mg, 2.90 mmol, 3.0 eq) in DMF (3 mL) at room temperature under an N2(g) atmosphere was added Cs2CO3 (629 mg, 1.93 mmol, 2.0 eq). The resulting reaction mixture was heated to 60 ° C and stirred for 3 hours. The reaction mixture was then cooled to room temperature. The residue was poured into H2O (60 mL) and extracted with EtOAc (3×60 mL). The combined organic phases were washed with brine (60 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 10:1) to give 6-bromo-4-fluorobenzo[d][1,3]dioxole (60 mg, 18% yield) as a clear liquid. 1 HNMR (400MHz, CDCl3) δ6.77 (dd, J = 9.2, 1H), 6.72 (s, 1H), 5.95 (s, 2H).

[0922] Intermediate 88. 2-(7-fluorobenzo[d][1,3]dioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0923]

[0924] To a solution of 6-bromo-4-fluoro-1,3-benzodioxole (340 mg, 1.55 mmol, 1.0 eq) and (bis)pinacolatodiborane (591 mg, 2.33 mmol, 1.5 eq) in dioxane (10 mL) at room temperature under an N2(g) atmosphere was added Pd(dppf)Cl2·CHCl2 (253 mg, 310 μmol, 0.2 eq) and KOAc (304 mg, 3.10 mmol, 2.0 eq). The resulting reaction mixture was heated to 100°C and stirred for 12 hours. The reaction mixture was cooled to room temperature, poured into H2O (50 mL) and extracted with EtOAc (3×50 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 10:1) to give 2-(7-fluoro-1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (240 mg, 58% yield) as a colorless transparent liquid. 1 H NMR (400MHz, CDCl3) δ7.19(s,1H),7.09(s,1H),5.95(s,2H),1.27(s,12H).

[0925] Intermediate 89. Ethyl 1-(6-(3-methoxyprop-1-yn-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[0926]

[0927] To a solution of ethyl 1-(6-iodopyrazin-2-yl)piperidine-4-carboxylate (Intermediate 76) (25.0 g, 69.22 mmol, 1.0 eq) and 3-methoxyprop-1-yne (9.7 g, 138.44 mmol, 2.0 eq) in ACN (250 mL) at room temperature under an N2(g) atmosphere was added chloro[(di(1-adamantyl)-N-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (cataCXium A-Pd-G2) (2.3 g, 3.46 mmol, 0.05 eq), Cs2CO3 (67.7 g, 207.65 mmol, 3.0 eq) and CuI (1.3 g, 6.92 mmol, 0.1 eq). The resulting reaction mixture was heated to 80°C and stirred for 12 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove most of the ACN. The residue was poured into H2O (1 L) and extracted with EtOAc (3×1 L). The combined organic phases were washed with brine (500 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=5:1 to 3:1) to give ethyl 1-(6-(3-methoxyprop-1-ynyl)pyrazin-2-yl)piperidine-4-carboxylate (13.1 g, 62% yield) as a brown oil. 1 H NMR (400MHz, CDCl3) δ8.10(s,1H),7.97(s,1H),4.37(s,2H),4.27(m,2H),4.19(q,J=7.2, 2H), 3.49 (s, 3H), 3.09 (m, 2H), 2.56 (m, 1H), 2.06 (m, 2H), 1.81 (m, 2H), 1.29 (t, J = 7.2, 3H).

[0928] Intermediate 90. Ethyl 1-(6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0929]

[0930] To a solution of 1- (6- (3-methoxyprop-1-ynyl) pyrazine-2-yl) piperidine-4-carboxylic acid ethyl ester (10.0 g, 32.96 mmol, 1.0 eq) in EtOH (500 mL) at room temperature was added 20% Pd (OH) / C (4.4 g). The suspension was degassed in vacuo and purged with H (g) three times. The resulting reaction mixture was stirred at room temperature under H (g) (15 psi) for 3 hours. The reaction mixture was then degassed in vacuo and purged with N (g) three times, then filtered through a celite pad to remove the catalyst. The filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 5: 1 to 3: 1) to obtain 1- (6- (3-methoxypropyl) pyrazine-2-yl) piperidine-4-carboxylic acid ethyl ester (9.6 g, 91% yield) as a brown oil. 1 H NMR (400MHz, CDCl3) δ7.89 (s, 1H), 7.64 (s, 1H), 4.19 (m, 2H), 4.10 (q, J = 7.2, 2H), 3.35 (t, J = 6.4, 2H), 3. 28(s,3H),2.95(m,2H),2.64(t,J=11.2,2H),2.47(m,1H),1.95(m,4H),1.71(m,2H),1.20(t,J=7.2,3H).

[0931] Intermediate 91. Ethyl 1-(5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0932]

[0933] To a solution of ethyl 1-(6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 90) (11.1 g, 36.18 mmol, 1.0 eq) in DMF (100 mL) at room temperature under an N2(g) atmosphere was added NIS (8.1 g, 36.18 mmol, 1.0 eq) and TFA (4.1 g, 36.18 mmol, 1.0 eq). The resulting reaction mixture was then stirred at room temperature for 1 hour. The reaction mixture was poured into H2O (500 mL) and extracted with EtOAc (3 x 500 mL). The combined organic phases were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=5:1 to 3:1) to give ethyl 1-(5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate (13.1 g, 84% yield) as a brown oil. 1H NMR (400MHz, CDCl3) δ7.67 (s, 1H), 4.11 (m, 4H), 3.40 (t, J = 6.4, 2H), 3.30 (s, 3H), 2.97 ( m, 2H), 2.76 (t, J = 7.6, 2H), 2.50 (m, 1H), 1.94 (m, 4H), 1.71 (m, 2H), 1.18 (t, J = 4.4, 3H).

[0934] Intermediate 92. Ethyl 1-(3-chloro-5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0935]

[0936] To a solution of ethyl 1-(5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate (intermediate 91) (32.0 g, 73.85 mmol, 1.0 eq) and NCS (9.9 g, 73.85 mmol, 1.0 eq) in DMF (320 mL) at room temperature under an atmosphere of N2(g) was added TFA (8.4 g, 73.85 mmol, 1.0 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 3 hours. The reaction mixture was then cooled to room temperature, poured into H2O (1 L) and extracted with EtOAc (3×1 L). The combined organic phases were washed with brine (500 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=5:1 to 3:1) to give ethyl 1-(3-chloro-5-iodo-6-(3-methoxypropyl)pyrazin-2-yl]piperidine-4-carboxylate (32.0 g, 92% yield) as a brown oil. 1 H NMR (400MHz, CDCl3) δ4.11(q,J=7.2,2H),3.88(m,2H),3.39(t,J=6.4,2H),3.29(s,3H),2 .82(m,2H),2.79(m,2H),2.51(m,1H),1.98(m,4H),1.92(m,2H),1.22-1.17(t,J=7.2,3H).

[0937] Intermediate 93. Ethyl 1-(3-chloro-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0938]

[0939] To a solution of ethyl 1-(3-chloro-5-iodo-6-(3-methoxypropyl)pyrazine-2-yl)piperidine-4-carboxylate (intermediate 92) (1.0 g, 2.1 mmol, 1.0 eq) in MeOH (100 mL) at room temperature was added 10% Pd / C (500 mg). The resulting suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under an H2(g) atmosphere (30 psi) for 3 hours. The reaction mixture was then degassed in vacuo and purged with N2(g) three times, filtered through a pad of celite to remove the catalyst, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE: EtOAc = 5: 1 to 3: 1) to give ethyl 1-(3-chloro-6-(3-methoxypropyl)pyrazine-2-yl)piperidine-4-carboxylate (750 mg) as a brown oil. 1 H NMR (400MHz, CDCl3) δ7.65(s,1H),4.13(q,J=7.2,2H),3.87(m,2H),3.34(t,J=6.4,2H),3 .27(s,3H),2.98(m,2H),2.68(m,2H),2.50(m,1H),1.98-1.84(m,6H),1.21(t,J=7.2,3H).

[0940] Intermediate 94. 1-(6-iodopyrazin-2-yl)piperidine-4-carbonitrile

[0941]

[0942] To a solution of 2,6-diiodopyrazine (intermediate 75) (10.00 g, 30.13 mmol, 1.0 eq) and piperidine-4-carbonitrile (4.99 g, 34.05 mmol, 1.1 eq) in dioxane (100 mL) at room temperature was added EtN (4.57 g, 45.20 mmol, 1.5 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 12 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove most of the dioxane. The residue was poured into H O (400 mL) and extracted with EtOAc (3×200 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na SO , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=50:1 to 2:1) to give 1-(6-iodopyrazin-2-yl)piperidine-4-carbonitrile (17.0 g, 60% yield) as a black oil. 1 H NMR (400MHz, CDCl3) δ8.02(s,1H),7.94(s,1H),3.76(m,2H),3.54(m,2H),2.87(m,1H),1.91(m,4H).

[0943] Intermediate 95. 1-(6-(3-methoxyprop-1-yn-1-yl)pyrazin-2-yl)piperidine-4-carbonitrile

[0944]

[0945] To a solution of 1-(6-iodopyrazin-2-yl)piperidine-4-carbonitrile (Intermediate 94) (4.50 g, 14.33 mmol, 1.0 eq) and 3-methoxyprop-1-yne (2.01 g, 28.65 mmol, 2.0 eq) in ACN (45 mL) at room temperature under N2(g) atmosphere was added chloro[(di(1-adamantyl)-N-butylphosphino)-2-(2-aminobiphenyl)]palladium(II) (cataCXium A-Pd-G2) (479 mg, 720 μmol, 0.05 eq), Cs2CO3 (14.00 g, 42.98 mmol, 3.0 eq) and CuI (270 mg, 1.3 mmol, 0.1 eq). The resulting reaction mixture was heated to 100°C and stirred for 12 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove most of the dioxane. The residue was poured into H2O (100 mL) and extracted with EtOAc (3×50 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 50: 1 to 2: 1) to give ethyl 1-(6-(3-methoxyprop-1-yn-1-yl)pyrazin-2-yl)piperidine-4-carbonitrile (2.4 g, 22% yield) as a black oil. 1 H NMR (400MHz, CDCl3) δ8.11(s,1H),8.02(s,1H),4.38(m,2H),3.91(m,2H),3.58(m,2H),3.50(s,3H),2.97(m,1H),2.02(m,4H).

[0946] Intermediate 96. 1-(6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0947]

[0948] To a solution of ethyl 1- (6- (3-methoxyprop-1-yn-1-yl) pyrazine-2-yl) piperidine-4-carbonitrile (1.20 g, 4.68 mmol, 1.0 eq) in MeOH (30 mL) at room temperature was added 10% Pd / C (1.00 g). The suspension was vacuum degassed and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under an H2(g) atmosphere (15 psi) for 2 hours. The reaction mixture was then vacuum degassed and purged with N2(g), and filtered through a celite pad to remove the catalyst. The filtrate was concentrated under reduced pressure to give ethyl 1- (6- (3-methoxypropyl) pyrazine-2-yl) piperidine-4-carbonitrile (3.2 g, 87% yield) as a yellow oil. 14 H 20 LCMS calculated value for N4O: m / z = 260; found: m / z = 261 (M+H).

[0949] Intermediate 97. 1-(5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0950]

[0951] To a solution of ethyl 1-(6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carbonitrile (Intermediate 96) (2.70 g, 10.37 mmol, 1.0 eq) in DMF (27 mL) at room temperature under an N2(g) atmosphere was added NIS (2.80 g, 12.45 mmol, 1.2 eq) and TFA (1.18 g, 10.37 mmol, 1.0 eq). The resulting reaction mixture was then stirred at room temperature for 1 hour. The reaction mixture was poured into H2O (300 mL) and extracted with EtOAc (3×100 mL). The combined organic phases were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 0:1) to give ethyl 1-(5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carbonitrile (3.8 g, 80% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.69 (s, 1H), 3.73 (m, 2H), 3.49 (m, 2H), 3.40 (t, J = 6.8, 2H), 3.30 (s, 3H), 2.86 (m, 1H), 2.77 (t, J = 7.6, 2H), 1.91 (m, 6H).

[0952] Intermediate 98. 1-(3-chloro-5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0953]

[0954] To a solution of ethyl 1-(5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carbonitrile (intermediate 97) (2.80 g, 7.25 mmol, 1.0 eq) and NCS (1.16 mg, 8.70 mmol, 1.2 eq) in DMF (28 mL) at room temperature under an N2(g) atmosphere was added TFA (827 mg, 7.25 mmol, 1.0 eq). The resulting reaction mixture was heated to 90 ° C and stirred for 1 hour. The reaction mixture was then cooled to room temperature, poured into H2O (200 mL), and extracted with EtOAc (3×100 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 0:1) to give ethyl 1-(3-chloro-5-iodo-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carbonitrile (3.0 g, 62% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ3.68 (m, 2H), 3.46 (t, J = 6.4, 2H), 3.37 (m, 5H), 2.90 (m, 3H), 2.06-1.97 (m, 6H).

[0955] Intermediate 99. 1-(3-chloro-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carbonitrile

[0956]

[0957] To a solution of ethyl 1- (3- chloro-5- iodo-6- (3- methoxypropyl) pyrazine-2-yl) piperidine-4-carbonitrile (intermediate 98) (1.00 g, 2.38 mmol, 1.0 eq) in MeOH (100 mL) at room temperature was added 10% Pd / C (100 mg). The suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under an H2(g) atmosphere (30 psi) for 1 hour. The reaction mixture was then degassed in vacuo and purged with N2(g), and filtered through a pad of celite to remove the catalyst. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 15: 1 to 10: 1) to give 1- (3- chloro-6- (3- methoxypropyl) pyrazine-2-yl) piperidine-4-carbonitrile (250 mg, 73% yield) as a yellow oil. 1H NMR (400MHz, CDCl3) δ7.82 (s, 1H), 3.71 (m, 2H), 3.46 (t, J = 6.4, 2H), 3.40 (m, 5H), 2.93 (m, 1H), 2.79 (t, J = 7.6, 2H), 2.11-2.00 (m, 6H).

[0958] Intermediate 100. Ethyl 1-(6-(3-cyanopropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0959]

[0960] To a suspension of Zn (1.35 g, 20.65 mmol, 1.38 eq) in N, N-dimethylacetamide (10 mL) at room temperature was added I2 (190 mg, 748 μmol, 0.05 eq). The mixture was stirred until the yellow color disappeared (1-2 min), and then 4-bromobutyronitrile (2.22 g, 15.00 mmol, 1.00 eq) was added. The resulting reaction mixture was heated to 70 ° C and stirred for 12 hours. The reaction mixture was cooled to room temperature, and then 1- (6-chloropyrazin-2-yl) piperidine-4-carboxylic acid ethyl ester (intermediate 8) (910 mg, 3.37 mmol, 1.00 eq) was added. The resulting reaction mixture was vacuum degassed and purged with N2 (g) three times, and then Pd (dppf) Cl2 · CH2Cl2 (552 mg, 674 μmol, 0.20 eq) was added. The resulting reaction mixture was heated to 60 ° C and stirred under an N2 (g) atmosphere for 12 hours. The reaction mixture was then cooled to room temperature and filtered through a pad of celite to remove the catalyst. The filtrate was diluted with H2O (10 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford ethyl 1-(6-(3-cyanopropyl)pyrazin-2-yl)piperidine-4-carboxylate (530 mg, 28% yield) as a brown oil. 1 H NMR (400MHz, CD3OD) δ8.02(s,1H),7.66(s,1H),4.33(m,2H),4.15(q,J=7.2,2H),3.12(m,2H),2.77( t,J=7.2,2H),2.65(m,1H),2.51(m,2H),2.23,(m,2H),2.00(m,2H),1.69(m,2H),1.26(t,J=7.2,3H).

[0961] Intermediate 101. Ethyl 1-(6-(3-cyanopropyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0962]

[0963] To a solution of ethyl 1-(6-(3-cyanopropyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 100) (1.50 g, 4.96 mmol, 1.0 eq) in DMF (15 mL) at room temperature was added TFA (566 mg, 4.96 mmol, 1.0 eq) and NIS (1.45 g, 6.45 mmol, 1.3 eq). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was adjusted to pH = 8 with a saturated aqueous solution of NaHCO (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (30 mL), dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=5:1 to 2:1) to give ethyl 1-(6-(3-cyanopropyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (1.78 g, 80% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ7.79 (s, 1H), 4.30-4.08 (m, 4H), 3.05 (t, J = 11.2, 2H), 2.92 (t, J = 7.2, 2H) ,2.58(m,1H),2.47(t,J=7.2,2H),2.14(m,2H),2.02(m,2H),1.76(m,2H),1.28(t,J=7.2,3H); C 16 H 21 LCMS calculated value for IN4O2: m / z=428; found: m / z=429 (M+H).

[0964] Intermediate 102. Ethyl 1-(3-chloro-6-(3-cyanopropyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate

[0965]

[0966] To a mixture of 1-(6-(3-cyanopropyl)-5-iodopyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 101) (1.78 g, 4.16 mmol, 1.0 eq) in DMF (20 mL) at room temperature was added TFA (474 ​​mg, 4.16 mmol, 1.0 eq) and NCS (833 mg, 6.23 mmol, 1.5 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 1 hour. The reaction mixture was then cooled to room temperature and adjusted to pH = 8 with a saturated aqueous solution of NaHCO (30 mL) and then extracted with EtOAc (3 × 30 mL). The combined organic layer was washed with brine (50 mL), dried over Na SO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=5:1 to 2:1) to give ethyl 1-(3-chloro-6-(3-cyanopropyl)-5-iodopyrazin-2-yl)piperidine-4-carboxylate (1.56 g, 80% yield) as a yellow oil. 16 H 20 LCMS calculated value for ClIN4O2: m / z=462; found: m / z=463 (M+H).

[0967] Intermediate 103. Ethyl 1-(3-chloro-6-(3-cyanopropyl)pyrazin-2-yl)piperidine-4-carboxylate

[0968]

[0969] To a mixture of 1-(3-chloro-6-(3-cyanopropyl)-5-iodopyrazine-2-yl)piperidine-4-carboxylic acid ethyl ester (intermediate 102) (780 mg, 1.69 mmol, 1.0 eq) in EtOH (20 mL) at room temperature, 10% Pd / C (1.60 g, 1.69 mmol, 1.0 eq) is added. The resulting suspension is degassed in vacuo and purged with H2(g) 3 times. The resulting reaction mixture is stirred at room temperature under H2(g) atmosphere (15 psi) for 12 hours. The reaction mixture is then degassed in vacuo and purged with N2(g). The reaction mixture is then filtered, and the filtrate is concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=4:1 to 2:1) to give ethyl 1-(3-chloro-6-(3-cyanopropyl)pyrazin-2-yl)piperidine-4-carboxylate (600 mg, 48% yield) as a yellow oil. 1H NMR (400MHz, CDCl3) δ7.74 (s, 1H), 4.18 (q, J = 7.2, 2H), 3.95 (m, 2H), 3.04-2.91 (m, 2H), 2.83 (t, J = 7. 2,2H),2.54(m,1H),2.45(t,J=7.2,2H),2.15(m,2H),2.04(m,2H),1.91(m,2H),1.29(t,J=7.2,3H).

[0970] Intermediate 104. 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furo[2,3-b]pyridine

[0971]

[0972] To a solution of 5-bromofuro[2,3-b]pyridine (4.00 g, 20.20 mmol, 1.0 eq) and bis(pinacolato)diboron (6.16 g, 24.24 mmol, 1.2 eq) in dioxane (40 mL) at room temperature under an N2(g) atmosphere was added Pd(dppf)Cl2·CHCl2 (1.65 g, 2.02 mmol, 0.1 eq) and KOAc (5.95 g, 60.60 mmol, 3.0 eq). The resulting reaction mixture was heated to 85°C and stirred for 2 hours. The reaction mixture was cooled to room temperature, poured into H2O (150 mL) and extracted with EtOAc (2×150 mL). The combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 5:1) to give 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furo[2,3-b]pyridine (6.4 g) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ8.64 (s, 1H), 8.29 (s, 1H), 7.62 (d, J = 2.8, 1H), 6.70 (d, J = 2.8, 1H), 1.30 (s, 12H).

[0973] Intermediate 105. 2-Methoxy-5-(3-methoxyprop-1-yn-1-yl)pyridine

[0974]

[0975] To a solution of 5-bromo-22-methoxypyridine (15.0 g, 79.78 mmol, 1.0 eq) and 3-methoxyprop-1-yne (11.18 g, 159.56 mmol, 2.0 eq) in acetone (300 mL) at room temperature under an N2(g) atmosphere was added CuI (1.52 g, 7.98 mmol, 0.1 eq) and Cs2CO3 (77.98 g, 239.33 mmol, 3.0 eq). The resulting reaction mixture was heated to 100°C and stirred for 12 hours. The reaction mixture was cooled to room temperature, poured into H2O (500 mL), and extracted with EtOAc (3×300 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 0:1) to give 2-methoxy-5-(3-methoxyprop-1-yn-1-yl)pyridine (32.0 g) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ8.20 (d, J = 2.4, 1H), 7.53 (dd,, J = 2.4, 8.4, 1H), 6.62 (d, J = 8.4, 1H), 4.24 (s, 2H), 3.87 (s, 3H), 3.38 (s, 3H).

[0976] Intermediate 106. 2-Methoxy-5-(3-methoxypropyl)pyridine

[0977]

[0978] To a solution of 2-methoxy-5-(3-methoxyprop-1-yn-1-yl)pyridine (intermediate 105) (10.0 g, 56.43 mmol, 1.0 eq) in MeOH (300 mL) at room temperature under N2 (g) atmosphere is added 10% Pd / C (10.0 g). The resulting suspension is degassed in vacuo and purged three times with H2 (g). The resulting reaction mixture is stirred at room temperature under H2 (g) atmosphere (15 psi) for 12 hours. The reaction mixture is then purged under vacuum and rinsed with N2 (g), filtered through a pad of celite to remove the catalyst, and the filtrate is concentrated in vacuo to give crude ethyl 2-methoxy-5-(3-methoxypropyl)pyridine (19.0 g, 93% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.91(d,J=2.0,1H),7.34(dd,J=2.0,8.4,1H),6.61(d,J=8 .4,1H),3.84(s,3H),3.30(t,J=8.2,2H),3.26(s,3H),2.56(m,2H),1.77(m,2H).

[0979] Intermediate 107. 3-Bromo-2-methoxy-5-(3-methoxypropyl)pyridine

[0980]

[0981] To a solution of 2-methoxy-5-(3-methoxypropyl)pyridine (intermediate 106) (6.50 g, 35.87 mmol, 1.0 eq) in concentrated H2SO4 (65 mL) at room temperature was added NBS (19.15 g, 107.60 mmol, 3.0 eq). The resulting reaction mixture was heated to 60 ° C and stirred for 2 hours. The reactant was cooled to 0 ° C and then quenched by adding ice water (500 mL). The resulting mixture was extracted with DCM (3 × 200 mL). The combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 20: 1 to 10: 1) to give 3-bromo-2-methoxy-5-(3-methoxypropyl)pyridine (2.80 g, 30% yield) as a colorless liquid. 1 HNMR (400MHz, CD3OD) δ7.82 (d, J = 2.0, 1H), 7.68 (d, J = 2.0, 1H) 3.84 (s, 3H), 3.28 (t, J = 8.2, 2H), 3.22 (s, 3H), 2.51 (t, J = 8.2, 2H), 1.72 (m, 2H).

[0982] Intermediate 108. 1-(2-methoxy-5-(3-methoxypropyl)pyridin-3-yl)piperidine-4-carbonitrile

[0983]

[0984] To a solution of 3-bromo-2-methoxy-5-(3-methoxypropyl)pyridine (Intermediate 107) (3.50 g, 13.45 mmol, 1.0 eq) and piperidine-4-carbonitrile (1.97 g, 13.45 mmol, 1.0 eq) in THF (35 mL) at room temperature under N2(g) atmosphere was added Pd2(dba)3 (778 mg, 1.35 mmol, 0.1 eq), t-BuONa (3.88 g, 40.36 mmol, 3.0 eq) and 9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane) (Xantphos) (1.23 g, 1.35 mmol, 0.1 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 12 hours. The reaction mixture was cooled to room temperature and combined with another batch (500 mg). The mixture was then poured into H2O (100 mL) and extracted with EtOAc (3×100 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 10: 1 to 1: 1) to give 1- (2-methoxy-5- (3-methoxypropyl) pyridin-3-yl) piperidine-4-carbonitrile (3.20 g, 72% yield) as a yellow liquid. 16 H 23 LCMS calculated value for N3O2: m / z=289; found: m / z=290 (M+H).

[0985] Intermediate 109. 1-(2-Hydroxy-5-(3-methoxypropyl)pyridin-3-yl)piperidine-4-carbonitrile

[0986]

[0987] A mixture of 1-(2-methoxy-5-(3-methoxypropyl)pyridin-3-yl)piperidine-4-carbonitrile (Intermediate 108) (2.90 g, 10.02 mmol, 1.0 eq) in HCl (3.0 M, 29 ml, 8.7 eq) was heated to 70 ° C and stirred for 3 hours. The reaction mixture was cooled to room temperature and quenched by careful addition of saturated aqueous NaHCO solution (50 ml), poured into H O (400 ml) and extracted with EtOAC (3×200 ml). The combined organic phases were washed with brine (100 ml), dried over anhydrous Na SO , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (DCM: MeOH = 7: 1 to 0: 1) to give 1-(2-hydroxy-5-(3-methoxypropyl)pyridin-3-yl)piperidine-4-carbonitrile (2.00 g, 66% yield) as a white solid. 1H NMR (400MHz, CDCl3) δ8.07(s,1H),6.62(s,1H),3.30(m,7H),3.02(m,2H),2.78(m,1H),2.40(m,2H),2.06(m,4H),1.74(m,2H).

[0988] Intermediate 110. 3-(4-cyanopiperidin-1-yl)-5-(3-methoxypropyl)pyridin-2-yl trifluoromethanesulfonate

[0989]

[0990] To a solution of 1-(2-hydroxy-5-(3-methoxypropyl)pyridin-3-yl)piperidine-4-carbonitrile (Intermediate 109) (1.70 g, 6.17 mmol, 1.0 eq) in DCM (17 mL) at 0° C. under N 2 (g(g) atmosphere was added Et 3 N (2.50 mg, 24.70 mmol, 4.0 eq) and Tf 2 O (4.35 g, 15.44 mmol, 2.5 eq). The resulting reaction mixture was warmed to room temperature and stirred for 16 Hour. The reaction mixture was poured into H2O (200 mL) and extracted with DCM (3 × 200 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 10: 1 to 0: 1) to give 3- (4- cyanopiperidin-1-yl) -5- (3-methoxypropyl) pyridin-2-yl trifluoromethanesulfonate (1.90 g, 64% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.77(d,J=2.0,1H),7.23(d,J=2.0,1H),3.33(t,J=6.0,2H),3.28(s, 3H), 3.17 (m, 2H), 2.98 (m, 2H), 2.81 (m, 1H), 2.65 (t, J = 7.6, 2H), 2.02 (m, 4H), 1.81 (m, 2H).

[0991] Intermediate 111. Ethyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate

[0992]

[0993] To a solution of 2,3,5-trichloropyrazine (2.00 g, 10.90 mmol, 1.0 eq) and ethyl piperidine-4-carboxylate (1.71 g, 10.90 mmol, 1.68 mL, 1.0 eq) in ACN (37 mL) at room temperature was added DIEA (4.23 g, 32.71 mmol, 5.70 mL, 3.0 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 12 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove most of the ACN. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (50 mL × 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 10:1) to give ethyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate (1.30 g, 78% yield) as a white solid. 12 H 15 LCMS calculated value for Cl2N3O2: m / z=303; found: m / z=304 (M+H).

[0994] Intermediate 112. Ethyl 1-(3-(benzofuran-5-yl)-6-chloropyrazin-2-yl)piperidine-4-carboxylate

[0995]

[0996] To a solution of ethyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate (Intermediate 111) (3.10 g, 10.19 mmol, 1.0 eq) and benzofuran-5-ylboronic acid (1.65 g, 10.19 mmol, 1.0 eq) in DME (90 mL) at room temperature was added Pd2(dba)3 (933 mg, 1.02 mmol, 0.1 eq), PPh3 (534 mg, 2.04 mmol, 0.2 eq) and Na2CO3 (1 M, 20.38 mL, 2.0 eq). The resulting reaction mixture was heated to 80 ° C under an N2(g) atmosphere and stirred for 2 hours. The reaction mixture was then cooled to room temperature, diluted with H2O (100 mL), and extracted with EtOAc (3×100 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 5:1) to give ethyl 1-(3-(benzofuran-5-yl)-6-chloropyrazin-2-yl)piperidine-4-carboxylate (3.80 g, 96% yield) as a white solid. 20 H 20LCMS calculated value for ClN3O3: m / z=385; found: m / z=386 (M+H).

[0997] Intermediate 113. Ethyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidine-4-carboxylate

[0998]

[0999] To a solution of ethyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate (Intermediate 111) (300 mg, 986 μmol, 1.0 eq) and benzo[d][1,3]dioxol-5-ylboronic acid (163 mg, 986 μmol, 1.0 eq) in DME (8 mL) at room temperature under an N2(g) atmosphere was added Pd2(dba)3 (90 mg, 98 μmol, 0.1 eq), PPh3 (51 mg, 197 μmol, 0.2 eq) and Na2CO3 (1 M, 1.97 mL, 2.0 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 2 hours. The reaction mixture was then cooled to room temperature, diluted with H2O (10 mL) and extracted with EtOAc (3×15 mL). The combined organic phases were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 10:1) to give ethyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidine-4-carboxylate (340 mg, 88% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δ8.07(s,1H),7.39(dd,J=1.6,8.2,1H),7.34(d,J=1.6,1H),6.89(d,J=8.2,1H),6.02(s,2 C 19 H 20 LCMS calculated value for ClN3O4: m / z=389; found: m / z=390 (M+H).

[1000] Intermediate 114. Methyl 2-(1-(3,6-dichloropyrazin-2-yl)piperidin-4-yl)acetate

[1001]

[1002] To a solution of 2,3,5-trichloropyrazine (500 mg, 2.73 mmol, 1.0 eq) and methyl 2-(piperidin-4-yl)acetate hydrochloride (791 mg, 4.09 mmol, 1.5 eq, HCl salt) in dioxane (10 mL) at room temperature under an N2(g) atmosphere was added Et3N (414 mg, 4.09 mmol, 1.5 eq). The resulting reaction mixture was heated to 100 ° C and stirred for 12 hours. The reaction mixture was cooled to room temperature and combined with another batch (100 mg scale). The combined mixture was then poured into H2O (50 mL) and extracted with EtOAc (3×40 mL). The combined organic phase was washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 5:1) to give methyl 2-(1-(3,6-dichloropyrazin-2-yl)piperidin-4-yl)acetate (650 mg, 65% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.72 (s, 1H), 4.03 (m, 2H), 3.63 (s, 3H), 2.85 (dt, J = 2 .0,12.8,2H),2.24(d,J=7.2,2H),1.98(m,1H),1.18(m,2H),1.36(m,2H).

[1003] Intermediate 115. Methyl 2-(1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidin-4-yl)acetate

[1004]

[1005] To a solution of methyl 2-(1-(3,6-dichloropyrazin-2-yl)piperidin-4-yl)acetate (intermediate 114) (550 mg, 1.81 mmol, 1.0 eq) and benzo[d][1,3]dioxol-5-ylboronic acid (300 mg, 1.81 mmol, 1.0 eq) in DME (11 mL) at room temperature under N2(g) atmosphere was added Pd2(dba)3 (166 mg, 180 μmol, 0.1 eq) and PPh3 (95 mg, 361 μmol, 0.2 eq) and Na2CO3 (1 M, 3.6 mL, 2.0 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 3 hours. The reaction mixture was cooled to room temperature and combined with another batch (100 mg scale). The combined mixture was then poured into H2O (50 mL) and extracted with EtOAc (3×40 mL). The combined organic phases were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 10: 1 to 5: 1) to give methyl 2-(1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidin-4-yl)acetate (800 mg, 96% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.97(s,1H),7.28(dd,J=1.6,8.4,1H),7.25(s,1H),6.80(d,J=8.4,1H),5.95(s,2 H), 3.63 (m, 5H), 2.65 (dt, J = 2.0, 12.0, 2H), 2.20 (d, J = 7.2, 2H), 1.98 (m, 1H), 1.64 (m, 2H), 1.20 (m, 2H).

[1006] Intermediate 116. Ethyl 3-(1-(3,6-dichloropyrazin-2-yl)piperidin-4-yl)propanoate

[1007]

[1008] To a solution of 2,3,5-trichloropyrazine (743 mg, 4.05 mmol, 1.0 eq) in ACN (7 mL) at room temperature was added ethyl 3-(piperidin-4-yl)propanoate (750 mg, 4.05 mmol, 1.0 eq) and Et3N (2.05 g, 20.24 mmol, 5.0 eq). The resulting reaction mixture was then heated to 80 ° C and stirred for 12 hours. The reaction mixture was then cooled to room temperature, diluted with H2O (15 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 1:1) to give ethyl 3-(1-(3,6-dichloropyrazin-2-yl)piperidin-4-yl)propanoate (920 mg, 65% yield) as a yellow oil. 1 HNMR (400MHz, CDCl3) δ7.79 (s, 1H), 4.17 (q, J = 7.2, 2H), 4.09 (m, 2H), 2.90 (dt, J = 2.0, 8.8, 2H) ,2.37(t,J=7.6,2H),1.82(m,2H),1.66(m,2H),1.54(m,1H),1.37(m,2H),1.27(t,J=7.2,3H).

[1009] Intermediate 117. Ethyl 3-(1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidin-4-yl)propanoate

[1010]

[1011] To a solution of ethyl 3-(1-(3,6-dichloropyrazin-2-yl)piperidin-4-yl)propanoate (Intermediate 116) (880 mg, 2.65 mmol, 1.0 eq) in DMF (10 mL) at room temperature under N2(g) atmosphere was added benzo[d][1,3]dioxol-5-ylboronic acid (440 mg, 2.65 mmol, 1.0 eq), Cs2CO3 (1.73 g, 5.30 mmol, 2.0 eq) and Pd(PPh3)4 (307 mg, 265 μmol, 0.1 eq). The resulting reaction mixture was then heated to 100 °C and stirred for 3 hours. The reaction mixture was cooled to room temperature, diluted with H2O (15 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=10:1 to 1:1) to give ethyl 3-(1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidin-4-yl)propanoate (600 mg, 53% yield) as a yellow oil. 21 H 24 LCMS calculated value for ClN3O4: m / z=417; found: m / z=418 (M+H).

[1012] Intermediate 118. 3-Chloro-5-(3-methoxyprop-1-yn-1-yl)pyridin-2-amine

[1013]

[1014] To a solution of 5-bromo-3-chloro-pyridin-2-amine (10.0 g, 48.20 mmol, 1.0 eq) and 3-methoxyprop-1-yne (3.72 g, 53.02 mmol, 1.1 eq) in ACN (100 mL) at room temperature under an N2 (g) atmosphere was added chloro[(di(1-adamantyl)-N-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (cataCXium A-Pd-G2) (1.61 g, 2.41 mmol, 0.05 eq), CuI (918 mg, 4.82 mmol, 0.1 eq) and Cs2CO3 (47.12 g, 144.61 mmol, 3.0 eq). The resulting reaction mixture was heated to 100° C. and stirred for 2 hours. The reaction mixture was cooled to room temperature, poured into H2O (500 mL), and extracted with EtOAc (3×500 mL). The combined organic phases were washed with brine (1000 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 3:1) to afford 3-chloro-5-(3-methoxyprop-1-ynyl)pyridin-2-amine (6.2 g, 65% yield) as a white solid. LCMS calculated for C9H9ClN2O: m / z=196; found: m / z=197 (M+H).

[1015] Intermediate 119. 3-Chloro-5-(3-methoxypropyl)pyridin-2-amine

[1016]

[1017] To a solution of 3-chloro-5-(3-methoxyprop-1-ynyl)pyridine-2-amine (intermediate 118) (6.90g, 35.09mmol, 1.0eq) in MeOH (150mL) at room temperature under N2(g) atmosphere was added 5% Rh / C (5.00g). The resulting suspension was degassed in vacuo and purged with H2(g) three times. The resulting reaction mixture was stirred at room temperature under H2(g) (15Psi) for 2 hours. The reaction mixture was then purged under vacuum and rinsed with N2(g), and filtered through a celite pad to remove the catalyst. The filtrate was concentrated under reduced pressure to obtain crude 3-chloro-5-(3-methoxypropyl)pyridine-2-amine (4.40g, 62% yield) as a white solid, which was used without further purification. C9H 13 LCMS calculated for ClN2O: m / z = 200; found: m / z = 201 (M+H).

[1018] Intermediate 120. 3-Chloro-5-(3-methoxypropyl)-2-nitropyridine

[1019]

[1020] To a solution of 3-chloro-5-(3-methoxypropyl)pyridin-2-amine (intermediate 119) (4.30 g, 21.43 mmol, 1.0 eq) in concentrated H2SO4 (43 mL) at -10 ° C was added 30% H2O2 (24.92 g, 219.79 mmol, 10.3 eq). The resulting reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then poured into ice water (400 mL) and then extracted with EtOAc (3 × 300 mL). The combined organic phases were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 3: 1) to give 3-chloro-5-(3-methoxypropyl)-2-nitropyridine (1.70 g, 34% yield) as a white solid. 1 C9H 11 LCMS calculated value for ClN2O3: m / z=230; found: m / z=231 (M+H).

[1021] Intermediate 121. Ethyl 1-(5-(3-methoxypropyl)-2-nitropyridin-3-yl)piperidine-4-carboxylate

[1022]

[1023] To a solution of 3-chloro-5-(3-methoxypropyl)-2-nitropyridine (intermediate 120) (300 mg, 1.30 mmol, 1.0 eq) in MeOH (3 mL) at room temperature was added piperidine-4-carboxylic acid ethyl ester (3.06 g, 19.46 mmol, 15.0 eq). The resulting reaction mixture was heated at 80 ° C under an N2 (g) atmosphere and stirred for 3 hours. The reaction mixture was cooled to room temperature, poured into H2O (60 mL) and extracted with EtOAc (3×60 mL). The combined organic phase was washed with brine (60 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by preparative TLC (SiO2, PE: EtOAc = 1: 1) to give 1- (5- (3-methoxypropyl) -2-nitropyridin-3-yl) piperidine-4-carboxylic acid ethyl ester (380 mg, 83% yield) as a yellow oil. C 17 H 25 LCMS calculated value for N3O5: m / z=351; found: m / z=352 (M+H).

[1024] Intermediate 122. Ethyl 1-(2-amino-5-(3-methoxypropyl)pyridin-3-yl)piperidine-4-carboxylate

[1025]

[1026] To a solution of 1-(5-(3-methoxypropyl)-2-nitro-3-pyridyl)piperidine-4-carboxylic acid ethyl ester (intermediate 121) (380 mg, 1.08 mmol, 1.0 eq) in MeOH (10 mL) at room temperature was added 10% Pd / C (0.4 g). The resulting suspension was degassed in vacuo and purged three times with H (g). The resulting reaction mixture was stirred at room temperature under an H (g) atmosphere (15 psi) for 2 hours. The reaction mixture was then purged under vacuum and rinsed with N (g), and filtered through a celite pad to remove the catalyst. The filtrate was concentrated under reduced pressure to give crude 1-(2-amino-5-(3-methoxypropyl)-3-pyridyl)piperidine-4-carboxylic acid ethyl ester (380 mg) as a yellow oil, which was used without further purification. 1 H NMR (400MHz, CD3OD) δ7.38(s,1H),7.04(s,1H),4.05(q,J=7.2,2H),3.27(t,J=6.4,2H),3.21(s,3H),3.05( m,2H),2.54(m,2H),2.43(m,2H),2.37(m,1H),1.91(m,2H),1.80(m,2H),1.68(m,2H),1.16(t,J=7.2,3H); C 17 H 27 LCMS calculated value for N3O3: m / z=321; found: m / z=322 (M+H).

[1027] Intermediate 123. Ethyl 1-(2-bromo-5-(3-methoxypropyl)pyridin-3-yl)piperidine-4-carboxylate

[1028]

[1029] To a solution of ethyl 1-(2-amino-5-(3-methoxypropyl)-3-pyridinyl)piperidine-4-carboxylate (Intermediate 122) (150 mg, 466 μmol, 1.0 eq) in dibromomethane (1.6 mL) at room temperature under an N2(g) atmosphere was added isoamyl nitrite (60 mg, 513 μmol, 1.1 eq). To the reaction was then added a solution of TMSBr (78 mg, 513 μmol, 1.1 eq) in dibromomethane (1.5 mL). The resulting reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then poured into H2O (40 mL) and extracted with EtOAc (3×40 mL). The combined organic phases were washed with brine (40 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (SiO 2 , PE:EtOAc=2:1) ​​to give ethyl 1-(2-bromo-5-(3-methoxypropyl)-3-pyridinyl)piperidine-4-carboxylate (70 mg, 38% yield) as a yellow oil. 1 HNMR (400MHz, CD3OD) δ7.39(s,1H),7.27(s,1H),4.06(q,J=7.2,2H),3.29(t,J=6.4,2H),3.23 (s,3H),2.67(m,2H),2.59(m,2H),2.41(m,1H),1.94(m,2H),1.79(m,6H),1.17(t,J=7.2,3H); C 17 H 25 LCMS calculated value for BrN2O3: m / z=384; found: m / z=387 (M+H).

[1030] Intermediate 124. Ethyl 1-(3-(4-hydroxyphenyl)-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate

[1031]

[1032] To a solution of ethyl 1-(3-chloro-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 93) (2.00 g, 5.85 mmol, 1.0 eq) and (4-hydroxyphenyl)boronic acid (1.21 g, 8.78 mmol, 1.5 eq) in THF (40 mL) and H2O (8 mL) at room temperature was added chloro[(di(1-adamantyl)-N-butylphosphino)-2-(2-aminobiphenyl)]palladium(II) (cataCXium A-Pd-G2) (391 mg, 585 μmol, 0.1 eq) and K3PO4 (3.10 g, 14.63 mmol, 2.5 eq). The resulting reaction mixture was heated to 80°C and stirred for 3 hours. The reaction mixture was cooled to room temperature, poured into H2O (100 mL) and extracted with EtOAc (3×60 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 20: 1 to 3: 1) to give ethyl 1-(3-(4-hydroxyphenyl)-6-(3-methoxypropyl)pyrazin-2-yl)piperidine-4-carboxylate (2.00 g, 85% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δ7.90 (s, 1H), 7.68 (d, J = 6.8, 2H), 6.72 (m, 2H), 6.29 (m, 1H), 4.10 (m, 2H), 3.63 (m, 2H) ,3.40(m,2H),3.29(s,3H),2.67(m,4H),2.33(m,1H),1.98(m,2H),1.81(m,2H),1.66(m,2H),1.20(m,3H).

[1033] Intermediate 125. tert-Butyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate

[1034]

[1035] To a solution of 2,3,5-trichloropyrazine (5.00 g, 27.26 mmol, 1.0 eq) and tert-butyl piperidine-4-carboxylate (6.65 g, 29.99 mmol, 1.1 eq) in dioxane (60 mL) was added Et3N (8.28 g, 81.78 mmol, 11.38 mL, 3.0 eq). The resulting reaction mixture was heated to 100 ° C and stirred under an N2 (g) atmosphere for 12 hours. The reaction mixture was cooled to room temperature, diluted with H2O (100 mL), and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=50:1 to 10:1) to give tert-butyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate (9.00 g, 98% yield) as a yellow oil. 14 H 19 LCMS calculated value for Cl2N3O2: m / z=331; found: m / z=332 (M+H).

[1036] Intermediate 126. tert-Butyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidine-4-carboxylate

[1037]

[1038] To a solution of tert-butyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate (Intermediate 125) (4.00 g, 12.04 mmol, 1.0 eq) and benzo[d][1,3]dioxol-5-ylboronic acid (1.95 g, 12.04 mmol, 1.0 eq) in DMF (50 mL) at room temperature was added CsCO (11.77 g, 36.12 mmol, 3.0 eq) and Pd(PPh) (1.39 g, 1.20 mmol, 0.1 eq). The resulting reaction mixture was degassed under vacuum and purged with N(g) three times, then the reaction mixture was heated to 80 ° C and stirred under N(g) atmosphere for 16 hours. The reaction mixture was cooled to room temperature, diluted with H(O) (50 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=1:0 to 5:1) to give tert-butyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidine-4-carboxylate (4.00 g, 75% yield) as a yellow solid. 21 H 24LCMS calculated value for ClN3O4: m / z=417; found: m / z=418 (M+H).

[1039] Intermediate 127. (E)-tert-Butyl 1-(3-(Benzo[d][1,3]dioxol-5-yl)-6-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate

[1040]

[1041] To a solution of tert-butyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloropyrazin-2-yl)piperidine-4-carboxylate (Intermediate 126) (8.00 g, 19.14 mmol, 1.0 eq) and (E)-tert-butyldimethyl((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)allyl)oxy)silane (6.85 g, 22.97 mmol, 1.2 eq) in dioxane (80 mL) and H2O (8 mL) at room temperature was added chloro[(di(1-adamantyl)-N-butylphosphino)-2-(2-aminobiphenyl)]palladium(II) (catalyzed by HPLC) and 1H2O (HPLC). A-Pd-G2) (640 mg, 957 μmol, 0.05 eq) and Cs2CO3 (18.71 g, 57.43 mmol, 3.0 eq). The resulting reaction mixture was degassed under vacuum and purged with N2(g) three times, then the reaction mixture was heated to 110°C and stirred under N2(g) atmosphere for 1 hour. The mixture was cooled to room temperature, diluted with H2O (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (2×100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=50:1 to 10:1) to give tert-butyl (E)-1-(3-(benzo[d][1,3]dioxol-5-yl)-6-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate (9.00 g, 84% yield) as a yellow oil. 1H NMR (400MHz, CDCl3) δ8.01(s,1H),7.62(m,H),7.49(m,H),7.43(d,J=1.6,H),6.90(m,1H),6.53(d,J=12.6,1H),6.01(s,2H),4.44( C 30 H 43 LCMS calculated value for N3O5Si: m / z=553; found: m / z=554 (M+H).

[1042] Intermediate 128. tert-Butyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-(3-((tert-butyldimethylsilyl)oxy)propyl)pyrazin-2-yl)piperidine-4-carboxylate

[1043]

[1044] To a solution of tert-butyl (E)-1-(3-(benzo[d][[1,3]dioxol-5-yl)-6-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 127) (9.00 g, 16.25 mmol, 1.0 eq) in MeOH (50 mL) was added 10% Pd / C (5.00 g). The resulting suspension was degassed under vacuum and purged with H2(g) three times, and the reaction mixture was then stirred at room temperature under an H2(g) atmosphere (15 psi) for 2 hours. The reaction mixture was then degassed under vacuum and purged with N2(g), filtered through a pad of celite, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=50:1 to 10:1) to give tert-butyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-(3-((tert-butyldimethylsilyl)oxy)propyl)pyrazin-2-yl)piperidine-4-carboxylate (7.00 g, 66% yield) as a yellow oil. 30 H 45 LCMS calculated value for N3O5Si: m / z=555; found: m / z=556 (M+H).

[1045] Intermediate 129. tert-Butyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-(3-hydroxypropyl)pyrazin-2-yl)piperidine-4-carboxylate

[1046]

[1047] To a solution of tert-butyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-(3-((tert-butyldimethylsilyl)oxy)propyl)pyrazin-2-yl)piperidine-4-carboxylate (Intermediate 128) (14 g, 25.19 mmol, 1.0 eq) in THF (100 mL) at 0°C was added TBAF (1 M, 37.78 mL, 1.5 eq). The resulting reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction mixture was diluted with saturated aqueous NaCO (100 mL) and then extracted with EtOAc (3×200 mL). The combined organic layers were washed with saturated NaCO (2×100 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE:EtOAc=20:1 to 5:1) to give tert-butyl 1-(3-(benzo[d][1,3]dioxol-5-yl)-6-(3-hydroxypropyl)pyrazin-2-yl)piperidine-4-carboxylate (8 g, 68% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ8.00(s,1H),7.45(d,J=8.4,1H),7.40(d,J=1.6,1H),6.89(d,J=8.4,1H),6.01(s,2H),3.75(t,J=6 C 24 H 31 LCMS calculated value for N3O5: m / z=441; found: m / z=442 (M+H).

[1048] Intermediate 130. Ethyl 1-(6-chloro-3-(7-fluorobenzofuran-5-yl)pyrazin-2-yl)piperidine-4-carboxylate

[1049]

[1050] To a solution of ethyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate (Intermediate 111) (200 mg, 658 μmol, 1.0 eq) and 2-(7-fluorobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate 41) (173 mg, 657 μmol, 1.0 eq) in DME (4 mL) and H2O (0.8 mL) at room temperature under N2(g) atmosphere was added Pd2(dba)3 (60 mg, 65 μmol, 0.1 eq), PPh3 (35 mg, 131 μmol, 0.2 eq) and Na2CO3 (139 mg, 1.32 mmol, 2.0 eq). The resulting reaction mixture was heated to 80°C and stirred for 2 hours. The reaction mixture was cooled to room temperature, poured into H2O (30 mL) and extracted with EtOAc (3 × 20 mL). The combined organic phase was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EtOAc = 10: 1 to 5: 1) to give ethyl 1- (6- chloro-3- (7- fluorobenzofuran-5-yl) pyrazine-2-yl) piperidine-4-carboxylate (300 mg, 90% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ8.04(s,1H),7.82(s,1H),7.53(s,1H),7.36(m,1H),6.81(m,1H),4.07(q,J=7. 2,2H),3.60(m,2H),2.74(t,J=11.2,2H),2.32(m,1H),1.82(m,2H),1.67(m,2H),1.19(t,J=7.2,3H).

[1051] Intermediate 131. tert-Butyl 1-(6-chloro-3-(7-fluorobenzofuran-5-yl)pyrazin-2-yl)piperidine-4-carboxylate

[1052]

[1053] To a solution of tert-butyl 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carboxylate (Intermediate 125) (1.00 g, 3.01 mmol, 1.0 eq) and 2-(7-fluorobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate 41) (788 mg, 3.01 mmol, 1.0 eq) in DME (20 mL) at room temperature under N2(g) atmosphere was added Pd2(dba)3 (275 mg, 301 μmol, 0.1 eq), PPh3 (157 mg, 602 μmol, 0.2 eq) and Na2CO3 (1 M, 6.02 mL, 2.0 eq). The resulting reaction mixture was heated to 80 ° C and stirred for 3 hours. The reaction mixture was cooled to room temperature, poured into H2O (60 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (20 mL), dried over Na SO , filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (PE: EtOAc = 1: 0 to 19: 1) to give tert-butyl 1- (6-chloro-3- (7-fluorobenzofuran-5-yl) pyrazin-2-yl) piperidine-4-carboxylate (850 mg, 65% yield) as a yellow oil. 1 HNMR (400MHz, CDCl3) δ8.03 (s, 1H), 7.81 (s, 1H), 7.66 (m, 1H), 7.02 (d, J = 15.6, 1H), 6.8 0(s,1H),3.59(m,2H),2.74(m,2H),2.29(m,1H),1.75(m,2H),1.58(m,2H),1.36(s,9H).

[1054] Intermediate 132. 1-(6-chloro-3-(7-fluorobenzofuran-5-yl)pyrazin-2-yl)piperidine-4-carbonitrile

[1055]

[1056] To a mixture of 1-(3,6-dichloropyrazin-2-yl)piperidine-4-carbonitrile (1.00 g, 3.89 mmol, 1.0 eq) and 2-(7-fluorobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate 41) (1.02 g, 3.89 mmol, 1.0 eq) in DME (10 mL) and H2O (2 mL) at room temperature under N2(g) atmosphere was added Pd2(dba)3 (356 mg, 389 μmol, 0.1 eq), PPh3 (204 mg, 778 μmol, 0.2 eq) and Na2CO3 (824 mg, 7.78 mmol, 2.0 eq). The resulting reaction mixture was heated to 80°C and stirred for 3 hours. The reaction mixture was then cooled to room temperature, poured into H2O (50 mL) and extracted with EtOAc (3×50 mL). The combined organic phases were washed ...

Claims

1. A compound of formula (I'): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4; X is selected from CH and N; Y is selected from CH, S, O and N; Z is selected from the key and CR 7 ; R 1 is selected from aryl and heteroaryl; R 2 is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which may be optionally substituted by one or more R 6 replace; R 3 Selected from: optionally SO2-alkyl-substituted alkyl, Alkoxyalkyl, Alkoxyalkoxyalkyl, Haloalkyl, Haloalkoxyalkyl, Cycloalkylalkyl, and Cycloalkoxyalkyl; Each R 4 Independently selected from: Optionally, R 5 Substituted alkoxy, Optionally, R 5 Substituted alkylamino, Optionally, R 5 Substituted dialkylamino, SO2R 8a , Alkylthio, Haloalkoxy, Cycloalkoxy, Cycloalkylalkoxy, Halogenated, Alkyl, and Haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy or alkoxyalkyl; Each R 5 independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino, haloalkoxy, and alkoxyalkoxy; Each R 6 independently selected from hydroxy, hydroxyalkoxy, carboxyl, methylcarboxyl, carboxylalkyl, carboxylalkoxy, halo, alkyl, alkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, cyano, and tetrazolyl; R 7 is selected from hydrogen and halo; and R 8a and R 8b Each is independently selected from alkyl, amino, alkylamino, dialkylamino; Where X and Y are not both CH.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: X is selected from CH and N; Y is selected from CH and N; and Z is CH.

3. The compound according to claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, wherein: X is CH; Y is N; and Z is CH; or X is N; Y is CH; and Z is CH; Or X is N; Y is N; and Z is CH.

4. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein: X is N; Y is N; and Z is CH.

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein: R 1 is phenyl, monocyclic heteroaryl or bicyclic heteroaryl.

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein: R 1 It is phenyl.

7. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein: R 1 It is a bicyclic heteroaryl group.

8. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein: Each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl, and haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy or alkoxyalkyl; Each R 5 are independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino, and haloalkoxy; and m is an integer of 0-3.

9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein: Each R 4 independently selected from alkoxy, haloalkoxy and halo; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl; and m is an integer of 0-3.

10. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein: R 3 is selected from alkyl, alkoxyalkyl, haloalkyl, haloalkoxyalkyl, cycloalkylalkyl and cycloalkoxyalkyl optionally substituted with SO2-alkyl.

11. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein: R 3 is selected from the group consisting of alkyl, alkoxyalkyl, haloalkyl and haloalkoxyalkyl.

12. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein: R 3 Selected from alkyl and alkoxyalkyl.

13. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein: R 3 It is an alkoxyalkyl group.

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein: R 2 For one or more R 6 substituted monocyclic or bicyclic heterocycloalkyl; Each R 6 independently selected from hydroxyl, carboxyl, carboxyalkyl, carboxyalkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, and tetrazolyl; and R 8b Selected from alkyl, amino, alkylamino, dialkylamino.

15. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein: R 2 For an R 6 substituted monocyclic heterocycloalkyl; R 6 Selected from carboxyl, carboxyalkyl, C(=O)NHSO2R 8b , heterocycloalkyl, and tetrazolyl; and R 8b Selected from alkyl, amino, alkylamino, dialkylamino.

16. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein: R 2 For an R 6 substituted piperidinyl; and R 6 Selected from carboxyl, carboxyalkyl and heterocycloalkyl.

17. The compound of claim 1, wherein the compound is a compound of formula (IV): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 3; R 2 For one or more R 6 substituted monocyclic or bicyclic heterocycloalkyl; R 3 is selected from alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, haloalkyl, haloalkoxyalkyl, cycloalkylalkyl and cycloalkoxyalkyl optionally substituted with SO2-alkyl; Each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy, halo, alkyl, and haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy or alkoxyalkyl; Each R 5 independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino and haloalkoxy; Each R 6 independently selected from hydroxyl, carboxyl, carboxyalkyl, carboxyalkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, and tetrazolyl; and R 8b Selected from alkyl, amino, alkylamino, dialkylamino.

18. The compound according to claim 17 or a pharmaceutically acceptable salt thereof, wherein: R 2 For an R 6 Substituted monocyclic heterocycloalkyl.

19. The compound of claim 17 or claim 18, wherein the compound is a compound of formula (V) or a pharmaceutically acceptable salt thereof:

20. The compound or pharmaceutically acceptable salt thereof according to any one of claims 17 to 19, wherein: R 3 is selected from the group consisting of alkyl, alkoxyalkyl, haloalkyl and haloalkoxyalkyl; Each R 4 independently selected from alkoxy, haloalkoxy and halo; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl; R 6 Selected from carboxyl, carboxyalkyl, C(=O)NHSO2R 8b , heterocycloalkyl, and tetrazolyl; and R 8b Selected from alkyl, amino, alkylamino, dialkylamino.

21. The compound or pharmaceutically acceptable salt thereof according to any one of claims 17 to 19, wherein: R 3 Selected from alkyl and alkoxyalkyl; Each R 4 independently selected from alkoxy, haloalkoxy and halo; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl; and R 6 Selected from carboxyl, carboxyalkyl and heterocycloalkyl.

22. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4; X is selected from CH and N; Y is selected from CH, S, O and N; Z is selected from the key and CR 7 ; R 1 is selected from aryl and heteroaryl, R 2 is a monocyclic or bicyclic heterocycloalkyl or a monocyclic or bicyclic heteroaryl, any of which may be optionally substituted by one or more R 6 replace; R 3 is selected from the group consisting of: alkyl, haloalkyl, haloalkoxyalkyl, cycloalkylalkyl and cycloalkoxyalkyl optionally substituted with SO2-alkyl; Each R 4 Independently selected from: optionally through R 5 Substituted alkoxy, SO2R 8a , haloalkoxy, cycloalkoxy, cycloalkylalkoxy, and halo; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, either of which may be optionally substituted with one or more alkyl, halo, oxo, alkoxy or alkoxyalkyl; Each R 5 independently selected from hydroxy, alkoxy, amino, alkylamino, dialkylamino and haloalkoxy; Each R 6 independently selected from hydroxy, hydroxyalkoxy, carboxyl, methylcarboxyl, carboxylalkyl, carboxylalkoxy, halo, alkyl, alkoxy, SO2R 8b 、C(=O)NHSO2R 8b , heterocycloalkyl, cyano, and tetrazolyl; R 7 is selected from hydrogen and halo; and R 8a and R 8b Each is independently selected from alkyl, amino, alkylamino, dialkylamino; Where X and Y are not both CH.

23. The compound of claim 22, wherein the compound is a compound of formula (II): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 3; R 2 is optionally through one or more R 6 substituted monocyclic or bicyclic heterocycloalkyl; Each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a and halogenated, or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl; R 5 Selected from alkoxy, amino, alkylamino and dialkylamino; Each R 6 independently selected from carboxyl, carboxyalkyl, halo, alkyl, SO2R 8b 、C(=O)NHSO2R 8b and tetrazolyl; and R 8a and R 8b Each is independently selected from alkyl, amino, alkylamino, and dialkylamino.

24. The compound of claim 23, wherein the compound is a compound of formula (III): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 3; Each R 4 Independently selected from optionally R 5 Substituted alkoxy, SO2R 8a and halogenated, or two R 1 The substituents together form a fused heterocycloalkyl or fused heteroaryl; R 5 Selected from alkoxy, amino, alkylamino and dialkylamino; R 6 Selected from carboxyl, carboxyalkyl, halo, alkyl, SO2R 8b 、C(=O)NHSO2R 8b and tetrazolyl; and R 8a and R 8b Each is independently selected from alkyl, amino, alkylamino, and dialkylamino.

25. The compound of claim 1, wherein the compound is a compound of formula (VI): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4; Y is N or CH; R 3 Selected from: C1-C6 alkyl optionally substituted with SO2-(C1-C6 alkyl), (C1-C6 alkoxy)-C1-C6 alkyl, (C1-C6 alkoxy)-(C1-C6 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, (C1-C6 haloalkoxy)-C1-C6 alkyl, (C3-C6 cycloalkyl)-C1-C6 alkyl, and (C3-C6 cycloalkoxy)-C1-C6 alkyl; Each R 4 Independently selected from: Optionally, R 5 Substituted C1-C6 alkoxy, Optionally, R 5 Substituted C1-C6 alkylamino, Optionally, R 5 Substituted di-(C1-C6 alkyl)-amino, SO2R 8a , C1-C6 alkylthio, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, Halogenated, C1-C6 alkyl, and C1-C6 haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C6 alkoxy)-C1-C6 alkyl; Each R 5 Independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C6 alkylamino, di-C1-C6 alkylamino, C1-C6 haloalkoxy and (C1-C6 alkoxy)-C1-C6 alkoxy; R 6 Selected from -C(=O)OH, -CH2C(=O)OH, -C(=O)O-C1-C6 alkyl, -C(=O)NHSO2R 8b , heterocycloalkyl, and tetrazolyl; R 8a and R 8b Each is independently selected from C1-C6 alkyl, amino, C1-C6 alkylamino, and di-(C1-C6 alkyl)-amino.

26. The compound according to claim 25 or a pharmaceutically acceptable salt thereof: m is an integer from 0 to 4; Y is N or CH; R 3 Selected from: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, (C1-C4 haloalkoxy)-C1-C6 alkyl, (C3-C6 cycloalkyl)-C1-C6 alkyl and (C3-C6 cycloalkyloxy)-C1-C6 alkyl; Each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C4 alkylamino, optionally R 5 Substituted di-(C1-C4 alkyl)-amino, SO2R 8a , C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused heterocycloalkyl or fused heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy or (C1-C4 alkoxy)-C1-C6 alkyl; Each R 5 Independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)-amino, C1-C6 haloalkoxy and (C1-C4 alkoxy)-C1-C6 alkoxy; R 6 Selected from -C(=O)OH, -CH2C(=O)OH, -C(=O)O-C1-C4alkyl, -C(=O)NHSO2R 8b and tetrazolyl; R 8a and R 8b Each is independently selected from C1-C6 alkyl, amino, C1-C4 alkylamino, and di-(C1-C4 alkyl)-amino.

27. The compound of claim 25, wherein the compound is a compound of formula (VI-1): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4; Y is N or CH; R 3 Selected from: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl, (C1-C4 haloalkoxy)-C1-C6 alkyl, (C3-C6 cycloalkyl)-C1-C6 alkyl and (C3-C6 cycloalkyloxy)-C1-C6 alkyl; Each R 4 Independently selected from: optionally through R 5 Substituted C1-C6 alkoxy, optionally R 5 Substituted C1-C4 alkylamino, optionally R 5 Substituted di-(C1-C4 alkyl)-amino, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, (C3-C6 cycloalkyl)-C1-C6 alkoxy, halo, C1-C6 alkyl and C1-C6 haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused 5-membered heterocycloalkyl or a fused 5-membered heteroaryl, any of which may be optionally substituted with one or more C1-C6 alkyl, halo, oxo, C1-C6 alkoxy, or (C1-C4 alkoxy)-C1-C6 alkyl; and Each R 5 Independently selected from hydroxy, C1-C6 alkoxy, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)-amino, C1-C6 haloalkoxy and (C1-C4 alkoxy)-C1-C6 alkoxy.

28. The compound of claim 25, wherein the compound is a compound of formula (VI-2): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4; Y is N or CH; R 3 Selected from: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl and (C1-C4 haloalkoxy)-C1-C6 alkyl; Each R 4 Independently selected from: C1-C6 alkoxy, C1-C4 haloalkoxy, halo, C1-C4 alkyl and C1-C4 haloalkyl; or R 1 Two R on adjacent carbon atoms 4 The substituents together form a fused 5-membered heterocycloalkyl containing 1 or 2 O atoms or a fused 5-membered heteroaryl containing 1 O atom and 0 or 1 N atoms, either of which may be optionally substituted with one or more C1-C4 alkyl, halo, C1-C4 alkoxy or (C1-C4 alkoxy)-C1-C4 alkyl.

29. The compound of claim 25, wherein the compound is a compound of formula (VI-3): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 2; Y is N or CH; R 3 is selected from the group consisting of: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl and (C1-C4 haloalkoxy)-C1-C6 alkyl; and Each R 4 Independently selected from: C1-C6 alkoxy, C1-C4 haloalkoxy, halo, C1-C4 alkyl and C1-C4 haloalkyl.

30. The compound of claim 25, wherein the compound is a compound of formula (VI-4): or a pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 2; Y is N or CH; R 3 is selected from the group consisting of: C1-C6 alkyl, (C1-C4 alkoxy)-C1-C6 alkyl, C1-C6 haloalkyl and (C1-C4 haloalkoxy)-C1-C6 alkyl; and Each R 4 Independently selected from: C1-C6 alkoxy, C1-C4 haloalkoxy, halo, C1-C4 alkyl and C1-C4 haloalkyl.

31. A compound according to claim 29 or claim 30, or a pharmaceutically acceptable salt thereof, wherein: m is 0 or 1; and R 4 Selected from: C1-C6 alkoxy, C1-C4 haloalkoxy and halo.

32. A compound according to any one of claims 25 to 31 or a pharmaceutically acceptable salt thereof, wherein: R 3 Selected from: C3-C6 alkyl, (C1-C4 alkoxy)-C3-C6 alkyl, C3-C6 haloalkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl.

33. A compound according to any one of claims 25 to 31 or a pharmaceutically acceptable salt thereof, wherein: R 3 Selected from: (C1-C4 alkoxy)-C3-C6 alkyl and (C1-C4 haloalkoxy)-C3-C6 alkyl.

34. A compound according to any one of claims 25 to 33, or a pharmaceutically acceptable salt thereof, wherein: Y is N.

35. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

36. A pharmaceutical composition comprising a compound according to any one of claims 1 to 35 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

37. A compound as claimed in any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, for use as a medicament.

38. A compound as claimed in any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, for use in treating a condition selected from hyperuricemia and gout.

39. A compound according to any one of claims 1 to 35 or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for preventing or treating a disease or condition that is improved by inhibiting GLUT9.

40. A method of inhibiting GLUT9, comprising contacting GLUT9 with a compound according to any one of claims 1 to 35 or a pharmaceutically acceptable salt thereof.

41. A method for treating a disease mediated by GLUT9 in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 35 or a pharmaceutically acceptable salt thereof.

42. The method of claim 41, wherein the disease is selected from hyperuricemia, gout and uncontrolled gout, including comorbidities and related diseases.

43. A method of treating a disease mediated by GLUT9 in a mammal, comprising administering to a mammal in need thereof: a. a therapeutically effective amount of a compound as described in any one of claims 1 to 35 or a pharmaceutically acceptable salt thereof; and b. Another therapeutic agent.

44. The method of claim 43, wherein the additional agent is selected from the group consisting of a uric acid synthesis inhibitor, a uricosuric drug, and a uric acid catabolist.

45. The method of claim 44, wherein the uricosuric drug is selected from probenecid, lesinade, benzbromarone, and sulfinpyrazone.

46. ​​The method of claim 44, wherein the uric acid synthesis inhibitor is selected from allopurinol and febuxostat.

47. The method of claim 44, wherein the uric acid catabolizing agent is pegloticase.

48. The method of claim 43, wherein the other agent is colchicine.

49. A method for reducing blood uric acid levels in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound as described in any one of claims 1 to 35 or a pharmaceutically acceptable salt thereof.